Amedeo Smart

Free Medical Literature Service

 

Amedeo

Inflammatory Bowel Diseases
  Free Subscription

Articles published in
Inflamm Bowel Dis
    August 2026
  1. LI H, Lu Z, Denson N, Pan W, et al
    Multi-modal ensemble learning prediction of anti-TNF treatment response in pediatric patients with Crohn's disease using clinical, radiomic, and deep learning MR enterography features.
    Inflamm Bowel Dis. 2026 Aug 7:izag156. doi: 10.1093.
    >> Share

  2. MIYATANI Y, Hudson A, Kellar A, St-Pierre J, et al
    Clinical appraisal of handheld intestinal ultrasound in inflammatory bowel disease: Where are we now?
    Inflamm Bowel Dis. 2026 Aug 7:izag147. doi: 10.1093.
    >> Share

  3. FUCHS T, Stadlbauer V
    Sarcopenia as a prognostic marker in inflammatory bowel disease: Implications for endoscopic outcomes and loss of response to biologic therapy-A systematic review with narrative synthesis.
    Inflamm Bowel Dis. 2026 Aug 7:izag162. doi: 10.1093.
    >> Share

  4. SHAH RS, Bachour SP, Xiao H, Yang Q, et al
    Reutilization of biologics for postoperative Crohn's disease recurrence prevention is effective.
    Inflamm Bowel Dis. 2026 Aug 6:izag157. doi: 10.1093.
    >> Share

  5. DESAI A, Dapke K, Habib H, Hashash JG, et al
    Appendectomy before or after ulcerative colitis diagnosis is not associated with improved long-term outcomes: a multicenter real-world study.
    Inflamm Bowel Dis. 2026 Aug 6:izag159. doi: 10.1093.
    >> Share

  6. YARATHA L, Deogaonkar A, Vemulakonda P, Ezhil SR, et al
    Readability and quality of online inflammatory bowel disease pregnancy resources.
    Inflamm Bowel Dis. 2026 Aug 4:izag153. doi: 10.1093.
    >> Share

  7. MOUTSOGLOU D, Staley C, Kabage AJ, Khoruts A, et al
    Colonoscopic and oral microbiota transplant therapy yield similar stool and neoterminal ileal engraftment profiles in a single-blind pilot randomized trial.
    Inflamm Bowel Dis. 2026;32:1576-1586.
    >> Share

  8. HILMI I, Khoo XH, Kwong DY, Tan PO, et al
    IBD in transition: a decade of data from the Malaysian Kinta Valley cohort.
    Inflamm Bowel Dis. 2026;32:1504-1512.
    >> Share

  9. KIM HK, Yoon YS, Lee JL, Park EJ, et al
    Effect of polydeoxyribonucleotide as a potential therapeutic agent to enhance the healing of Crohn's perianal fistula.
    Inflamm Bowel Dis. 2026;32:1471-1480.
    >> Share

  10. FERNANDES SR, Bronze S, Rodrigues IC, Saraiva S, et al
    Transmural improvement may be an acceptable target in patients with Crohns disease.
    Inflamm Bowel Dis. 2026;32:1495-1503.
    >> Share

  11. KAUR A, Kaur A, Goren I
    Safety and outcomes of advanced IBD therapies in patients with HIV: a propensity-matched cohort analysis.
    Inflamm Bowel Dis. 2026;32:1452-1459.
    >> Share

    July 2026
  12. XU H, Zeng T, Wang W
    Interpreting oral dysbiosis during nutritional therapy in pediatric Crohn disease.
    Inflamm Bowel Dis. 2026 Jul 28:izag149. doi: 10.1093.
    >> Share

  13. RUBIN DT, Schreiber S, Peyrin-Biroulet L, Danese S, et al
    Risk of serious infection, myocardial infarction, stroke, and thromboembolic events in patients in the United States with ulcerative colitis treated with tofacitinib compared with biologic treatments.
    Inflamm Bowel Dis. 2026 Jul 28:izag142. doi: 10.1093.
    >> Share

  14. VIOLANTE T, Cardelli S, Calini G, Novelli M, et al
    The hostile abdomen dilemma: the safety of primary anastomosis in the presence of an intraoperative abscess in Crohn disease.
    Inflamm Bowel Dis. 2026 Jul 26:izag148. doi: 10.1093.
    >> Share

  15. NARDONE OM, Yuan Y, Caso F, Pope J, et al
    Classifications of rheumatological extraintestinal manifestations in inflammatory bowel disease: Unmet needs in clinical practice and trials.
    Inflamm Bowel Dis. 2026 Jul 23:izag144. doi: 10.1093.
    >> Share

  16. ELDESOUKI MH, Hafez Y, Salem AE, Alomari M, et al
    Increased risk of respiratory syncytial virus infection in patients with active inflammatory bowel disease: a matched cohort study.
    Inflamm Bowel Dis. 2026 Jul 22:izag134. doi: 10.1093.
    >> Share

  17. UNAL NG, Bakkaloglu OK, Kav T, Eskazan T, et al
    Upadacitinib as a rescue therapy for steroid- and infliximab-refractory acute severe ulcerative colitis: short- and long-term effectiveness and safety in a multicenter cohort study.
    Inflamm Bowel Dis. 2026 Jul 22:izag126. doi: 10.1093.
    >> Share

  18. VANOJAN MJNR, Agbabiaka OO, Kumaresan D, Yahia S, et al
    Appendicectomy in ulcerative colitis: a narrative review of epidemiology, pathophysiology, and emerging therapeutic implications.
    Inflamm Bowel Dis. 2026 Jul 21:izag145. doi: 10.1093.
    >> Share

  19. GILL PK, Finch H, Stein L, Kaplan GG, et al
    Underevaluation of bowel urgency in clinical care: patient experiences and outcomes in ulcerative colitis: a retrospective cohort study.
    Inflamm Bowel Dis. 2026 Jul 17:izag102. doi: 10.1093.
    >> Share

  20. GEORGE AT, Gottlieb K, Colucci DR, Eastman WJ, et al
    Artificial intelligence assessment of endoscopic severity and extent: A machine learning approach to continuous evaluation of endoscopic inflammation in ulcerative colitis.
    Inflamm Bowel Dis. 2026 Jul 17:izag135. doi: 10.1093.
    >> Share

  21. KUENZIG ME, Bernstein CN, Coward S, Dummer TJB, et al
    The association between artificial light at night and inflammatory bowel disease incidence, surgery, and health services utilization: population-based observational studies.
    Inflamm Bowel Dis. 2026 Jul 17:izag141. doi: 10.1093.
    >> Share

  22. KURIAKOSE KUZHIYANJAL AJ, Rhodes S, Sethi-Arora K, Hancock L, et al
    Healthcare professionals' knowledge, attitudes, and practice with addressing sexual health among people living with inflammatory bowel disease: A UK cross-sectional survey.
    Inflamm Bowel Dis. 2026 Jul 10:izag121. doi: 10.1093.
    >> Share

  23. SAFARI K, Ma WJ, Sekhon P, Rai P, et al
    Mast cell-derived IL-13 as a driver of Crohn disease-associated intestinal fibrosis.
    Inflamm Bowel Dis. 2026 Jul 8:izag127. doi: 10.1093.
    >> Share

  24. SUSKIND DL, Hoffman LR, Lee D, Verster AJ, et al
    Metabolome remodeling with reverse-engineered exclusive enteral nutrition in children with active Crohn's disease.
    Inflamm Bowel Dis. 2026 Jul 8:izag095. doi: 10.1093.
    >> Share

  25. DEL GAUDIO A, Di Vincenzo F, Cuccia G, Coppola G, et al
    Timing of biologic prophylaxis and postoperative recurrence in Crohn's disease: A real-life cohort study using propensity score weighting.
    Inflamm Bowel Dis. 2026 Jul 8:izag130. doi: 10.1093.
    >> Share

  26. FAYE AS, Kochar B, Choi D, Gift T, et al
    Inflammatory bowel disease in the aging population.
    Inflamm Bowel Dis. 2026 Jul 8:izag122. doi: 10.1093.
    >> Share

  27. VUYYURU SK, Goodwin SW, Solitano V, Ramsewak D, et al
    Patients with Crohn's disease achieving transmural healing experience superior long-term outcomes compared with those with endoscopic or radiologic healing alone.
    Inflamm Bowel Dis. 2026 Jul 3:izag114. doi: 10.1093.
    >> Share

  28. LEE J, Porth R, Saraga A, Gade A, et al
    Higher body mass index is associated with lower drug concentrations in patients with inflammatory bowel disease treated with ustekinumab but not vedolizumab.
    Inflamm Bowel Dis. 2026 Jul 2:izag139. doi: 10.1093.
    >> Share

  29. LEDDY RS, Hudachek CL, Phelan HM, Aherne CM, et al
    CB2R promotes T cell gut homing and exacerbates ileitis in a murine Crohn's model.
    Inflamm Bowel Dis. 2026;32:1219-1234.
    >> Share

  30. YOON J, Jun YK, Lee HS, Yoo JH, et al
    Early immunomodulator therapy reduces the risk of intestinal resection in Crohns disease: a systematic review and meta-analysis.
    Inflamm Bowel Dis. 2026;32:1333-1343.
    >> Share

  31. DUBINSKY MC, Schreiber S, Yarur AJ, Sands BE, et al
    Recovery of response and long-term outcomes following loss of response and dose escalation of subcutaneous infliximab: a post hoc analysis of the LIBERTY-CD & LIBERTY-UC trials.
    Inflamm Bowel Dis. 2026;32:1235-1247.
    >> Share

  32. DESTER E, Powers JC, Zemanek M, Smith R, et al
    Preoperative anorectal manometry is associated with cuffitis but not proximal pouch inflammation after IPAA creation.
    Inflamm Bowel Dis. 2026;32:1248-1255.
    >> Share

  33. BRONZE S, Ibing S, Jimenez D, Mercedes PR, et al
    Fecal calprotectin is an accurate noninvasive screening tool for pouchitis.
    Inflamm Bowel Dis. 2026;32:1298-1303.
    >> Share

    June 2026
  34. POWERS JC, Zemanek M, Dave M, Dester E, et al
    Association of preoperative neoplasia and rectal cuff inflammation on initial pouchoscopy with subsequent neoplasia development in inflammatory bowel disease patients with an ileal pouch-anal anastomosis: a case-control study.
    Inflamm Bowel Dis. 2026 Jun 30:izag112. doi: 10.1093.
    >> Share

  35. HUSSAIN M, Lai AY, Franklin D, Lenz K, et al
    Preclinical development of SL-325, a novel high-affinity DR3-blocking antibody for durable inhibition of the DR3/TL1A axis in inflammatory bowel disease.
    Inflamm Bowel Dis. 2026 Jun 27:izag101. doi: 10.1093.
    >> Share

  36. KHAN N, Sundararajan R, Caldera F, Farraye FA, et al
    Respiratory syncytial virus incidence and clinical outcomes in patients with inflammatory bowel disease: a National Veterans Affairs cohort study.
    Inflamm Bowel Dis. 2026 Jun 23:izag103. doi: 10.1093.
    >> Share

  37. MANCHERON A, Martinez-Vinson C, Beaugerie L, Pigneur B, et al
    Benefit-risk balance of advanced therapies in pediatric inflammatory bowel disease: evidence and gaps versus adults.
    Inflamm Bowel Dis. 2026 Jun 23:izag123. doi: 10.1093.
    >> Share

  38. BAKHSHI Z, Kumari R, Devi J
    Imaging-based prediction of biologic failure in perianal Crohn's disease: the emerging role of 3D transrectal ultrasound.
    Inflamm Bowel Dis. 2026 Jun 22:izag125. doi: 10.1093.
    >> Share

  39. GUASCH M, Calafat M, Gargallo-Puyuelo CJ, De Francisco R, et al
    Clinical features and therapeutic requirements of perianal disease in adult patients with ulcerative colitis: the PERICO study of the ENEIDA registry.
    Inflamm Bowel Dis. 2026 Jun 21:izag120. doi: 10.1093.
    >> Share

  40. MORAN GP, McQuillan A, Ho GT, Whelan RJ, et al
    Modified Crohn's Disease Exclusion Diet and exclusive enteral nutrition (EEN) resolve oral dysbiosis in pediatric Crohn's disease: a prospective cohort study.
    Inflamm Bowel Dis. 2026 Jun 20:izag107. doi: 10.1093.
    >> Share


  41. Expression of Concern: Pediatric Inflammatory Bowel Disease and Hereditary Hemolytic Anemia: A Retrospective Analysis.
    Inflamm Bowel Dis. 2026 Jun 16:izag118. doi: 10.1093.
    >> Share

  42. KAWAMURA T, Yamamura T, Nakamura M, Maeda K, et al
    Comparative efficiency of leucine-rich alpha-2 glycoprotein and fecal calprotectin to assess endoscopic activity in Crohn's disease: a prospective observational study.
    Inflamm Bowel Dis. 2026 Jun 16:izag105. doi: 10.1093.
    >> Share

  43. HE BQ, Lai XQ, Yang X, Zhou J, et al
    Association analysis of short-chain fatty acid levels and intestinal mucosal healing in ulcerative colitis patients.
    Inflamm Bowel Dis. 2026 Jun 13:izag106. doi: 10.1093.
    >> Share

  44. HUANG JS, Bauman LE, Katibian D, Polk DB, et al
    Between-visit care represents a substantial and underrecognized component of health care utilization in pediatric inflammatory bowel disease.
    Inflamm Bowel Dis. 2026 Jun 11:izag097. doi: 10.1093.
    >> Share

  45. SIGVARDSSON I, Ludvigsson J, Lerchova T, Imberg H, et al
    Timing of complementary food introduction is not associated with inflammatory bowel disease risk: A prospective birth cohort study.
    Inflamm Bowel Dis. 2026 Jun 9:izag093. doi: 10.1093.
    >> Share

  46. TAMILARASAN AG, Chiu C, Bestawros D, Oborn S, et al
    Transmural healing is significantly associated with prevention of clinical relapse in Crohn's disease.
    Inflamm Bowel Dis. 2026 Jun 9:izag041. doi: 10.1093.
    >> Share

  47. ABDUL REHMAN K, Us Sehar N, Akram U, Fatima E, et al
    Clinical significance of isolated periappendiceal red patch in ulcerative colitis: A systematic review, meta-analysis, and meta-regression.
    Inflamm Bowel Dis. 2026 Jun 9:izag092. doi: 10.1093.
    >> Share

  48. TAO M, Zhang Z, Dai L, Zeng Y, et al
    Metagenomic insights into potential horizontal transfer of resistance/virulence genes in gut microbiota from patients with Crohn disease.
    Inflamm Bowel Dis. 2026 Jun 7:izag090. doi: 10.1093.
    >> Share

  49. KIM ES, Kim DH, Kim SJ, Park SH, et al
    Distinct predictive factors for acute severe ulcerative colitis in East Asian and Western populations.
    Inflamm Bowel Dis. 2026 Jun 5:izag098. doi: 10.1093.
    >> Share

  50. BRAND EC, Vandoren R, Lutter L, Van Deuren VML, et al
    Clonal overlap and convergent clustering of T cell receptor signatures in Crohn's disease in monozygotic twins.
    Inflamm Bowel Dis. 2026 Jun 5:izag078. doi: 10.1093.
    >> Share

  51. ORLIN I, Younis B, Gasparetto M, Yerushalmy-Feler A, et al
    Clinical and radiological outcomes of ustekinumab in pediatric perianal Crohn's disease: a multicenter retrospective study from the Pediatric IBD Porto Group of ESPGHAN.
    Inflamm Bowel Dis. 2026 Jun 2:izag091. doi: 10.1093.
    >> Share

  52. ST-PIERRE J, Delisle M, Miyatani Y, Falloon K, et al
    Ultrasound criteria for transmural healing and response in Crohn's disease: a systematic review of definitions and thresholds.
    Inflamm Bowel Dis. 2026 Jun 1:izag052. doi: 10.1093.
    >> Share

    May 2026
  53. NORGARD BM, Zeiss KE, Dalal RS, Lund K, et al
    Chronic opioid use and the risk of infections and death in patients with inflammatory bowel disease: a nationwide cohort study based on real-world data.
    Inflamm Bowel Dis. 2026 May 31:izag085. doi: 10.1093.
    >> Share

  54. YUAN Y, Jairath V, Hanzel J, Hupe M, et al
    Biologics and small molecules for perianal Crohn's disease: a systematic review and meta-analyses of randomized placebo-controlled trials.
    Inflamm Bowel Dis. 2026 May 30:izag099. doi: 10.1093.
    >> Share

  55. MACONI G, Bezzio C, Saleh A, Silva Mendes S, et al
    Transperineal contrast-enhanced ultrasound: a rapid and reliable tool for differentiating abscesses from inflammatory masses in perianal Crohn's disease.
    Inflamm Bowel Dis. 2026 May 26:izag089. doi: 10.1093.
    >> Share

  56. KOCHKARIAN T, Lopez KM, Ou R, Powell DW, et al
    Matrix metalloproteinases in intestinal fibrosis and fibrostenosing Crohn's disease: Current evidence, mechanistic hypotheses, and translational challenges.
    Inflamm Bowel Dis. 2026 May 25:izag088. doi: 10.1093.
    >> Share

  57. SHINAGAWA T, Komatsu K, Uchino M, Ikeuchi H, et al
    Clinicopathological features and cancer-specific survival in young patients with ulcerative colitis-associated colorectal neoplasia: a nationwide cohort study in Japan.
    Inflamm Bowel Dis. 2026 May 19:izag069. doi: 10.1093.
    >> Share

  58. KANG H, Karlin KL, Brensinger CM, Ehrlich OG, et al
    Prevalence of inflammatory bowel disease across states: estimates based on claims database.
    Inflamm Bowel Dis. 2026 May 18:izag076. doi: 10.1093.
    >> Share

  59. VEENSTRA FE, Griesbaum MG, Bourgonje AR
    Translating multiomics prediction into clinical care in Crohn's disease: Moving beyond proof of concept.
    Inflamm Bowel Dis. 2026 May 17:izag081. doi: 10.1093.
    >> Share

  60. AFZALI A, Van Rampelbergh R
    Reply: "Entering a new GALAXI: The importance of long-term data in Crohn's disease clinical trials".
    Inflamm Bowel Dis. 2026 May 15:izag082. doi: 10.1093.
    >> Share

  61. AZULAY A, Turner D
    Multi-omics-based machine learning model predicts response and guides treatment in Crohn's disease: a case study in nutritional therapy-response to editorial.
    Inflamm Bowel Dis. 2026 May 14:izag087. doi: 10.1093.
    >> Share

  62. MEROLA E, La Rocca D, Scaglione M, Pes GM, et al
    The missing evidence: Stricturing Crohn's disease in clinical trials, a systematic review.
    Inflamm Bowel Dis. 2026 May 14:izag079. doi: 10.1093.
    >> Share


  63. Correction to: Early Top-Down Treatment With Biologics Improves the Rates of Transmural Remission in Crohn's Disease-A Risk-Adjusted Propensity Score Matched Analysis.
    Inflamm Bowel Dis. 2026 May 13:izag084. doi: 10.1093.
    >> Share

  64. ATREYA R, Kuhbacher T, Vieth M, Jefremow A, et al
    Targeting the transcription factor GATA3 by the DNAzyme formulation SB012 in patients with moderately-to-severely active ulcerative colitis: a multicenter, randomized, placebo-controlled, phase 2a induction trial.
    Inflamm Bowel Dis. 2026 May 12:izag046. doi: 10.1093.
    >> Share

  65. ATREYA R, Neurath MF
    Authors' response to letter to editor-silencing GATA3: DNAzymes enter the therapeutic landscape of ulcerative colitis.
    Inflamm Bowel Dis. 2026 May 11:izag077. doi: 10.1093.
    >> Share

  66. PORTELA F, Ministro P, de Sousa HT, Roseira J, et al
    Soluble transferrin receptor as a reliable inflammation-independent marker of iron deficiency in Crohn's disease and ulcerative colitis.
    Inflamm Bowel Dis. 2026 May 9:izag057. doi: 10.1093.
    >> Share

  67. FOULSER PFG, Martinez-Gili L, Balarajah S, Sundramoorthi R, et al
    Disease phenotype affects treatment of late-onset inflammatory bowel disease: Analysis of a large UK cohort.
    Inflamm Bowel Dis. 2026 May 8:izag072. doi: 10.1093.
    >> Share

  68. AZULAY A, Gotesdyner L, Aharoni-Frutkoff Y, Focht G, et al
    Multi-omics-based machine learning model predicts response and guides treatment in Crohn disease: a case study in nutritional therapy.
    Inflamm Bowel Dis. 2026 May 4:izag060. doi: 10.1093.
    >> Share

  69. AFZALI A, Danese S, Panaccione R, Rubin DT, et al
    Five-year efficacy and safety of guselkumab for moderately to severely active Crohn's disease: Results from the phase 2 GALAXI 1 trial.
    Inflamm Bowel Dis. 2026 May 1:izag055. doi: 10.1093.
    >> Share

  70. DE CRISTOFARO E, Zorzi F, Colella A, Basile L, et al
    Early Intestinal Ultrasound Assessment Predicts Therapy Response: An Easy Tool for Clinical Decision-Making.
    Inflamm Bowel Dis. 2026;32:938-944.
    >> Share

  71. STORDAL K, Andersen S, Marild K, Larsson V, et al
    Systematic review and meta-analysis of childhood exposure to antibiotics and the subsequent risk of IBD.
    Inflamm Bowel Dis. 2026;32:990-997.
    >> Share

    April 2026
  72. PARK SS, Kim YJ, Ahn BK
    Extraintestinal manifestations in Korean patients with inflammatory bowel disease: A nationwide population-based study from 2005 to 2017.
    Inflamm Bowel Dis. 2026 Apr 30:izag068. doi: 10.1093.
    >> Share

  73. PUCA P, Masi L, Parello S, Poscia A, et al
    OCTN1 variants shape innate immunity and predict individual response to anti-TNFalpha in ulcerative colitis patients: An exploratory study.
    Inflamm Bowel Dis. 2026 Apr 28:izag061. doi: 10.1093.
    >> Share

  74. SLEIMAN J, El Ouali S, Noor NM
    Entering a new GALAXI: The importance of long-term data in Crohn's disease clinical trials.
    Inflamm Bowel Dis. 2026 Apr 25:izag073. doi: 10.1093.
    >> Share

  75. SHEEHAN JL, Eloubeidi D, Newman KL, Johnson LA, et al
    Socioeconomic disparities in biologic persistence among patients with inflammatory bowel disease are associated with increased health care utilization.
    Inflamm Bowel Dis. 2026 Apr 25:izag062. doi: 10.1093.
    >> Share

  76. GILBOA I, Gabbai D, Segal N, Gold R, et al
    Inflammatory bowel disease and risk of perineal injury in primiparous vaginal births: a retrospective cohort study.
    Inflamm Bowel Dis. 2026 Apr 25:izag067. doi: 10.1093.
    >> Share

  77. GOYAL MK, Dutta P, Choy MC, Berinstein JA, et al
    Rethinking the dose: A Bayesian meta-analysis of infliximab intensification in acute severe ulcerative colitis.
    Inflamm Bowel Dis. 2026 Apr 24:izag042. doi: 10.1093.
    >> Share

  78. DING SS, Liu C, Zhang GQ, Ren WW, et al
    Development and validation of a predictive model for early failure of biological therapy in perianal fistulizing Crohn's disease based on three-dimensional transrectal ultrasound.
    Inflamm Bowel Dis. 2026 Apr 23:izag048. doi: 10.1093.
    >> Share


  79. Correction to: Characterization of mesocolic adipose hyperplasia in a rat 2,4,6-trinitrobenzenesulfonic acid colitis model and comparison to creeping fat in Crohn disease.
    Inflamm Bowel Dis. 2026 Apr 19:izag071. doi: 10.1093.
    >> Share

  80. AZWARD A, Ripstein G, Medawar E, Murthy S, et al
    The prevalence of abdominal computed tomography imaging findings in patients with inflammatory bowel disease who present to the emergency department: a systematic review and meta-analysis.
    Inflamm Bowel Dis. 2026 Apr 18:izag053. doi: 10.1093.
    >> Share

  81. CLEMOW DB
    Response to: The Long Game in Ulcerative Colitis: Mirikizumab's Four-Year Outcomes.
    Inflamm Bowel Dis. 2026 Apr 16:izag065. doi: 10.1093.
    >> Share

  82. BRIGGS KC, Tam A, Chaaban L, Luo A, et al
    Ustekinumab resistance in individuals with ulcerative colitis is associated with an alteration of a subset of proinflammatory mucosal regulatory T cells.
    Inflamm Bowel Dis. 2026 Apr 15:izag059. doi: 10.1093.
    >> Share

  83. RAHMAN S, Xu B, Farah M, Kwok A, et al
    Longitudinal TCR repertoires in ulcerative colitis patients show features distinguishing disease states.
    Inflamm Bowel Dis. 2026 Apr 15:izag039. doi: 10.1093.
    >> Share

  84. CHIN S, Demase K, Corte C, Wong D, et al
    Quality of healthcare delivery in inflammatory bowel disease pregnancy: a scoping review.
    Inflamm Bowel Dis. 2026 Apr 15:izag064. doi: 10.1093.
    >> Share

  85. MOHAMEDRASHED M, Yogakanthi S, Chauhan A, Lucas S, et al
    Skin-deep connections: likelihood of skin-scarring history in patients with stricturing/penetrating Crohn disease compared with patients with nonstricturing/nonpenetrating disease and non-inflammatory bowel disease controls.
    Inflamm Bowel Dis. 2026 Apr 13:izag058. doi: 10.1093.
    >> Share

  86. LE COSQUER G, Gilletta C, Kochar B, Ananthakrishnan AN, et al
    Frailty in inflammatory bowel disease: a missing link in personalized care for the aging IBD population.
    Inflamm Bowel Dis. 2026 Apr 11:izag031. doi: 10.1093.
    >> Share

  87. COSTA C, Estevinho MM
    Silencing GATA3: DNAzymes enter the therapeutic landscape of ulcerative colitis.
    Inflamm Bowel Dis. 2026 Apr 10:izag063. doi: 10.1093.
    >> Share

  88. VERLEYE LMM, Pierik MJ, de Vries AC, van Schaik FDM, et al
    Prospective real-world experience with risankizumab in difficult-to-treat Crohn's disease: results from the Dutch Initiative on Crohn and Colitis Registry.
    Inflamm Bowel Dis. 2026 Apr 4:izag045. doi: 10.1093.
    >> Share

  89. WONG ECL, Marshall JK, Ma C, Jairath V, et al
    Efficacy and safety of ulcerative colitis therapies do not differ by age: A post hoc analysis of randomized controlled trials.
    Inflamm Bowel Dis. 2026 Apr 4:izag054. doi: 10.1093.
    >> Share

  90. SINGH S, Oliver BJ, Hou JK, Lum D, et al
    Real-World Implementation of Treat to Target in Patients With IBD in a Learning Health System: An IBD Qorus Collaborative Study.
    Inflamm Bowel Dis. 2026;32:702-710.
    >> Share

  91. ARZIVIAN A, Rubin DT, Seow CH, Kerkham A, et al
    The Risk of Relapse Associated With Discontinuation of 5-Aminosalicylates in Inflammatory Bowel Diseases: A Systematic Review and Meta-Analysis.
    Inflamm Bowel Dis. 2026;32:661-676.
    >> Share

    March 2026
  92. WARD TM, Unal E, Kirschling S, Giri B, et al
    Penetrating ileocolic Crohn disease with intra-abdominal abscess: diagnose, drugs, drain, divert?
    Inflamm Bowel Dis. 2026 Mar 31:izag030. doi: 10.1093.
    >> Share

  93. RAMAKRISHNAN P, Campbell J, Moutsoglou D, Ghai M, et al
    Discordant Clostridioides difficile testing as a predictor of inflammatory bowel disease therapy escalation.
    Inflamm Bowel Dis. 2026 Mar 25:izag038. doi: 10.1093.
    >> Share

  94. FAROOQ A, Naveed M, Chowdhury R, Seminerio J, et al
    Enhancing Inflammatory Bowel Disease (IBD) competency in gastroenterology fellowship through traditional, digital, and experiential learning pathways.
    Inflamm Bowel Dis. 2026 Mar 22:izag043. doi: 10.1093.
    >> Share

  95. GHONEIM S, Dicken Q, Omede M, Harris H, et al
    Disease reprogression following surgical resection in Crohn disease.
    Inflamm Bowel Dis. 2026 Mar 19:izag035. doi: 10.1093.
    >> Share

  96. TAMURA A, Fujii T, Fujiwara S, Maeyashiki C, et al
    Efficacy and Rapid Response of Ustekinumab for Hospitalized Patients With Severe Ulcerative Colitis.
    Inflamm Bowel Dis. 2026 Mar 16:izaf326. doi: 10.1093.
    >> Share

  97. GUO Q, Wang Q, Chen J, Lu M, et al
    Impact of visceral adipose tissue and skeletal muscle on early and long-term biologic treatment failure in Crohn's disease: A multicenter retrospective cohort study.
    Inflamm Bowel Dis. 2026 Mar 16:izag023. doi: 10.1093.
    >> Share

  98. SHI H, Zhang S, Peng Y
    Letter to the editor: enhancing the robustness of early vs late switch to subcutaneous infliximab in inflammatory bowel disease (IBD): the value of propensity score analysis.
    Inflamm Bowel Dis. 2026 Mar 14:izag033. doi: 10.1093.
    >> Share

  99. BERTANI L, Ribaldone DG, Bossa F, Guerra M, et al
    Response to Letter to the Editor: "Enhancing the robustness of early vs late switch to subcutaneous infliximab in inflammatory bowel disease (IBD): the value of propensity score analysis".
    Inflamm Bowel Dis. 2026 Mar 14:izag034. doi: 10.1093.
    >> Share

  100. XIA J, Zhang Y
    A methodological concern regarding small-sample propensity score matching and overfitting in the study of postoperative biologic strategies for Crohn's disease.
    Inflamm Bowel Dis. 2026 Mar 13:izag024. doi: 10.1093.
    >> Share

  101. KAKKAR R, Byrne MF
    Artificial intelligence and the future of inflammatory bowel disease trial recruitment: from bottleneck to breakthrough.
    Inflamm Bowel Dis. 2026 Mar 13:izag036. doi: 10.1093.
    >> Share

  102. NARDONE OM, Calabrese G, Ford AC, Castiglione F, et al
    Prevalence of disability in inflammatory bowel disease: a systematic review and meta-analysis.
    Inflamm Bowel Dis. 2026 Mar 5:izag022. doi: 10.1093.
    >> Share

  103. QURAISHI MN, Alahmad MA, Swaid TK, Facciorusso A, et al
    Incidence of acne in patients with inflammatory bowel disease treated with Janus kinase inhibitors: a systematic review and meta-analysis.
    Inflamm Bowel Dis. 2026 Mar 5:izag032. doi: 10.1093.
    >> Share

  104. FENG T, Qiu Y, Chen B, Huang X, et al
    Mesenchymal stem cell-derived exosomes derived from induced pluripotent stem cells ameliorate inflammation and promote mucosal healing via miR-34a-5p in Crohn disease.
    Inflamm Bowel Dis. 2026 Mar 3:izag014. doi: 10.1093.
    >> Share

  105. SANDS BE, Clemow DB, D'Haens G, Irving PM, et al
    Mirikizumab four-year sustained and durable efficacy and safety in ulcerative colitis: Final findings from the LUCENT-3 open-label extension study.
    Inflamm Bowel Dis. 2026 Mar 2:izag007. doi: 10.1093.
    >> Share

  106. MUNERA-RODRIGUEZ AM, Leiva-Castro C, Reina-Perez I, Benitez-Marquez JM, et al
    The Role of Autophagy in Inflammatory Diseases: Challenges and Therapeutic Potential.
    Inflamm Bowel Dis. 2026;32:562-571.
    >> Share

  107. TSILIMPOTIS D, Kyriakou G, Biedermann L, Vavricka S, et al
    Cutaneous Manifestations and Dermatologic Adverse Events in IBD: A Clinical Update.
    Inflamm Bowel Dis. 2026;32:542-561.
    >> Share

    February 2026
  108. GEICULESCU I, Niklinska-Schirtz BJ, Munasinghe S, Rajendra C, et al
    Unique challenges faced by tweens and teens with inflammatory bowel disease: a global perspective.
    Inflamm Bowel Dis. 2026 Feb 28:izag010. doi: 10.1093.
    >> Share

  109. ROBBERTZ A, Hommel K, Keefer L, Reed B, et al
    Model psychosocial care for youth with inflammatory bowel disease.
    Inflamm Bowel Dis. 2026 Feb 28:izag005. doi: 10.1093.
    >> Share

  110. HARPAZ N, Odze RD
    Updated pathologic classification of inflammatory bowel disease-associated colorectal dysplasia: A guide for clinicians.
    Inflamm Bowel Dis. 2026 Feb 27:izag011. doi: 10.1093.
    >> Share

  111. NAPOLITANO D, Bozzetti M, Vanzi V, Lo Cascio A, et al
    Bowel urgency in inflammatory bowel disease: A concept analysis.
    Inflamm Bowel Dis. 2026 Feb 25:izag018. doi: 10.1093.
    >> Share

  112. PAL P, Mateen MA, Sekaran A, Naaz SM, et al
    Comparing diagnostic accuracy of transperineal ultrasound using microconvex probe versus conventional linear probe to predict rectal histoendoscopic activity in ulcerative colitis: a paired prospective, head-to-head comparative study.
    Inflamm Bowel Dis. 2026 Feb 25:izag016. doi: 10.1093.
    >> Share

  113. WANCHAITANAWONG W, Lohsiriwat V, Srisajjakul S, Salaemae M, et al
    Clinical characteristics of isolated perianal Crohn's disease and validation of the TOpClass criteria: a retrospective cohort pilot study.
    Inflamm Bowel Dis. 2026 Feb 20:izag028. doi: 10.1093.
    >> Share

  114. ZHANG C, Li Y
    Reply: "A methodological concern regarding small-sample propensity score matching and overfitting in the study of postoperative biologic strategies for Crohn's disease".
    Inflamm Bowel Dis. 2026 Feb 19:izag025. doi: 10.1093.
    >> Share

  115. NOVIELLO D, Caprioli F
    The long game in ulcerative colitis: mirikizumab's four-year outcomes.
    Inflamm Bowel Dis. 2026 Feb 19:izag020. doi: 10.1093.
    >> Share

  116. CLUA L, Suau R, Guasch M, Monfort-Ferre D, et al
    Characterization of mesocolic adipose hyperplasia in a rat 2,4,6-trinitrobenzenesulfonic acid colitis model and comparison to creeping fat in Crohn disease.
    Inflamm Bowel Dis. 2026 Feb 18:izaf328. doi: 10.1093.
    >> Share

  117. GUPTA A, Ungaro RC, Steinlauf A, Colombel JF, et al
    Artificial intelligence enhances screening efficiency for inflammatory bowel disease clinical trials: a prospective study.
    Inflamm Bowel Dis. 2026 Feb 18:izag021. doi: 10.1093.
    >> Share

  118. LIU X, Gao JB, Li WX, Xu CY, et al
    Electroacupuncture at Baliao Points Alleviates Ulcerative Colitis via alpha7nAChR-Mediated Macrophage Polarization and Gut Microbiota Modulation.
    Inflamm Bowel Dis. 2026 Feb 17:izaf321. doi: 10.1093.
    >> Share

  119. ORTOFT F, Nissen MJ, Kjeldsen J, Steenholdt C, et al
    Acute severe ulcerative colitis without systemic toxicity: A retrospective multicenter cohort study suggesting refining the definition of acute severe ulcerative colitis.
    Inflamm Bowel Dis. 2026 Feb 12:izaf323. doi: 10.1093.
    >> Share

  120. DELL'ERA A, Antonelli E, Fousekis FS, Katsanos KH, et al
    Persistent Abdominal Pain in Patients with Inactive Inflammatory Bowel Disease: A Clinical Conundrum.
    Inflamm Bowel Dis. 2026 Feb 12:izaf327. doi: 10.1093.
    >> Share

  121. RUBIN DT, Danese S, Nakase H, Ungaro RC, et al
    Integrated long-term safety of 10-year ozanimod treatment: results from clinical trials in patients with moderate-to-severe ulcerative colitis or relapsing multiple sclerosis.
    Inflamm Bowel Dis. 2026 Feb 12:izaf319. doi: 10.1093.
    >> Share

  122. LI DK, Chaar A, Arabi T, Quraishi MN, et al
    Advanced therapies for inflammatory bowel disease associated with primary sclerosing cholangitis: a systematic review and meta-analysis.
    Inflamm Bowel Dis. 2026 Feb 12:izag001. doi: 10.1093.
    >> Share

  123. COLWILL M, Patel K, Sebastian S, Din S, et al
    Nomenclature of therapies in inflammatory bowel disease: A journey through time and terminology.
    Inflamm Bowel Dis. 2026 Feb 11:izaf334. doi: 10.1093.
    >> Share

  124. RICCIUTO A, Turinsky AL, Griffiths AM, Mack DR, et al
    Primary infliximab failure in pediatric colonic inflammatory bowel disease: Development of a proteomics predictive model using a prospective Canadian cohort.
    Inflamm Bowel Dis. 2026 Feb 11:izaf329. doi: 10.1093.
    >> Share

  125. TAKENAKA K, Kawamoto A, Hibiya S, Tamura A, et al
    Stricture dynamics and prognosis during biologic therapy in ileal Crohn's disease: a real-world cohort.
    Inflamm Bowel Dis. 2026 Feb 10:izag012. doi: 10.1093.
    >> Share

  126. SOLITANO V, Peyrin-Biroulet L, Vermeire S, Dubinsky MC, et al
    Immunometabolism as a New Bimodal Therapeutic Concept in Inflammatory Bowel Disease and Immune-Mediated Inflammatory Disorders.
    Inflamm Bowel Dis. 2026 Feb 10:izaf315. doi: 10.1093.
    >> Share

  127. DUBINSKY MC, Chaparro M, Irving PM, Hur P, et al
    Rapid symptomatic improvement with etrasimod in ulcerative colitis: a post-hoc analysis of the ELEVATE UC program.
    Inflamm Bowel Dis. 2026 Feb 8:izaf333. doi: 10.1093.
    >> Share

  128. PATEL PV, Zuniga DJ, Goyal A, Bensen R, et al
    Integrating intestinal ultrasound into routine clinical care improves prediction of biochemical disease activity in pediatric inflammatory bowel disease.
    Inflamm Bowel Dis. 2026 Feb 6:izaf337. doi: 10.1093.
    >> Share

  129. GROS B, Orti Cuerva M, Valenzuela Garcia MA, Valdivia Krag C, et al
    Dynamic changes in clinical response to corticosteroids in ulcerative colitis.
    Inflamm Bowel Dis. 2026 Feb 5:izag002. doi: 10.1093.
    >> Share

  130. TOME J, Jin MF, Williams T, Tariq R, et al
    Clinical outcomes in pregnancy after ileal pouch-anal anastomosis for ulcerative colitis.
    Inflamm Bowel Dis. 2026 Feb 2:izag004. doi: 10.1093.
    >> Share

  131. PAL P
    Steroid response in ulcerative colitis is not binary: learning from dynamic trajectories.
    Inflamm Bowel Dis. 2026 Feb 2:izag009. doi: 10.1093.
    >> Share

  132. SHIMODAIRA Y, Ohkubo R, Iijima K
    Repeated Administration of Carotegrast Methyl Maintained Clinical Remission With Difficult-to-Treat Ulcerative Colitis.
    Inflamm Bowel Dis. 2026;32:418-419.
    >> Share

  133. ARRAS W, Oosterlinck B, Gassman J, De Man JG, et al
    Clinical Significance of Mucin Signatures in Inflammatory Bowel Diseases: A Systematic Review of Their Expression Patterns, Polymorphisms, and Post-translational Modifications.
    Inflamm Bowel Dis. 2026;32:375-389.
    >> Share

  134. FUNG ICN, Koelink PJ, Mulders LGM, Admiraal I, et al
    Mucosal B Cell Expansion and Maturation Contribute to Colitis Pathogenesis.
    Inflamm Bowel Dis. 2026;32:290-302.
    >> Share

  135. VALDISERRA G, Fantini MC, Favale A, Antonioli L, et al
    The Importance of Treatment Timing and Positioning in IBD.
    Inflamm Bowel Dis. 2026;32:401-403.
    >> Share

  136. BERTIN L, Savarino EV
    Bridging the Gap: From Clinic to Home in IBD Monitoring.
    Inflamm Bowel Dis. 2026;32:404-405.
    >> Share

  137. SCHUURMAN GS, Tiel Groenestege W, Hirdes MMC, Fidder HH, et al
    Implementation of a Capillary Blood Self-Sampling Technique at Home for Monitoring of Patients With IBD.
    Inflamm Bowel Dis. 2026;32:282-289.
    >> Share

    January 2026
  138. BOUTE EH, Gianolio L, Mahmmod S, Pochesci S, et al
    Persistence and safety of subcutaneous infliximab up to 1 year after switching from intravenous infliximab in pediatric inflammatory bowel disease: a multicenter real-world cohort study.
    Inflamm Bowel Dis. 2026 Jan 31:izaf335. doi: 10.1093.
    >> Share

  139. GOODRICH HWF, Saeed F, Dharmadhikari ND, Moran M, et al
    Frequency of computed tomography scans in Crohn's disease patients in the emergency department.
    Inflamm Bowel Dis. 2026 Jan 31:izag008. doi: 10.1093.
    >> Share

  140. AR E, Solomonidou I, Lenzen H, Wiestler M, et al
    Long-term clinical and endoscopic outcomes of ulcerative colitis after liver transplantation: a multicenter cohort study on the use and safety of advanced therapies.
    Inflamm Bowel Dis. 2026 Jan 30:izaf330. doi: 10.1093.
    >> Share

  141. GILLILAND A, Chen Y, Ng I, Han X, et al
    Biopsy-derived colonoid air-liquid interface monolayers reveal persistent mucosal defects in ulcerative colitis patients.
    Inflamm Bowel Dis. 2026 Jan 27:izaf318. doi: 10.1093.
    >> Share

  142. SAAGER ES, Lutter L, Mahmmod N, Delemarre EM, et al
    Distinct Effects of Autologous Hematopoietic Stem Cell Transplantation on T Cell Composition and Profile in Refractory Crohn's Disease.
    Inflamm Bowel Dis. 2026 Jan 26:izaf331. doi: 10.1093.
    >> Share

  143. YOUN J, Nielsen J, Sorensen E, Wod M, et al
    The Prevalence of Chronic Opioid Use in Patients With Inflammatory Bowel Disease: A Nationwide Danish Register-Based Study Over a 25-Year Period of Time.
    Inflamm Bowel Dis. 2026 Jan 20:izaf308. doi: 10.1093.
    >> Share

  144. KIM GH, Kim J, Ahn JY, Park SH, et al
    Endoscopic and pathologic findings of esophagogastroduodenal involvement in Crohn disease in Korea: a prospective single-center cohort study.
    Inflamm Bowel Dis. 2026 Jan 20:izaf320. doi: 10.1093.
    >> Share

  145. GAN X, Zhang Y, Zhang Y, Ye Z, et al
    Plasma Proteomics for Risk Prediction and Therapeutic Target Discovery in Crohn's Disease and Ulcerative Colitis.
    Inflamm Bowel Dis. 2026 Jan 16:izaf325. doi: 10.1093.
    >> Share

  146. JONES ASK, Seaton N, Harding S, Duff A, et al
    A Real-World Longitudinal Case-Study Implementing Digital Screening and Treatment for Distress in Inflammatory Bowel Disease: The COMPASS-IBD Patient Journey.
    Inflamm Bowel Dis. 2026 Jan 13:izaf259. doi: 10.1093.
    >> Share

  147. VERBURGT CM, Dunn KA, Bielawski JP, Otley AR, et al
    Timing is Everything: Lessons Learned for Building Microbiome-Based Models in Pediatric Crohn's Disease.
    Inflamm Bowel Dis. 2026 Jan 11:izaf313. doi: 10.1093.
    >> Share

  148. HUANG YJ, Lin JA, Chen WM, Shia BC, et al
    Low-Dose Aspirin and the Prevention of Colorectal Cancer in Inflammatory Bowel Disease: A Nationwide Cohort Study.
    Inflamm Bowel Dis. 2026 Jan 9:izaf304. doi: 10.1093.
    >> Share

  149. TURNER D, Lomax KG, Veereman G, Griffiths AM, et al
    Efficacy, Safety, and Pharmacokinetics of Golimumab in Children with Moderately-To-Severely Active Ulcerative Colitis: Results from the PURSUIT 2 Study.
    Inflamm Bowel Dis. 2026 Jan 8:izaf322. doi: 10.1093.
    >> Share

  150. ANDERSON SR, Osman A, Zamani M, Alayo Q, et al
    Systematic Review With Meta-Analysis: Safety and Effectiveness of Combining Biologics and Small Molecules in Inflammatory Bowel Diseases.
    Inflamm Bowel Dis. 2026;32:39-52.
    >> Share

    December 2025
  151. STEPHENS IJB, Murphy B, Burns L, Hannan E, et al
    CRUCIAL Insights From a Decade Long Retrospective National Audit of Total Abdominal Colectomy Outcomes for Ulcerative Colitis.
    Inflamm Bowel Dis. 2025 Dec 28:izaf314. doi: 10.1093.
    >> Share

  152. VIOLANTE T, Ferrari D, Rottoli M, Novelli M, et al
    Surgical management of small bowel adenocarcinoma in Crohn disease: a multicenter retrospective analysis.
    Inflamm Bowel Dis. 2025 Dec 28:izaf312. doi: 10.1093.
    >> Share

  153. MASSIRONI S, Danese S
    Unmasking a New Trauma in Inflammatory Bowel Disease: Unequal Psychological Burden.
    Inflamm Bowel Dis. 2025 Dec 25:izaf307. doi: 10.1093.
    >> Share

  154. ST-PIERRE J, Kellar A, George T, Miyatani Y, et al
    The Chicago Mesenteric Fat Index: A Novel Metric for Point-of-Care Intestinal Ultrasound Evaluation of Mesenteric Fat Wrapping in Crohn's Disease.
    Inflamm Bowel Dis. 2025 Dec 24:izaf268. doi: 10.1093.
    >> Share

  155. GUO JY, Wu MC, Wang YH, Lin CC, et al
    Tonsillectomy and the Risk of Inflammatory Bowel Disease: A Retrospective Cohort Study Using Real-World US Data.
    Inflamm Bowel Dis. 2025 Dec 23:izaf306. doi: 10.1093.
    >> Share

  156. LI C, Ciorba MA
    Hidden Clues in the Epithelial Brush Border: A New Prognostic Marker for Pediatric Crohn's Disease.
    Inflamm Bowel Dis. 2025 Dec 22:izaf316. doi: 10.1093.
    >> Share

  157. ZHANG P, Zhang C, Liu Z, Chen L, et al
    Risk-Stratified Biologic Efficacy in Ulcerative Colitis: A Multicenter Machine Learning Study.
    Inflamm Bowel Dis. 2025 Dec 22:izaf272. doi: 10.1093.
    >> Share

  158. GISBERT JP, Chaparro M
    Janus Kinase Inhibitors for Inflammatory Bowel Disease: Concise Questions and Answers on Their Use in Clinical Practice.
    Inflamm Bowel Dis. 2025 Dec 22:izaf273. doi: 10.1093.
    >> Share

  159. SALEM G, Bouvette CA, Hernandez-Rocha C, Hernandez Dominguez O, et al
    Disease Outcomes After Segmental Resection of Colonic Crohn's Disease: A Retrospective Multicenter Study.
    Inflamm Bowel Dis. 2025 Dec 22:izaf252. doi: 10.1093.
    >> Share

  160. GORDON ES, Goc J, Grier A, Thomas C, et al
    Altered Gut Microbiota in Pediatric Quiescent Crohn's Disease Patients with Iron Deficiency Anemia.
    Inflamm Bowel Dis. 2025 Dec 22:izaf295. doi: 10.1093.
    >> Share

  161. CLAYTOR JD, Rajauria P, Peraza J, Colombel JF, et al
    Statin Use is Associated With Lower Odds of IBD-Related Surgery Among Patients With Moderate-to-Severe Inflammatory Bowel Disease.
    Inflamm Bowel Dis. 2025 Dec 19:izaf227. doi: 10.1093.
    >> Share

  162. SUCHAN A, Chaaban L, Kobeissi L, Hassan BA, et al
    Characterizing Healthcare Disparities, Utilization, and Trends of Inflammatory Bowel Disease in Transgender and Nonbinary Patients: A Population-Based Study.
    Inflamm Bowel Dis. 2025 Dec 16:izaf266. doi: 10.1093.
    >> Share

  163. RUIZ MA, Kaiser Junior RL, Piron-Ruiz G
    Sustained Clinical Remission Following a Second Autologous Hematopoietic Stem Cell Transplantation for Refractory Crohn Disease.
    Inflamm Bowel Dis. 2025 Dec 16:izaf292. doi: 10.1093.
    >> Share

  164. OSOOLI M, Voghera S, Bruze G, Nordenvall C, et al
    Trends in Use of Prescribed Opioids in Incident and Prevalent Patients With Ulcerative Colitis: A Nationwide Study in Sweden.
    Inflamm Bowel Dis. 2025 Dec 11:izaf278. doi: 10.1093.
    >> Share

  165. MARCHESE SH, Raza HS, Naffouj S, Mutlu E, et al
    Black and Latino/a Participants With Inflammatory Bowel Disease Are More Likely to Be at Risk for Post-Traumatic Stress Than Their White Counterparts: A Matched Control Comparison Study.
    Inflamm Bowel Dis. 2025 Dec 10:izaf290. doi: 10.1093.
    >> Share

  166. SYED S, Moayyedi P, Kao D, Patel J, et al
    Combination Therapy With Fecal Microbiota Transplantation and Vedolizumab for Induction of Remission in Ulcerative Colitis: An Open-Label Pilot Study.
    Inflamm Bowel Dis. 2025 Dec 10:izaf284. doi: 10.1093.
    >> Share

  167. DESAI A, Habib H, Khataniar H, Farraye FA, et al
    Real-World Outcomes of Glucagon-Like Peptide-1 Receptor Agonist Therapy in Obese Patients With Ulcerative Colitis and IPAA With a History of Pouchitis.
    Inflamm Bowel Dis. 2025 Dec 9:izaf301. doi: 10.1093.
    >> Share

  168. KAIEDA Y, Sugimoto S, Suzuki T, Matsumoto S, et al
    Characterization of Computed Tomography Colonography Findings of Ulcerative Colitis-Associated Neoplasia.
    Inflamm Bowel Dis. 2025 Dec 9:izaf303. doi: 10.1093.
    >> Share

  169. RAISANEN L, Lang R, Couper M, Lewindon P, et al
    Bowel Wall Thickness Cutoff Value for Assessing Inflammatory Bowel Disease Activity Using Intestinal Ultrasonography in Children.
    Inflamm Bowel Dis. 2025 Dec 8:izaf298. doi: 10.1093.
    >> Share

  170. NISHIDA Y, Hosomi S, Fujimoto K, Kobayashi Y, et al
    Thromboembolic Risk in Ulcerative Colitis Patients on Advanced Therapy: A Real-World Data Analysis.
    Inflamm Bowel Dis. 2025 Dec 8:izaf302. doi: 10.1093.
    >> Share

  171. BERTANI L, Ribaldone DG, Bossa F, Guerra M, et al
    Reply: "Early Switching to Subcutaneous Infliximab as a Pragmatic Strategy for Optimized Inflammatory Bowel Disease Care".
    Inflamm Bowel Dis. 2025 Dec 5:izaf264. doi: 10.1093.
    >> Share

  172. TOME J, Alsakarneh S, Hashash JG, Farraye FA, et al
    Evaluating Choice of Biologics for Isolated Small-Bowel Crohn's Disease.
    Inflamm Bowel Dis. 2025 Dec 3:izaf294. doi: 10.1093.
    >> Share

  173. GU P, Karime C, Fleshner P, Falloon K, et al
    Intestinal Ultrasound for Monitoring Postoperative Crohn's Disease: A Review and Visual Atlas.
    Inflamm Bowel Dis. 2025 Dec 3:izaf248. doi: 10.1093.
    >> Share

  174. GIDDINGS HL, Ng KS, Solomon MJ, Arzivian A, et al
    Low Rates of Surgical Recurrence Following Ileocolic Resections for Crohn's Disease in the Biologic Era.
    Inflamm Bowel Dis. 2025 Dec 2:izaf244. doi: 10.1093.
    >> Share

  175. YAN K, Vuyyuru SK, Taylor A, Figueredo G, et al
    Clinical Response for 12 Months or More to the First Advanced Therapy is Associated with a Significant Decrease in the Long-Term Risk of Hospitalization: A Nation-Wide Analysis of Patients From the UK Inflammatory Bowel Disease (IBD) BioResource.
    Inflamm Bowel Dis. 2025 Dec 2:izaf276. doi: 10.1093.
    >> Share

  176. HOU G, Lee A, Golob JL, Grasberger H, et al
    IL-15 Promotes Inflammatory Th17 Cells in the Intestine.
    Inflamm Bowel Dis. 2025;31:3417-3428.
    >> Share

  177. BERLIN P, Fischer A, Bergmann-Ewert W, Kordt M, et al
    Perioperative anti-alpha4beta7 Integrin Blockade Alters Wound Cell Infiltrate but Not the Functional Outcome of Ileocecal Anastomoses in Mice With Crohn's-like Ileitis.
    Inflamm Bowel Dis. 2025;31:3385-3397.
    >> Share

  178. FIRMBACH D, Lang-Schwarz C, Rubio CA, Hartmann A, et al
    Quantitative Analysis of Distinct Colon Crypt Branching Modes Using Interpretable Machine Learning.
    Inflamm Bowel Dis. 2025;31:3407-3416.
    >> Share

  179. BERTANI L, Ribaldone DG, Bossa F, Guerra M, et al
    When to Switch to Subcutaneous Infliximab? The RE-WATCH Multicenter Study.
    Inflamm Bowel Dis. 2025;31:3363-3369.
    >> Share

  180. GOLDMAN A, Idan L, Ben-Horin S, Kopylov U, et al
    Computer-Aided Detection Colonoscopy for Surveillance in IBD Patients: Insights from a Single-Center Experience.
    Inflamm Bowel Dis. 2025;31:3379-3384.
    >> Share

    November 2025
  181. ZHANG C, Wu J, Liu Z, Luo L, et al
    Efficacy of Consistency Versus Switching of Biologics for Prevention of Postoperative Recurrence in Crohn's Disease: A Multicenter Real-World Retrospective Study.
    Inflamm Bowel Dis. 2025 Nov 29:izaf299. doi: 10.1093.
    >> Share

  182. MO X, Mo H, Wang C, Pu Q, et al
    Shared Genetic Basis Between Systemic Lupus Erythematosus and Inflammatory Bowel Disease in East Asian Ancestry: A Genome-Wide Cross-trait Analysis.
    Inflamm Bowel Dis. 2025 Nov 28:izaf297. doi: 10.1093.
    >> Share

  183. HABERMAN Y, Braun T, Karns R, Bartel CA, et al
    Short Ileal Microvillus Length Phenotype Associates with Progression from Inflammatory to Complicated Disease Behavior in Pediatric Crohn's Disease.
    Inflamm Bowel Dis. 2025 Nov 28:izaf288. doi: 10.1093.
    >> Share

  184. WONG ECL, Dulai PS, Marshall JK, Jairath V, et al
    Serum and Histologic Eosinophilia as a Predictive Biomarker of Response to Mirikizumab in Ulcerative Colitis.
    Inflamm Bowel Dis. 2025 Nov 24:izaf267. doi: 10.1093.
    >> Share

  185. FAYE AS, Rubin DT, Siegel CA, Long MD, et al
    Safety and Efficacy of Ozanimod in Patients With Moderately to Severely Active Ulcerative Colitis Stratified by Age.
    Inflamm Bowel Dis. 2025 Nov 22:izaf258. doi: 10.1093.
    >> Share

  186. KAKUTA Y, Li D, Debbas P, Okazaki S, et al
    Differences in Anti-alphavbeta6 Integrin Antibody Expression between U.S. and Japanese Cohorts in Inflammatory Bowel Disease.
    Inflamm Bowel Dis. 2025 Nov 22:izaf246. doi: 10.1093.
    >> Share

  187. VEMULAKONDA P, Stark VS, Deogaonkar A, Borum ML, et al
    Artificial Intelligence as a New Player in Dietary Management of Inflammatory Bowel Disease.
    Inflamm Bowel Dis. 2025 Nov 22:izaf286. doi: 10.1093.
    >> Share

  188. SHOJAEI JESHVAGHANI Z, Argmann C, de Vries MH, van Es JH, et al
    A Collection of Patient-Derived Intestinal Organoid Lines Reveals Epithelial Phenotypes Associated with Genetic Drivers of Pediatric Inflammatory Bowel Disease.
    Inflamm Bowel Dis. 2025 Nov 22:izaf296. doi: 10.1093.
    >> Share

  189. GODDARD Q, Coward S, Seow CH, Bertazzon S, et al
    Association of Geography With Screening and Development of Cervical Neoplasia in Those With Inflammatory Bowel Disease.
    Inflamm Bowel Dis. 2025 Nov 20:izaf249. doi: 10.1093.
    >> Share

  190. BANIQUED MR, Greb AC, Shah ND, Parian AA, et al
    Nationwide Analysis of Food Insecurity among Individuals with Inflammatory Bowel Disease in the United States.
    Inflamm Bowel Dis. 2025 Nov 19:izaf289. doi: 10.1093.
    >> Share

  191. KURIAKOSE AC, Abraham D, Benny B, Govindan K, et al
    Exploring Gut Mucosal Microbiota to Distinguish Crohn's Disease from Intestinal Tuberculosis.
    Inflamm Bowel Dis. 2025 Nov 19:izaf285. doi: 10.1093.
    >> Share

  192. LI L, Yuan X
    Early-Life Body Mass Index and Inflammatory Bowel Disease Risk: A Scandinavian Birth Cohort Study.
    Inflamm Bowel Dis. 2025 Nov 18:izaf260. doi: 10.1093.
    >> Share

  193. COMER-CALDER H, Morad HOJ
    The Paradox of NET Involvement in the Pathogenesis of Inflammatory Bowel Disease.
    Inflamm Bowel Dis. 2025 Nov 18:izaf283. doi: 10.1093.
    >> Share

  194. JIMBO K, Arai N, Suzuki M, Suzuki E, et al
    Real-World Effectiveness of and Optimization Strategies for Mirikizumab in Pediatric Ulcerative Colitis: A Prospective, Observational Study.
    Inflamm Bowel Dis. 2025 Nov 18:izaf291. doi: 10.1093.
    >> Share

  195. DALAL RS, Zeiss KE, Nielsen J, Madsen SD, et al
    Association of Spondyloarthritis With Chronic Opioid Use in Inflammatory Bowel Disease: A Nationwide Danish Cohort Study.
    Inflamm Bowel Dis. 2025 Nov 14:izaf281. doi: 10.1093.
    >> Share

  196. WANG D, Zhu D, Zhao X, Wang J, et al
    Fibroblast-Mediated MMP2 Contribution to Nonresponse in Anti-TNFalpha Therapy for Crohn's Disease.
    Inflamm Bowel Dis. 2025 Nov 14:izaf263. doi: 10.1093.
    >> Share

  197. OLIVEIRA R, Roseira J
    Breaking Free from Corticosteroids in Crohn's Disease.
    Inflamm Bowel Dis. 2025 Nov 13:izaf274. doi: 10.1093.
    >> Share

  198. ANJIE SI, D'Haens GR, Baert F, Bossuyt P, et al
    Higher Vedolizumab Clearance Associates with Poor Therapeutic Outcomes during Intravenous Vedolizumab Maintenance Therapy in Crohn's Disease.
    Inflamm Bowel Dis. 2025 Nov 10:izaf255. doi: 10.1093.
    >> Share

  199. QURAISHI MN, Ahmad MA, Ali NA, Church RD, et al
    Initial Management of Intra-Abdominal Abscess in Crohn's Disease: A Systematic Review and Meta-Analysis.
    Inflamm Bowel Dis. 2025 Nov 10:izaf242. doi: 10.1093.
    >> Share

  200. KELLAR A, George T, Dolinger MT, Smyth M, et al
    Reliability and Validity of Mesenteric Fat Assessment by Intestinal Ultrasound in Pediatric Crohn's Disease Using the Chicago Mesenteric Fat Index.
    Inflamm Bowel Dis. 2025 Nov 6:izaf238. doi: 10.1093.
    >> Share

  201. YANG X, Yang S
    Comment on "The Severity of Rectal Inflammation and Pouch Surgery Outcome in Patients with Ulcerative Colitis: A Retrospective Cohort Study".
    Inflamm Bowel Dis. 2025 Nov 6:izaf253. doi: 10.1093.
    >> Share

  202. JUN YK, Ji E, Choi Y, Shin CM, et al
    Trends and Impacts of Advanced Therapy on Chronic Opioid Use in Asian Patients with Inflammatory Bowel Disease.
    Inflamm Bowel Dis. 2025 Nov 4:izaf221. doi: 10.1093.
    >> Share

  203. SELVAKUMAR B, Samsudin R
    Intestinal Barrier Dysfunction in Inflammatory Bowel Disease: Pathophysiology to Precision Therapeutics.
    Inflamm Bowel Dis. 2025 Nov 4:izaf225. doi: 10.1093.
    >> Share

  204. DUBINSKY MC, D'Haens G, Dewit O, Juillerat P, et al
    Efficacy and Safety with Upadacitinib by Baseline Corticosteroid Use in Patients with Moderately to Severely Active Crohn's Disease.
    Inflamm Bowel Dis. 2025 Nov 4:izaf250. doi: 10.1093.
    >> Share

  205. KIM K, Ye BD
    Early Switching to Subcutaneous Infliximab as a Pragmatic Strategy for Optimized Inflammatory Bowel Disease Care.
    Inflamm Bowel Dis. 2025 Nov 4:izaf243. doi: 10.1093.
    >> Share

  206. RUBIN DT, Reinisch W, Narula N, Colucci DR, et al
    Machine Learning Models for the Assessment of the Mayo Endoscopic Score in Ulcerative Colitis Trial Endpoints: A Systematic Review.
    Inflamm Bowel Dis. 2025 Nov 4:izaf232. doi: 10.1093.
    >> Share


  207. Correction to: Efficacy and Safety of Upadacitinib in a Case of Pediatric Acute Severe Ulcerative Colitis and Immune Thrombocytopenia.
    Inflamm Bowel Dis. 2025 Nov 2:izaf245. doi: 10.1093.
    >> Share

  208. CAO X, Zeng Z, Cao X, He Y, et al
    Generation and Phenotypic Analysis of the IL-10RAR104W/R104W Mouse Model.
    Inflamm Bowel Dis. 2025;31:3149-3159.
    >> Share

  209. CAMARA H, Vicaut E, Caron B, Honap S, et al
    Bayesian Statistics: A Narrative Review on Application in Inflammatory Bowel Diseases.
    Inflamm Bowel Dis. 2025;31:3183-3193.
    >> Share

  210. TSE CS, Hunt MG, Lewis JD, Ostrov A, et al
    Preferences, Acceptability, and Utilization of Multimodal Self-Help Interventions in Adults With Inflammatory Bowel Diseases: A Pragmatic Multicenter Study With Patients and Clinicians.
    Inflamm Bowel Dis. 2025;31:3132-3141.
    >> Share

  211. TER AVEST MM, Huijbers MJ, Horjus CS, Romkens TEH, et al
    Group-Delivered Mindfulness-Based Cognitive Therapy to Reduce Psychological Distress and Improve Sleep in Patients With Inflammatory Bowel Diseases: A Multicenter Randomized Controlled Trial (MindIBD).
    Inflamm Bowel Dis. 2025;31:3021-3032.
    >> Share

  212. ZITTAN E, Levy M, Vered S, Steinhart AH, et al
    Construct Validity of the Toronto IBD Global Endoscopic Reporting Score Compared to Inflammatory Biomarkers After 12-Month Follow-Up.
    Inflamm Bowel Dis. 2025;31:3120-3131.
    >> Share

  213. LAW CCY, Sheskier R, Viera-Feliciano N, Delgado-Nieves A, et al
    Evaluation and Management of Glucocorticoid-Induced Adrenal Insufficiency in IBD: An Expert Opinion.
    Inflamm Bowel Dis. 2025;31:3077-3092.
    >> Share

  214. D'HOOGHE AT, Poulsen GJ, Sorensen CN, Tandon P, et al
    Unraveling Genetic Versus Environmental Factors Determining Disease Course in Inflammatory Bowel Diseases: A Population-Based Cohort Study in First- and Second-Generation Immigrants.
    Inflamm Bowel Dis. 2025;31:2955-2964.
    >> Share

    October 2025
  215. CEJUDO-GARCES A, Carda-Dieguez M, Navarro-Vicente F, Calatayud S, et al
    Characterization of Intestinal Mycobiome in Surgical Resections from Inflammatory Bowel Disease Patients: A Deeper Analysis in Complicated Crohn's Disease Phenotypes.
    Inflamm Bowel Dis. 2025 Oct 30:izaf178. doi: 10.1093.
    >> Share

  216. LIU K, Wang J, Li J
    Comments on the Study of Colonic Taste Receptors, Fecal Amino Acids, and Ulcerative Colitis: Methodological Considerations for Enhanced Generalizability.
    Inflamm Bowel Dis. 2025 Oct 29:izaf237. doi: 10.1093.
    >> Share

  217. THOBANI H, Ehsan AN, Moturu A, Nepomuceno HML, et al
    Outcomes of Pouch Creation in 2-Stage Versus 3-Stage Procedures for Pediatric Ulcerative Colitis: A Propensity Score Matched Comparative Analysis.
    Inflamm Bowel Dis. 2025 Oct 23:izaf241. doi: 10.1093.
    >> Share

  218. LARIMORE CF, Albaek Jacobsen H, Graugaard C, Andersson M, et al
    Sexual Health Challenges in Individuals With and Without Inflammatory Bowel Disease: A Population-Based Study in Denmark.
    Inflamm Bowel Dis. 2025 Oct 23:izaf234. doi: 10.1093.
    >> Share

  219. DI PETRILLO A, Fais A, Raho N, Era B, et al
    Xanthine Oxidase-Dependent Activation of NLPR3 Inflammasome in Epithelial Cells Sustains Inflammation in Inflammatory Bowel Disease.
    Inflamm Bowel Dis. 2025 Oct 22:izaf231. doi: 10.1093.
    >> Share

  220. HENDERSON P, Gerasimidis K, Russell RK, Chalmers I, et al
    Incidence and Natural History of Very Early-Onset Inflammatory Bowel Disease in Scotland: National and Regional Cohort Studies.
    Inflamm Bowel Dis. 2025 Oct 22:izaf229. doi: 10.1093.
    >> Share

  221. KEETHA RAO N, Ghodous S, Gurram A, Khorasani M, et al
    Prevalence and Associated Factors of Nonalcoholic Fatty Liver Disease in Patients with Inflammatory Bowel Disease: An Updated Global Systematic Review and Meta-Analysis of over 1.5 Million Individuals.
    Inflamm Bowel Dis. 2025 Oct 17:izaf226. doi: 10.1093.
    >> Share

  222. KHAN N, Sundararajan R, Patel D, Patel M, et al
    Comparative Risk of Serious Infections Associated With Treatment of Inflammatory Bowel Disease.
    Inflamm Bowel Dis. 2025 Oct 16:izaf218. doi: 10.1093.
    >> Share

  223. YANAI H, Achler T, Ben-Tov A, Sharar Fischler T, et al
    Incidence of Ocular Manifestation After Adult-Onset Inflammatory Bowel Disease: A 20-Year Population-Based Cohort Study.
    Inflamm Bowel Dis. 2025 Oct 15:izaf213. doi: 10.1093.
    >> Share

  224. LIU Y, Sha S, Ran Q, Shi H, et al
    Response to Letter to the Editor regarding "The Correlation between Fecal Amino Acids, Colonic Mucosal Taste Receptors, and Clinical Features and Indicators of Ulcerative Colitis: A Multicenter Exploratory Study".
    Inflamm Bowel Dis. 2025 Oct 13:izaf233. doi: 10.1093.
    >> Share


  225. Correction to: Controlled Hookworm Infection for Medication-free Maintenance in Patients with Ulcerative Colitis: A Pilot, Double-blind, Randomized Control Trial.
    Inflamm Bowel Dis. 2025 Oct 11:izaf235. doi: 10.1093.
    >> Share

  226. DEMERS K, van den Bergh N, Bongers BC, van Kuijk SMJ, et al
    Health-Related Physical Fitness in Patients With Inflammatory Bowel Disease vs Healthy Control Subjects.
    Inflamm Bowel Dis. 2025 Oct 8:izaf169. doi: 10.1093.
    >> Share

  227. SCHULT-HANNEMANN D, Gassner C, Thur N, Hennig C, et al
    Comparison of Different Sites of Microbiota Shows Increased Pseudomonas Species in the Gut Mucosa in Inflammatory Bowel Disease.
    Inflamm Bowel Dis. 2025 Oct 8:izaf185. doi: 10.1093.
    >> Share

  228. KALE T, Yoo L, Kroeger E, Iqbal A, et al
    Menopause and Inflammatory Bowel Disease: A Systematic Review.
    Inflamm Bowel Dis. 2025 Oct 1:izaf204. doi: 10.1093.
    >> Share

  229. TURPIN W, Kalili H, Halfvarson J, Croitoru K, et al
    IBD Prediction Is Possible, but How Far Are We from Implementing It?
    Inflamm Bowel Dis. 2025;31.
    >> Share

  230. KUGATHASAN S, Fiocchi C
    Towards IBD Prediction and Prevention: The Contribution of Genetics and Genomics.
    Inflamm Bowel Dis. 2025;31.
    >> Share

  231. RIBEIRO-MOURAO F, Agrawal M, Torres J, Peter I, et al
    Intervention(s) in the Early-Life Period to Modulate Inflammatory Bowel Disease Risk: What Could Be the Impact?
    Inflamm Bowel Dis. 2025;31.
    >> Share

  232. GOETGEBUER RL, Ungaro RC, Feagan BG, Jairath V, et al
    How Should an IBD Prevention Trial Be Designed?
    Inflamm Bowel Dis. 2025;31.
    >> Share

  233. TORRES J, Moss A
    Introduction to the IBD Journal Supplement: "Prevention of IBD: Forecasting and Forestalling Inflammatory Bowel Disease Onset".
    Inflamm Bowel Dis. 2025;31.
    >> Share

  234. MENDES-FRIAS A, Vieira MC, Araujo M, Duarte-Oliveira C, et al
    Branched-Chain Amino Acids Exacerbate Colitis Progression by Lowering Colonic Fumarate Levels.
    Inflamm Bowel Dis. 2025;31:2840-2852.
    >> Share

  235. GORDON M, Shaban N, Sinopoulou V, Vuyyuru S, et al
    Developing IBD Outcome Effect Size Thresholds to Inform Research, Guidelines, and Clinical Decisions.
    Inflamm Bowel Dis. 2025;31:2798-2804.
    >> Share

  236. TEICHERT C, Anjie SI, Stevens TW, Bahur B, et al
    Clinical Utility and Accuracy of Point-of-Care Testing for Anti-TNF Drug Monitoring and Loss of Response.
    Inflamm Bowel Dis. 2025;31:2886-2894.
    >> Share

  237. SCHREIBER S, Colombel JF, Hanauer SB, Sandborn WJ, et al
    Comparing Outcomes With Subcutaneous Infliximab (CT-P13 SC) by Baseline Immunosuppressant Use: A Post Hoc Analysis of the LIBERTY-CD and LIBERTY-UC Studies.
    Inflamm Bowel Dis. 2025;31:2714-2724.
    >> Share

  238. LIU EY, An A, Khan S, Battat R, et al
    The Impact of Endoscopic Healing on Disease-Related Outcomes in Patients With Ulcerative Proctitis.
    Inflamm Bowel Dis. 2025;31:2725-2734.
    >> Share

    September 2025
  239. BACHOUR SP, Srinivas-Rao S, Baskaran NU, Agrawal M, et al
    Cross-Sectional Imaging Features Associated With Disease Progression in Crohn's Disease.
    Inflamm Bowel Dis. 2025 Sep 30:izaf219. doi: 10.1093.
    >> Share

  240. KANG B, Moon JS, Choi S, Oh SH, et al
    Perianal Disease Modifiers Are Associated With Less Severe Luminal Disease Activity in Children With Crohn's Disease at Diagnosis.
    Inflamm Bowel Dis. 2025 Sep 30:izaf209. doi: 10.1093.
    >> Share

  241. YARUR A, Irving P, Siegmund B, Dubinsky MC, et al
    Long-Term Ozanimod Therapy in Patients With Moderately Active Ulcerative Colitis After Failure of 5-Aminosalicylic Acid.
    Inflamm Bowel Dis. 2025 Sep 26:izaf195. doi: 10.1093.
    >> Share

  242. SALWEN-DEREMER JK, Westvold SJ, Aschbrenner K, Smith MT, et al
    Cognitive Behavioral Therapy for Insomnia May Improve Sleep and Pain in Crohn's Disease: A Waitlist Control Pilot Trial.
    Inflamm Bowel Dis. 2025 Sep 25:izaf210. doi: 10.1093.
    >> Share

  243. WONG ECL, Dulai PS, Marshall JK, Jairath V, et al
    Anti-TNF Therapies Promote a Proximal-to-Distal Healing Pattern in Moderate-to-Severe Ulcerative Colitis.
    Inflamm Bowel Dis. 2025 Sep 25:izaf199. doi: 10.1093.
    >> Share

  244. MCKEIGUE PM, Iakovliev A, Erabadda B, Colhoun HM, et al
    Genome-Wide Aggregated Trans-Effects Analysis Implicates Deficient Type III Interferon Signaling as a Key Cause of Inflammatory Bowel Disease.
    Inflamm Bowel Dis. 2025 Sep 25:izaf214. doi: 10.1093.
    >> Share

  245. FUCHTBAUER JD, Brovkina O, Sivickis K, Aalykke C, et al
    Gut Mycobiome in Inflammatory Bowel Disease: A Systematic Review of Case-Control Studies.
    Inflamm Bowel Dis. 2025 Sep 24:izaf217. doi: 10.1093.
    >> Share

  246. LIN YF, Truchon A, Djoukam Mbuko B, Dai HYL, et al
    Factors Associated with Fistulizing Crohn's Disease in Children at Diagnosis: A Cross-Sectional Study.
    Inflamm Bowel Dis. 2025 Sep 24:izaf220. doi: 10.1093.
    >> Share

  247. HANNA LN, Quraishi B, Pelly T, Lung P, et al
    Therapeutic Benefit of Upadacitinib in Severe Post-Proctectomy (Class 4) Perianal Crohn's Disease: A Three-Patient Case Series.
    Inflamm Bowel Dis. 2025 Sep 24:izaf216. doi: 10.1093.
    >> Share

  248. TEIGEN L
    Deciphering Mechanisms Underlying Success of Microbiome-Targeted Diet Therapy in Ulcerative Colitis.
    Inflamm Bowel Dis. 2025 Sep 23:izaf203. doi: 10.1093.
    >> Share

  249. INNOCENTI T, Rocco C, Scarallo L, Lionetti P, et al
    Systematic Review of Available Intestinal Ultrasound Scores for Inflammatory Bowel Disease and Update on Validation Studies.
    Inflamm Bowel Dis. 2025 Sep 20:izaf183. doi: 10.1093.
    >> Share

  250. SINOPOULOU V, Gordon M, Liu S, Albuquerque DAN, et al
    Immunomodulators and Advanced Therapies for Induction of Remission in Crohn's Disease: A Systematic Review and Network Meta-Analysis.
    Inflamm Bowel Dis. 2025 Sep 19:izaf191. doi: 10.1093.
    >> Share

  251. TAN EX, An V, Garg M
    Diverting Loop Ileostomy as an Alternative to Emergent Colectomy in Acute Severe Ulcerative Colitis Flare following Checkpoint-Inhibitor Therapy.
    Inflamm Bowel Dis. 2025 Sep 19:izaf187. doi: 10.1093.
    >> Share

  252. DRUGG HAHN G, Lakatos PL, Maedler-Kron C, Marcus V, et al
    Defining Fecal Calprotectin Cutoffs That Predict Endoscopic and Histologic Remission in Patients With Ulcerative Colitis.
    Inflamm Bowel Dis. 2025 Sep 19:izaf008. doi: 10.1093.
    >> Share

  253. OH SH, Rajendra C
    Capsule Endoscopy in Very Early-Onset Inflammatory Bowel Disease: Supporting the Clinician's Role in Disease Interpretation.
    Inflamm Bowel Dis. 2025 Sep 18:izaf165. doi: 10.1093.
    >> Share

  254. SHEHAB M, Alrashed O, Alrashed F, Alyousefi R, et al
    Comparative Efficacy of Medical Therapies in Reducing the Risk of Postoperative Recurrence in Crohn's Disease: A Systematic Review and Network Meta-Analysis.
    Inflamm Bowel Dis. 2025 Sep 18:izaf186. doi: 10.1093.
    >> Share

  255. BAEKGAARD FRW, Kjaer MD, Moller S, Hovvang SW, et al
    The Severity of Rectal Inflammation and Pouch Surgery Outcome in Patients with Ulcerative Colitis: A Retrospective Cohort Study.
    Inflamm Bowel Dis. 2025 Sep 16:izaf194. doi: 10.1093.
    >> Share

  256. SCHREIBER S, Lee SD, van der Woude CJ, Marin-Jimenez I, et al
    Ustekinumab Intravenous Reinduction after Secondary Loss of Response in Patients with Crohn's Disease.
    Inflamm Bowel Dis. 2025 Sep 15:izaf163. doi: 10.1093.
    >> Share

  257. CHEN Q, McNinch C, May E, LaPoint P, et al
    Distinct Retrotransposon Transcriptome in Pediatric Crohn's Disease.
    Inflamm Bowel Dis. 2025 Sep 15:izaf190. doi: 10.1093.
    >> Share

  258. FROST S, Ambastha C, Patel D, Roney A, et al
    Incidence of Anti-Drug Antibody Development in Older Adults with Inflammatory Bowel Disease Treated with Tumor Necrosis Factor Alpha Inhibitors: A Large Multicenter Cohort Study.
    Inflamm Bowel Dis. 2025 Sep 15:izaf170. doi: 10.1093.
    >> Share

  259. JAIRATH V, Adsul S, Allocca M, Danese S, et al
    Integrating Intestinal Ultrasound to Clinical Trials in Patients With Crohn's Disease: Opportunities and Challenges.
    Inflamm Bowel Dis. 2025 Sep 15:izaf196. doi: 10.1093.
    >> Share

  260. VERMEER E, Prins FM, Hidding IJ, Jagt JZ, et al
    Metagenomic Sequencing Reveals Distinct Gut Microbiome Profiles in Therapy-Naive de Novo Pediatric Inflammatory Bowel Disease.
    Inflamm Bowel Dis. 2025 Sep 12:izaf184. doi: 10.1093.
    >> Share

  261. BOHAR B, Thomas JP, Liu Y, Brooks-Warburton J, et al
    Patient-Specific Regulatory Network Rewiring in Inflammatory Bowel Disease: How Genetic Polymorphisms Divert Incoming Signals and Contribute to Disease Pathogenesis.
    Inflamm Bowel Dis. 2025 Sep 7:izaf173. doi: 10.1093.
    >> Share

  262. D'ARCANGELO G, De Mitri D, Busato L, Bottino L, et al
    The Impact of Sarcopenia on Clinical Outcomes in Pediatric Crohn's Disease.
    Inflamm Bowel Dis. 2025 Sep 5:izaf193. doi: 10.1093.
    >> Share

  263. KLEIN S, Sivasailam B, Alizadeh M, Malter L, et al
    Clinical Research: Disparities in Outcomes for Patients With Inflammatory Bowel Disease at a Private vs Public Hospital in New York City.
    Inflamm Bowel Dis. 2025 Sep 5:izaf174. doi: 10.1093.
    >> Share


  264. Correction to: Fecal Microbial Community Profiling Allows Discrimination of Phenotype and Treatment Response in Pediatric Crohn's Disease and Ulcerative Colitis-An International Meta-Analysis.
    Inflamm Bowel Dis. 2025 Sep 4:izaf200. doi: 10.1093.
    >> Share

  265. DAY AS, Slater R, Young RB, Wheeler RZ, et al
    Functional Profiling Demonstrates That a Sulfide-Reducing Diet Achieves Microenvironmental Targets in Ulcerative Colitis.
    Inflamm Bowel Dis. 2025 Sep 3:izaf177. doi: 10.1093.
    >> Share

  266. AKASH H, Pandis N, Manschiebel W, Burisch J, et al
    A Systematic Review and Meta-Analysis of Animal Models on the Possible Link Between Periodontitis and Inflammatory Bowel Diseases.
    Inflamm Bowel Dis. 2025;31:2561-2583.
    >> Share

  267. STENKE E, Alhassan D, Moclair M, Cooper S, et al
    Higher-Dose Infliximab Induction Achieves Better Maintenance Trough Levels in a National Pediatric IBD Cohort-A Retrospective Study.
    Inflamm Bowel Dis. 2025;31:2331-2337.
    >> Share

    August 2025
  268. TAL N, Baram L, Gehlhaar A, Gu W, et al
    RELA Haploinsufficiency Manifesting as an Atypical Phenotype of Crohn's Disease.
    Inflamm Bowel Dis. 2025 Aug 28:izaf159. doi: 10.1093.
    >> Share

  269. MAHADEVAN U, Seow CH, Barnes EL, Chaparro M, et al
    Global Consensus Statement on the Management of Pregnancy in Inflammatory Bowel Disease.
    Inflamm Bowel Dis. 2025 Aug 28:izaf171. doi: 10.1093.
    >> Share

  270. DEISSOVA T, Al Tukmachi D, Radova L, Bohosova J, et al
    Tissue MicroRNA Expression Signatures as Diagnostic Biomarkers and Predictors of Residual Disease Activity and Relapse in Treatment-Naive Pediatric Inflammatory Bowel Disease.
    Inflamm Bowel Dis. 2025 Aug 26:izaf120. doi: 10.1093.
    >> Share

  271. GEEGANAGE G, Gade A, Saraga A, Deyhim T, et al
    Long-term Outcomes of Patients with Crohn's Disease Treated with Risankizumab.
    Inflamm Bowel Dis. 2025 Aug 26:izaf162. doi: 10.1093.
    >> Share

  272. LERCHOVA T, Ludvigsson J, Marild S, Imberg H, et al
    Early-Life Body Mass Index and Inflammatory Bowel Disease Risk: A Scandinavian Birth Cohort Study.
    Inflamm Bowel Dis. 2025 Aug 25:izaf167. doi: 10.1093.
    >> Share


  273. Correction to: A Role for Leucine-Rich alpha2-Glycoprotein in Leukocyte Trafficking and Mucosal Inflammation in Inflammatory Bowel Disease.
    Inflamm Bowel Dis. 2025 Aug 25:izaf198. doi: 10.1093.
    >> Share

  274. EREN DURMUS M, Koker G
    Comment on "Plasma Calprotectin and Myeloperoxidase as Biomarkers in Inflammatory Bowel Disease".
    Inflamm Bowel Dis. 2025 Aug 23:izaf192. doi: 10.1093.
    >> Share

  275. ZHOU R, Bai X, Zhang D, Zhu Y, et al
    Role of lncRNA MGP202 in Modulating B Cell Dynamics and Its Implications in Ulcerative Colitis.
    Inflamm Bowel Dis. 2025 Aug 23:izaf176. doi: 10.1093.
    >> Share

  276. MAR JS, Nguyen A, Scherl A, Wittke M, et al
    InflammationBacterial Dysbiosis Observed in the Terminal Ileum of Ulcerative Colitis.
    Inflamm Bowel Dis. 2025 Aug 22:izaf160. doi: 10.1093.
    >> Share

  277. BOYD T, Friedman S, Newman KL, Chedid V, et al
    Sexual Health Concerns and Health Care Experiences of LGBTQ+ Patients with Inflammatory Bowel Disease.
    Inflamm Bowel Dis. 2025 Aug 21:izaf158. doi: 10.1093.
    >> Share

  278. SWAMINATHAN A, Hou D, Borichevsky GM, Kettle AJ, et al
    Author's Response to Comment on "Plasma Calprotectin and Myeloperoxidase as Biomarkers in Inflammatory Bowel Disease".
    Inflamm Bowel Dis. 2025 Aug 21:izaf189. doi: 10.1093.
    >> Share

  279. NOVIELLO D, Atreya R, Noor NM
    Resolving Loss of Response to Ustekinumab in Crohn's Disease: POWER Through or Switch Treatment?
    Inflamm Bowel Dis. 2025 Aug 20:izaf179. doi: 10.1093.
    >> Share

  280. BAKER NM, Soltero KS, Ebriani J, Dalal RS, et al
    Clinical Characteristics and Treatment Patterns in a Large Cohort of Patients with Metastatic Crohn's Disease.
    Inflamm Bowel Dis. 2025 Aug 20:izaf164. doi: 10.1093.
    >> Share

  281. YERUSHALMY-FELER A, Spencer EA, Bergstein S, Mitrova K, et al
    Real-World Experience with Upadacitinib for Pediatric Acute Severe Ulcerative Colitis: An International Multicenter Retrospective Study from the Pediatric IBD Porto Group of ESPGHAN.
    Inflamm Bowel Dis. 2025 Aug 20:izaf166. doi: 10.1093.
    >> Share

  282. LEE SH, Lopes E, Colombel JF, Ungaro R, et al
    Identifying Potential Targets for the Interception of Inflammatory Bowel Disease: Toward Precision Prevention.
    Inflamm Bowel Dis. 2025 Aug 20:izaf168. doi: 10.1093.
    >> Share

  283. KUANG X, Jia X, Peng X, Zheng X, et al
    Ulcerative Colitis Aggravates Periodontitis via Inducing Myelopoiesis.
    Inflamm Bowel Dis. 2025 Aug 12:izaf150. doi: 10.1093.
    >> Share

  284. LUSHNIKOVA A, Wickbom A, Bohr J, Kruse R, et al
    Increased Colonic Levels of CD8+ Cytotoxic T lymphocyte-Associated Mediators in Patients With Microscopic Colitis.
    Inflamm Bowel Dis. 2025;31:2231-2243.
    >> Share

  285. JIANG M, Jia Y, Ma C, Zeng Z, et al
    Akkermansia muciniphila Protects Against Trinitrobenzene Sulfonic Acid Induced Colitis by Inhibiting IL6/STAT3 Pathway.
    Inflamm Bowel Dis. 2025;31:2217-2230.
    >> Share

  286. LEWIN S, Long M, Cohen R, Scherl E, et al
    Wound Healing After Vaginal Delivery, Episiotomy, and Cesarean Section Delivery Among Women With IBD: Results From the PIANO Registry.
    Inflamm Bowel Dis. 2025;31:2106-2111.
    >> Share

  287. BOUWKNEGT DG, van der Weide AHC, Dijkstra G, Goetgebuer RL, et al
    Pregnancy With a Stoma is Feasible, Though Associated With Manageable Complications.
    Inflamm Bowel Dis. 2025;31:2195-2203.
    >> Share

  288. YARUR AJ, Chiorean MV, Allegretti JR, Cross RK, et al
    Etrasimod as a Monotherapy or With Concomitant Use of Corticosteroids and/or Aminosalicylates: Results From the ELEVATE UC Clinical Program.
    Inflamm Bowel Dis. 2025;31:2144-2153.
    >> Share

    July 2025
  289. PARK S, Keyashian K, Ho A, Limsui D, et al
    Efficacy and Safety of Ustekinumab and Vedolizumab for Crohn's Disease of the Pouch.
    Inflamm Bowel Dis. 2025 Jul 25:izaf146. doi: 10.1093.
    >> Share

  290. YE S, Yang X, Chen X
    Comment On: Predictors of Complicated Disease Course in Children and Adults With Ulcerative Colitis: A Nationwide Study From the epi-IIRN.
    Inflamm Bowel Dis. 2025 Jul 21:izaf069. doi: 10.1093.
    >> Share

  291. MA J, Feng W, Zhou N
    Breaking Conventions: Innovative Reflections on the Medication Use Research of Inflammatory Bowel Disease in Adults and the Elderly.
    Inflamm Bowel Dis. 2025 Jul 21:izaf056. doi: 10.1093.
    >> Share

  292. BAK MTJ, Olivera PA, Hernandez-Rocha C, Borowski K, et al
    Isolated Anastomotic Ulcers Are Associated with a Higher Long-Term Risk for Postoperative Recurrence and a Differential Mucosa-Associated Microbiome Composition in Patients with Crohn's Disease Following Ileocolic Resection.
    Inflamm Bowel Dis. 2025 Jul 16:izaf147. doi: 10.1093.
    >> Share

  293. KITAHATA S, Saito M, Kimura Y, Nakamura A, et al
    Mirikizumab Efficacy in Ulcerative Colitis: Association With Pretreatment Geboes Score Features in a Case Series.
    Inflamm Bowel Dis. 2025 Jul 16:izaf152. doi: 10.1093.
    >> Share

  294. DAI C, Huang YH
    The Association of Inflammatory Bowel Disease and Eosinophilic Esophagitis: True Link or Surveillance Artifact?
    Inflamm Bowel Dis. 2025 Jul 12:izaf151. doi: 10.1093.
    >> Share

  295. OLDENBURG L, Hens B, Hollenberg M, D'Haens G, et al
    Endoscopic Recurrence in Crohn's Disease Patients With Long-Term Ileostomy.
    Inflamm Bowel Dis. 2025 Jul 12:izaf153. doi: 10.1093.
    >> Share

  296. HAGIWARA SI, Shimizu H, Nambu R, Jimbo K, et al
    Feasibility and Safety of Small Bowel Capsule Endoscopy in Very Early-Onset Inflammatory Bowel Disease: A Multi-Institutional Study.
    Inflamm Bowel Dis. 2025 Jul 8:izaf144. doi: 10.1093.
    >> Share

  297. GREYWOODE R, Philippou A, Ullman T, Keefer L, et al
    Culturally Informed Digital Behavioral Intervention Development for Inflammatory Bowel Disease: A Qualitative Study.
    Inflamm Bowel Dis. 2025 Jul 8:izaf145. doi: 10.1093.
    >> Share

  298. YANOFSKY R, Tandon P
    Response to "The Association of Inflammatory Bowel Disease and Eosinophilic Esophagitis: True Link or Surveillance Artifact?
    Inflamm Bowel Dis. 2025 Jul 8:izaf149. doi: 10.1093.
    >> Share

  299. BLESL A, Binder L, Halwachs B, Baumann-Durchschein F, et al
    The Fecal Microbiome of IBD Patients Is Less Divertible by Bowel Preparation Compared to Healthy Controls: Results From a Prospective Study.
    Inflamm Bowel Dis. 2025;31:2007-2018.
    >> Share

  300. LAURETI S, Cappelli A, Isopi C, Gentilini L, et al
    Autologous Microfragmented Adipose Tissue Injection in Refractory Complex Crohn's Perianal Fistulas: Long-Term Results at 6.7 Years Mean Follow-up.
    Inflamm Bowel Dis. 2025;31:1943-1951.
    >> Share

  301. CENTORRINO E, Ferrari D, Harmsen WS, Larson DW, et al
    Undetected Dysplasia at Colectomy in Patients With Inflammatory Bowel Diseases. What Are We Missing?
    Inflamm Bowel Dis. 2025;31:1952-1960.
    >> Share

  302. MIYAZAWA A, Nambu R, Shimizu H, Kudo T, et al
    Long-Term Course and Prognostic Factors in Pediatric Ulcerative Proctitis: A Multicenter Cohort Study.
    Inflamm Bowel Dis. 2025;31:1902-1909.
    >> Share

  303. BOCCHINI B, Martinelli M, Strisciuglio C, Stellato P, et al
    Efficacy and Safety of Upadacitinib in a Case of Pediatric Acute Severe Ulcerative Colitis and Immune Thrombocytopenia.
    Inflamm Bowel Dis. 2025 Jul 1:izaf139. doi: 10.1093.
    >> Share


  304. Correction to: Novel mRNA Signature for Anti-TNF-alpha Therapy Primary Response in Patients With Ulcerative Colitis.
    Inflamm Bowel Dis. 2025 Jul 1:izaf140. doi: 10.1093.
    >> Share

  305. PATRICK D, Siddiq L, Boyce A
    An Acute Onset Sweet Syndrome After First Vedolizumab Dose in Crohn's Disease.
    Inflamm Bowel Dis. 2025 Jul 1:izaf122. doi: 10.1093.
    >> Share

    June 2025
  306. AHUJA D, Anvari S, Wong ECL, Dulai P, et al
    Validation of the Modified Multiplier of SES-CD (MM-SES-CD) to Predict Endoscopic Healing in Crohn's Disease: A Post Hoc Analysis of the SEAVUE Trial.
    Inflamm Bowel Dis. 2025 Jun 30:izaf137. doi: 10.1093.
    >> Share

  307. TAKEDA T, Nishimata N, Fujioka S, Tsuruoka N, et al
    Fecal Calprotectin is a Useful Biomarker for Defining Small Bowel Endoscopic Remission in Crohn's Disease Without Active Colonic Lesions: A Prospective Multicenter Study from the IBD-Quality Team.
    Inflamm Bowel Dis. 2025 Jun 30:izaf138. doi: 10.1093.
    >> Share

  308. ALDRIAN D, Pollio A, Mayerhofer C, Diederen K, et al
    Fecal Microbial Community Profiling Allows Discrimination of Phenweotype and Treatment Response in Pediatric Crohn's Disease and Ulcerative Colitis-An International Meta-Analysis.
    Inflamm Bowel Dis. 2025 Jun 28:izaf135. doi: 10.1093.
    >> Share

  309. FERNANDES SR, Rodrigues IC, Neves ADS, Saraiva S, et al
    Early Top-Down Treatment With Biologics Improves the Rates of Transmural Remission in Crohn's Disease-A Risk-Adjusted Propensity Score Matched Analysis.
    Inflamm Bowel Dis. 2025 Jun 25:izaf112. doi: 10.1093.
    >> Share

  310. FUMERY M, Savoye G, Sarter H, Dupont-Lucas C, et al
    Long-Term Outcome of Colonic and Ileal Crohn's Disease: A Two-Decade Population-Based Study in Pediatric-Onset Disease.
    Inflamm Bowel Dis. 2025 Jun 25:izaf133. doi: 10.1093.
    >> Share

  311. HUANG JL, Tan WT, Liu H
    Prostaglandins and Inflammatory Bowel Disease: From Mechanism to Clinic.
    Inflamm Bowel Dis. 2025 Jun 25:izaf121. doi: 10.1093.
    >> Share

  312. SCHREIBER-STAINTHORP W, Faye AS, Axelrad JE
    Efficacy of Risankizumab Dose Escalation Among Patients With Inflammatory Bowel Disease.
    Inflamm Bowel Dis. 2025 Jun 24:izaf130. doi: 10.1093.
    >> Share

  313. POWERS JC, Westbrook Cates K, Dester E, Zemanek M, et al
    Inflammation of the Rectal Cuff is Associated With Strictures and Fistulas in Patients With Ulcerative Colitis who Have an Ileal Pouch-Anal Anastomosis.
    Inflamm Bowel Dis. 2025 Jun 24:izaf127. doi: 10.1093.
    >> Share

  314. KOCHHAR GS, Khataniar H, Hashash JG, Regueiro M, et al
    Natural History, Treatment Persistence and Predictors of Treatment Failure in Patients With Ulcerative Colitis on 5-Aminosalicylic Acid: A US Population-Level Cohort Study.
    Inflamm Bowel Dis. 2025 Jun 24:izaf129. doi: 10.1093.
    >> Share

  315. MIKHAIL I, Al Ta'ani O, Aburumman R, Alsakarneh S, et al
    Patients With Crohn's Disease and Terminal Ileum Resection are at Increased Risk of Colorectal Cancer: A Population-Based Study.
    Inflamm Bowel Dis. 2025 Jun 18:izaf118. doi: 10.1093.
    >> Share

  316. MEIMA M, Westerhout J, Meijerink M, Bijlsma S, et al
    Food Compounds Associated With Disease Activity in Inflammatory Bowel Disease.
    Inflamm Bowel Dis. 2025 Jun 16:izaf126. doi: 10.1093.
    >> Share

  317. BOURGONJE AR
    Dualistic Implications of Angiotensin-Converting Enzyme 2 (ACE2) Expression in Inflammatory Bowel Disease.
    Inflamm Bowel Dis. 2025 Jun 16:izaf131. doi: 10.1093.
    >> Share

  318. WONG ECL, Dulai PS, Marshall JK, Jairath V, et al
    Comparative Predictive Utility of MM-SES-CD and SES-CD for Week 52 Endoscopic Remission in the Ileum and Colon in Crohn's Disease.
    Inflamm Bowel Dis. 2025 Jun 16:izaf124. doi: 10.1093.
    >> Share


  319. Correction to: Screen Failures and Causes in Inflammatory Bowel Disease Randomized Controlled Trials: A Study of 16 913 Screened Patients.
    Inflamm Bowel Dis. 2025 Jun 16:izaf134. doi: 10.1093.
    >> Share

  320. YOGEV D, Weintraub Y, Ledder O, Matar M, et al
    Safety and Effectiveness of QingDai (Indigo naturalis) in Children With Mild-to-Moderate Ulcerative Colitis: A Short-Term 6-Week Open-Label Trial.
    Inflamm Bowel Dis. 2025 Jun 13:izaf119. doi: 10.1093.
    >> Share

  321. RUBIN DT, Hart AL
    A Guide to the Patient-Centric Use of Vedolizumab for Crohn's Disease.
    Inflamm Bowel Dis. 2025 Jun 13:izaf072. doi: 10.1093.
    >> Share

  322. PISANI LF, Albertini Petroni G, Crespi G, Mola S, et al
    Lower Expression of SARS-CoV-2 Host Cell Entry Genes in the Intestinal Mucosa of IBD Patients With Quiescent or Mildly Active Disease.
    Inflamm Bowel Dis. 2025;31:1690-1701.
    >> Share

  323. WHITE I, Karki C, Geransar P, Leisle L, et al
    Impact of Seton Use on Clinical, Patient-Reported, and Healthcare Resource Utilization Outcomes in Complex Crohn's Perianal Fistulas: A Systematic Literature Review.
    Inflamm Bowel Dis. 2025;31:1556-1566.
    >> Share

  324. WOOD DW, Treiman K, Rivell A, van Deen WK, et al
    Communicating Information Regarding IBD Remission to Patients: Evidence From a Survey of Adult Patients in the United States.
    Inflamm Bowel Dis. 2025;31:1605-1615.
    >> Share

  325. DAVE M, Power S, Herfarth HH, Barnes EL, et al
    Assessing the Value of Histology and Anatomic Segment Evaluation Among Patients Undergoing Pouchoscopy.
    Inflamm Bowel Dis. 2025;31:1514-1519.
    >> Share

  326. YANOFSKY R, Jogendran R, Hoxha T, Pathak A, et al
    The Association of Inflammatory Bowel Disease and Eosinophilic Esophagitis: A Systematic Review and Meta-analysis.
    Inflamm Bowel Dis. 2025 Jun 4:izaf095. doi: 10.1093.
    >> Share

    May 2025
  327. YZET C, Moreau C, Chatelain D, Meudjo E, et al
    Rectal and Rectosigmoid Endoscopy to Assess Endoscopic and Histological Remission in Ulcerative Colitis: A Prospective Study.
    Inflamm Bowel Dis. 2025 May 24:izaf094. doi: 10.1093.
    >> Share

  328. HOU D, Swaminathan A, Borichevsky GM, Frampton CM, et al
    Plasma Calprotectin and Myeloperoxidase as Biomarkers in Inflammatory Bowel Disease.
    Inflamm Bowel Dis. 2025 May 24:izaf110. doi: 10.1093.
    >> Share

  329. BORICHEVSKY GM, Swaminathan A, Smith BR, Edwards TS, et al
    Myeloperoxidase Enzyme Activity in Feces Reflects Endoscopic Severity in Inflammatory Bowel Disease.
    Inflamm Bowel Dis. 2025 May 24:izaf109. doi: 10.1093.
    >> Share

  330. CHOI D, Kellar A, Klein J, Choi NK, et al
    Incidence and Risk Factors for Development of Acne (JAKne) in Patients with Inflammatory Bowel Disease Treated With Upadacitinib.
    Inflamm Bowel Dis. 2025 May 24:izaf115. doi: 10.1093.
    >> Share

  331. BAK MTJ, de Vries AC, Witjes CDM, Arkenbosch JHC, et al
    Intraoperative Autologous Platelet-Rich Stroma Injection as Add-On to Fistula Curettage and Closure of the Internal Orifice Demonstrates a Favorable Outcome in Long-Term in Patients Suffering from Therapy-Refractory Perianal Fistulizing Crohn's Diseas
    Inflamm Bowel Dis. 2025 May 24:izaf011. doi: 10.1093.
    >> Share

  332. SUN J, Brooks EC, Houshyar Y, Connor SJ, et al
    Unravelling the Relationship Between Obesity and Inflammatory Bowel Disease.
    Inflamm Bowel Dis. 2025 May 21:izaf098. doi: 10.1093.
    >> Share

  333. ISHIDA N, Tamura S, Takebe T, Takahashi K, et al
    Usefulness of Prostaglandin E-Major Urinary Metabolite in Monitoring Crohn's Disease Activity: A Prospective Cross-Sectional Study.
    Inflamm Bowel Dis. 2025 May 21:izaf025. doi: 10.1093.
    >> Share

  334. NISHIDA Y, Hosomi S, Fujimoto K, Kobayashi Y, et al
    Lack of Efficacy of Concomitant 5-Aminosalicylic Acid With Vedolizumab in Inflammatory Bowel Disease: A Large-Scale Administrative Database Analysis.
    Inflamm Bowel Dis. 2025 May 21:izaf088. doi: 10.1093.
    >> Share

  335. AOYAMA K, Yamamura R, Katsurada T, Shimizu T, et al
    Decreased Fecal Nicotinamide and Increased Bacterial Nicotinamidase Gene Expression in Ulcerative Colitis Patients.
    Inflamm Bowel Dis. 2025 May 13:izaf092. doi: 10.1093.
    >> Share

  336. WANG H, Chen Y, He J, Luo Z, et al
    Biological Ageing and the Risk of Inflammatory Bowel Disease: Exploring the Role of Lifestyle and Genetic Susceptibility in a Nationwide Prospective Study.
    Inflamm Bowel Dis. 2025 May 13:izaf106. doi: 10.1093.
    >> Share

  337. STRATIL AS, Friedrich B, Brunner P, Rath S, et al
    Six-Year Observation Data Reveal Reduction in Concomitant Steroid Overuse for Inflammatory Bowel Disease in Germany.
    Inflamm Bowel Dis. 2025 May 13:izaf108. doi: 10.1093.
    >> Share

  338. PIROLLI NH, Raufman JP, Jay SM
    Therapeutic Potential and Translational Challenges for Bacterial Extracellular Vesicles in Inflammatory Bowel Disease.
    Inflamm Bowel Dis. 2025 May 13:izaf107. doi: 10.1093.
    >> Share

  339. MASSIRONI S, Pigoni A, Vegni EAM, Keefer L, et al
    The Burden of Psychiatric Manifestations in Inflammatory Bowel Diseases: A Systematic Review With Meta-analysis.
    Inflamm Bowel Dis. 2025;31:1441-1459.
    >> Share

  340. SILA S, Aloi M, Cucinotta U, Gianolio L, et al
    Effect of Overweight and Obesity on the Response to Anti-TNF Therapy and Disease Course in Children With IBD.
    Inflamm Bowel Dis. 2025;31:1263-1271.
    >> Share

  341. PRENTICE RE, Cho SX, Bell SJ, Nold-Petry CA, et al
    Innate and Adaptive Immunity is not Impacted by Inflammatory Bowel Disease Medications in Pregnant Women and Their Offspring.
    Inflamm Bowel Dis. 2025 May 9:izaf052. doi: 10.1093.
    >> Share

  342. KOKKOTIS G, Bamias G
    Past But Not Forgotten: Innate Factors Affect the Course of Severe Acute Respiratory Syndrome Coronavirus 2 Infection in Patients With Inflammatory Bowel Disease.
    Inflamm Bowel Dis. 2025 May 9:izaf105. doi: 10.1093.
    >> Share

  343. GOZDZIK M, Unninayar D, Siegal DM, Sarker AK, et al
    Risk Factors for Venous Thromboembolism in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis by Phase of Care.
    Inflamm Bowel Dis. 2025 May 9:izaf078. doi: 10.1093.
    >> Share

  344. MUNASINGHE S, Chandrakasan S
    Maternal Microchimerism, a Red Flag or a Red Herring in Very-Early-Onset Inflammatory Bowel Disease?
    Inflamm Bowel Dis. 2025 May 9:izaf070. doi: 10.1093.
    >> Share

  345. LOVETT GC, Schulberg JD, Hamilton AL, Wright EK, et al
    Crohn's Disease Stricture Response to Treatment Assessed with Magnetic Resonance Imaging and Intestinal Ultrasound: STRIDENT Randomized Trial.
    Inflamm Bowel Dis. 2025 May 8:izaf073. doi: 10.1093.
    >> Share

  346. ALBERT S, Marques P, Algarra A, Blanc E, et al
    Monitoring Structural Bowel Damage in Patients With Crohn's Disease Using Intestinal Ultrasonography: Can It Be Reversed by Biological Treatment?
    Inflamm Bowel Dis. 2025 May 8:izaf100. doi: 10.1093.
    >> Share

  347. MCAULIFFE T, Salwen-Deremer JK, Siegel CA
    Disparities in Access and Treatment for Rural Patients With Inflammatory Bowel Disease: A Survey of Inflammatory Bowel Disease Patients and Providers.
    Inflamm Bowel Dis. 2025 May 8:izaf090. doi: 10.1093.
    >> Share

  348. FENG Y, Wang S, Li S
    Non-Typhoidal Salmonella Infections and Inflammatory Bowel Disease Risk: New Findings and Multidimensional Perspectives for Future Research.
    Inflamm Bowel Dis. 2025 May 5:izaf082. doi: 10.1093.
    >> Share

  349. PAL P, Mateen MA, Gupta R, Tandan M, et al
    Multifaceted Endoscopic Approach (Stricturotomy, Balloon Dilation, Fistulotomy, and Seton Placement) Guided by Intestinal Ultrasound to Avert Surgery in Complicated Crohn's Disease During Lactation.
    Inflamm Bowel Dis. 2025 May 2:izaf076. doi: 10.1093.
    >> Share

    April 2025
  350. ERNEST-SUAREZ K, Noor NM
    Not All Transmural Healing is Equal in Crohn's Disease: Magnetic Resonance Enterography and Intestinal Ultrasound for Stricture Assessment in the STRIDENT Trial.
    Inflamm Bowel Dis. 2025 Apr 29:izaf093. doi: 10.1093.
    >> Share

  351. BARENBOIM A, Maharshak N
    Reply: Extraintestinal Manifestations in Patients With Ulcerative Colitis Post-Restorative Proctocolectomy and Ileal Pouch-Anal Anastomosis.
    Inflamm Bowel Dis. 2025 Apr 29:izaf091. doi: 10.1093.
    >> Share

  352. PLAKOTARIS E, Theriot T, Langley C, Haas C, et al
    Diagnosing the Overlap: Metastatic Crohn's Disease With Hidradenitis Suppurativa-Like Features.
    Inflamm Bowel Dis. 2025 Apr 29:izaf083. doi: 10.1093.
    >> Share

  353. REA K, Robbertz A, Westbrook A, Buzenski J, et al
    Biofeedback-Enhanced Cognitive-Behavioral Therapy Delivered Virtually to Youth With Inflammatory Bowel Disease: A Randomized Controlled Trial.
    Inflamm Bowel Dis. 2025 Apr 29:izaf061. doi: 10.1093.
    >> Share

  354. DAI C, Huang YH
    Extraintestinal Manifestations in Patients With Ulcerative Colitis Post-Restorative Proctocolectomy and Ileal Pouch-Anal Anastomosis.
    Inflamm Bowel Dis. 2025 Apr 26:izaf080. doi: 10.1093.
    >> Share

  355. RODRIGUEZ A, Quintero MA, Hazime H, Killian R, et al
    Risk Factors for Chronic Kidney Disease in Patients With Crohn's Disease.
    Inflamm Bowel Dis. 2025 Apr 25:izaf039. doi: 10.1093.
    >> Share

  356. HANSEN SH, Maseng MG, Granno O, Vestergaard MV, et al
    Fecal Microbiome Reflects Disease State and Prognosis in Inflammatory Bowel Disease in an Adult Population-Based Inception Cohort.
    Inflamm Bowel Dis. 2025 Apr 25:izaf060. doi: 10.1093.
    >> Share

  357. HUET J, Mathieu K, Dodel M, Coban D, et al
    Transmural Healing Assessed by Combination of Fecal Calprotectin and Intestinal Ultrasonography Is Associated With Reduced Risk of Bowel Damage Progression in Patients With Crohn's Disease.
    Inflamm Bowel Dis. 2025 Apr 25:izaf068. doi: 10.1093.
    >> Share

  358. KHALILI H, Forss A, Soderling J, Broms G, et al
    Statin Use is Associated with a Less Severe Disease Course In Inflammatory Bowel Disease: A Nationwide Cohort Study 2006-2020.
    Inflamm Bowel Dis. 2025 Apr 25:izaf077. doi: 10.1093.
    >> Share

  359. LIMDI JK
    Contraception, Unintended Pregnancy, and Inflammatory Bowel Disease: When (and Why) Failure is Not an Option....
    Inflamm Bowel Dis. 2025 Apr 23:izaf081. doi: 10.1093.
    >> Share

  360. LENTI MV, Santacroce G, Di Sabatino A
    Rethinking the Use of Biologics in Inflammatory Bowel Disease Patients With Malignancy: Insights From the Treatment of Immune Checkpoint Inhibitor-Induced Colitis.
    Inflamm Bowel Dis. 2025 Apr 21:izaf065. doi: 10.1093.
    >> Share


  361. Correction to: Improving Brain-Gut Studies in Crohn's Disease: Methodological Considerations.
    Inflamm Bowel Dis. 2025 Apr 17:izaf075. doi: 10.1093.
    >> Share

  362. HACKER KS, Friedlander A
    Inclusive Inflammatory Bowel Disease Care for Sexual and Gender Minorities: An Urgent Need in Uncertain Times.
    Inflamm Bowel Dis. 2025 Apr 16:izaf059. doi: 10.1093.
    >> Share

  363. PATEL PV, Goyal A
    Editorial: Defining Fecal Calprotectin Cutoffs That Predict Endoscopic and Histologic Remission Patients With Ulcerative Colitis.
    Inflamm Bowel Dis. 2025 Apr 16:izaf049. doi: 10.1093.
    >> Share

  364. BULDUKOGLU OC, Ocal S, Cekin AH
    Alterations in Pain Perception in Inflammatory Bowel Disease Patients with Psychiatric Comorbidity.
    Inflamm Bowel Dis. 2025 Apr 13:izaf074. doi: 10.1093.
    >> Share

  365. GROSSBERG LB, Mishra K, Rabinowitz LG, Mecsas-Faxon B, et al
    A Multicenter Study to Assess Avoidant/Restrictive Food Intake Disorder in Patients with Inflammatory Bowel Disease.
    Inflamm Bowel Dis. 2025 Apr 13:izaf016. doi: 10.1093.
    >> Share

  366. REGUEIRO MD, Bewtra M, Dubinsky MC, Branquinho D, et al
    Safety Outcomes in Patients With Ulcerative Colitis Using a Healthcare Administrative Database in the United States.
    Inflamm Bowel Dis. 2025 Apr 12:izaf067. doi: 10.1093.
    >> Share

  367. ZHOU Z, Su J, van Os BW, Plug LG, et al
    Stromal Cell Subsets Show Model-Dependent Changes in Experimental Colitis and Affect Epithelial Tissue Repair and Immune Cell Activation.
    Inflamm Bowel Dis. 2025;31:1051-1066.
    >> Share

  368. ARGUELLES-ARIAS F, Rodriguez Gonzalez FJ, Gonzalez Antuna J, Castro Laria L, et al
    Long-Term Outcomes of Intravenous Ustekinumab Maintenance Treatment in Patients With Loss of Response to Subcutaneous Dosing.
    Inflamm Bowel Dis. 2025;31:1003-1009.
    >> Share

  369. LIN J, Zuo L, Yang B, Yang R, et al
    Identification of the M2 Macrophage-associated Gene THBS2 as a Predictive Marker for Inflammatory Cancer Transformation.
    Inflamm Bowel Dis. 2025;31:963-974.
    >> Share

  370. JAIRATH V, Rubin DT, Verstockt B, Cekin AH, et al
    The Effect of Etrasimod on Fecal Calprotectin and High-sensitivity C-reactive Protein: Results From the ELEVATE UC Clinical Program.
    Inflamm Bowel Dis. 2025;31:923-934.
    >> Share

  371. MUJAGIC Z
    Gut Feelings Matter: The Unresolved Questions of Irritable Bowel Syndrome-Like Symptoms in Inflammatory Bowel Disease in Remission.
    Inflamm Bowel Dis. 2025 Apr 9:izaf066. doi: 10.1093.
    >> Share

  372. ATTAUABI M, Madsen GR, Holm JP, Bendtsen F, et al
    Incidence of Osteoporosis and Osteopenia in Newly Diagnosed Inflammatory Bowel Disease: A Population-Based Cohort Study.
    Inflamm Bowel Dis. 2025 Apr 8:izaf063. doi: 10.1093.
    >> Share

  373. ATIA O, Turner D
    Letter: Predictors of Complicated Disease Course in Children and Adults With Ulcerative Colitis-Authors' Reply.
    Inflamm Bowel Dis. 2025 Apr 8:izaf071. doi: 10.1093.
    >> Share

  374. NEWMAN KL, Wren PA, Long MD, Higgins PDR, et al
    Health Outcomes, Discrimination, and Stigma Among Sexual and Gender Minority People With Inflammatory Bowel Disease.
    Inflamm Bowel Dis. 2025 Apr 8:izaf054. doi: 10.1093.
    >> Share

  375. LICHTENSTEIN GR, Allegretti JR, Loftus EV Jr, Irving PM, et al
    Assessment and Impact of Age on the Safety and Efficacy of Etrasimod in Patients With Ulcerative Colitis: A Post Hoc Analysis of Data From the ELEVATE UC Clinical Program.
    Inflamm Bowel Dis. 2025 Apr 4:izae308. doi: 10.1093.
    >> Share

    March 2025
  376. LEE MCM, Farahvash A, Zezos P
    Artificial Intelligence for Classification of Endoscopic Severity of Inflammatory Bowel Disease: A Systematic Review and Critical Appraisal.
    Inflamm Bowel Dis. 2025 Mar 31:izaf050. doi: 10.1093.
    >> Share

  377. BRENNER EJ, Zhang X, Mahadevan U, Bryant AG, et al
    Risk Factors for Contraceptive Failure and Unintended Pregnancy Among Women With Inflammatory Bowel Disease.
    Inflamm Bowel Dis. 2025 Mar 14:izaf046. doi: 10.1093.
    >> Share

  378. THOMANN AK, Wolf RC
    Reply to "Improving Brain-Gut Studies in Crohn's Disease: Methodological Considerations".
    Inflamm Bowel Dis. 2025 Mar 13:izaf051. doi: 10.1093.
    >> Share

  379. DUNLEAVY K, Raffals L
    Total Proctocolectomy Versus Subtotal/Total Colectomy for Neoplasia in Patients With Inflammatory Bowel Disease and Primary Sclerosing Cholangitis.
    Inflamm Bowel Dis. 2025 Mar 13:izaf003. doi: 10.1093.
    >> Share

  380. WU J, Wang W
    Improving Brain-Gut Studies in Crohn's Disease: Methodological Considerations.
    Inflamm Bowel Dis. 2025 Mar 13:izaf055. doi: 10.1093.
    >> Share

  381. CERVERA-SECO L, Baldan-Martin M, Fernandez-Tome S, Ortega Moreno L, et al
    Characterization of the Regulatory Landscape in Crohn's Disease Reveals microRNA-Associated Alterations that Shape Anti-TNF Response.
    Inflamm Bowel Dis. 2025 Mar 11:izaf029. doi: 10.1093.
    >> Share

  382. DUNLEAVY KA, Rypstra CR, Busciglio I, Eckert D, et al
    Intestinal Permeability In Vivo in Patients With Inflammatory Bowel Disease: Comparison of Active Disease and Remission.
    Inflamm Bowel Dis. 2025 Mar 11:izaf043. doi: 10.1093.
    >> Share

  383. TODA M, Jimbo K, Suzuki M, Nagata M, et al
    The Role of Human Leukocyte Antigen Alleles and Maternal Microchimerism in Very-Early-Onset Ulcerative Colitis in Japanese Children.
    Inflamm Bowel Dis. 2025 Mar 10:izaf048. doi: 10.1093.
    >> Share

  384. OLSEN BC, Opheim R, Kristensen VA, Hoivik ML, et al
    Prevalence of Irritable Bowel Syndrome Based on Rome IV Criteria in Patients in Biochemical and Endoscopic Remission From Newly Diagnosed Inflammatory Bowel Disease: One- and Three-Year Results (the IBSEN III Cohort).
    Inflamm Bowel Dis. 2025 Mar 10:izaf047. doi: 10.1093.
    >> Share

  385. MOHAN M, Thoma OM, Sharma S, Sharma G, et al
    Longitudinal Monitoring of Inflammatory Bowel Disease in Mice Using Endoscopic Optical Coherence Tomography.
    Inflamm Bowel Dis. 2025 Mar 10:izaf045. doi: 10.1093.
    >> Share

  386. HABERKAMP S, Fischmann D, Wilde J, Strobel D, et al
    Superb Microvascular Imaging Is Superior to Doppler Imaging in Ruling Out Ulcerative Colitis Disease Activity.
    Inflamm Bowel Dis. 2025 Mar 8:izaf033. doi: 10.1093.
    >> Share

  387. BARENBOIM A, Weiss TE, Argyriou O, Cohen NA, et al
    Evolution of Extraintestinal Manifestations in Patients With Ulcerative Colitis Post-Restorative Proctocolectomy and Ileal Pouch-Anal Anastomosis: A Single-Center Retrospective Study.
    Inflamm Bowel Dis. 2025 Mar 8:izaf037. doi: 10.1093.
    >> Share

  388. SCHELL TL, Caldera F
    Optimizing Hepatitis B Vaccination Strategies for Patients With Inflammatory Bowel Disease.
    Inflamm Bowel Dis. 2025 Mar 7:izaf042. doi: 10.1093.
    >> Share

  389. PLUMB AA, Moran G, Chowdhury K, Ahmed N, et al
    Small Bowel Motility Quantified by Cine MRI to Predict Longer-Term Response in Patients with Crohn's Disease Commencing Biological Therapy: The Motility Study.
    Inflamm Bowel Dis. 2025 Mar 7:izaf023. doi: 10.1093.
    >> Share

  390. ZHANG L, Liu Q, Yang X, Su C, et al
    Mechanosensitive Ion Channel PIEZO1 as a Key Regulator of Intestinal Fibrosis in Crohn's Disease.
    Inflamm Bowel Dis. 2025 Mar 7:izaf041. doi: 10.1093.
    >> Share

  391. LOPES EW, Yu Z, Walsh SE, Casey K, et al
    Dietary Nut and Legume Intake and Risk of Crohn's Disease and Ulcerative Colitis.
    Inflamm Bowel Dis. 2025 Mar 4:izaf032. doi: 10.1093.
    >> Share

  392. KUMAR A, Husain N, Anbazhagan AN, Jayawardena D, et al
    Dexamethasone Upregulates the Expression of the Human SLC26A3 (DRA, Down-Regulated in Adenoma) Transporter (an IBD Susceptibility Gene) in Intestinal Epithelial Cells and Attenuates Gut Inflammation.
    Inflamm Bowel Dis. 2025;31:625-635.
    >> Share

  393. VERSTOCKT S, Hannes L, Jans DS, Deman S, et al
    MIP4IBD: An Easy and Rapid Genotyping-by-Sequencing Assay for the Inflammatory Bowel Diseases Risk Loci.
    Inflamm Bowel Dis. 2025;31:786-799.
    >> Share

  394. LOWELL JA, Sharma G, Swaminath A, Sultan K, et al
    Pharmacologic Anticoagulation Is Associated With a Lower Risk of Recurrent Venous Thromboembolic Events During Janus Kinase Inhibitor Use for Patients With a Prior Thrombosis.
    Inflamm Bowel Dis. 2025;31:725-732.
    >> Share

  395. SILVERMAN AL, Bhasuran B, Mosenia A, Yasini F, et al
    Accurate, Robust, and Scalable Machine Abstraction of Mayo Endoscopic Subscores From Colonoscopy Reports.
    Inflamm Bowel Dis. 2025;31:665-670.
    >> Share

  396. MALTER L, Hong SJ, Lopatin S, Murphy M, et al
    Increasing Exposure to Inflammatory Bowel Diseases Education in Gastroenterology Fellowship: The Pilot IBD 101 Experience.
    Inflamm Bowel Dis. 2025;31:746-750.
    >> Share

    February 2025
  397. SANDS BE, Dubinsky MC, Kotze PG, Vermeire S, et al
    Efficacy and Safety of Etrasimod in Patients With Moderately to Severely Active Ulcerative Colitis Stratified by Baseline Modified Mayo Score: A Post Hoc Analysis From the Phase 3 ELEVATE UC Clinical Program.
    Inflamm Bowel Dis. 2025 Feb 28:izaf036. doi: 10.1093.
    >> Share

  398. EHRLICH S, Long M, Kane S, Mahadevan U, et al
    Placental Transfer of Upadacitinib Among Pregnant Women with Inflammatory Bowel Disease.
    Inflamm Bowel Dis. 2025 Feb 21:izaf027. doi: 10.1093.
    >> Share

  399. VERMEER E, Struys EA, Lin M, van Limbergen JE, et al
    Erythrocyte Methotrexate-Polyglutamate Concentrations in Pediatric Inflammatory Bowel Disease.
    Inflamm Bowel Dis. 2025 Feb 21:izaf035. doi: 10.1093.
    >> Share

  400. WILS P, Habibi Kavashkohie MR, Selos Guerra F, Landais S, et al
    Single-Cell Transcriptomic Profile of Innate Cell Populations in Mesenteric Lymph Nodes of Inflammatory Bowel Disease Patients.
    Inflamm Bowel Dis. 2025 Feb 21:izaf017. doi: 10.1093.
    >> Share

  401. LIN K, Feng W, Li S
    Addressing the Challenges of Inflammatory Bowel Disease-Primary Sclerosing Cholangitis Treatment: Prognosis Optimization Strategies in the Era of Precision Medicine.
    Inflamm Bowel Dis. 2025 Feb 20:izaf007. doi: 10.1093.
    >> Share

  402. NAKAMURA A, Jimbo K, Suzuki M, Hibio M, et al
    Impact of Psychosocial and Neurodevelopmental Disorders on Pediatric Ulcerative Colitis: A Single-Center, Retrospective, Observational Study.
    Inflamm Bowel Dis. 2025 Feb 20:izaf034. doi: 10.1093.
    >> Share

  403. ACHARJEE A, Shivaji U, Santacroce G, Akiror S, et al
    Novel Transcriptomic Signatures in Fibrostenotic Crohn's Disease: Dysregulated Pathways, Promising Biomarkers, and Putative Therapeutic Targets.
    Inflamm Bowel Dis. 2025 Feb 20:izaf021. doi: 10.1093.
    >> Share

  404. JACOBSEN GE, Gonzalez EE, Mendygral P, Faust KM, et al
    Deep Sequencing of Crohn's Disease Lamina Propria Phagocytes Identifies Pathobionts and Correlates With Pro-Inflammatory Gene Expression.
    Inflamm Bowel Dis. 2025 Feb 14:izae316. doi: 10.1093.
    >> Share

  405. KIOROGLOU D, Pena-Cearra A, Corraliza AM, Seoane I, et al
    Mitochondrial Dysfunction: Unraveling the Elusive Biology Behind Anti-TNF Response During Ulcerative Colitis.
    Inflamm Bowel Dis. 2025 Feb 13:izaf015. doi: 10.1093.
    >> Share

  406. HOWE CS, Chulkina M, Syrcle R, McAninch C, et al
    MK2 Inhibition in CD4+ T Cells Protects Against IFNgamma and IL-17A, Chronic Inflammation, and Fibrosis in Inflammatory Bowel Disease Models.
    Inflamm Bowel Dis. 2025 Feb 12:izaf026. doi: 10.1093.
    >> Share


  407. Correction to: Estimation of the Harvey Bradshaw Index from the Patient Reported Outcome-2 in Crohn's Disease.
    Inflamm Bowel Dis. 2025 Feb 11:izaf014. doi: 10.1093.
    >> Share

  408. LOPETUSO LR, Deleu S, Puca P, Abreu MT, et al
    Guidance for Fecal Microbiota Transplantation Trials in Ulcerative Colitis: The Second ROME Consensus Conference.
    Inflamm Bowel Dis. 2025 Feb 11:izaf013. doi: 10.1093.
    >> Share

  409. KALAFATELI M, Tourkochristou E, Tsounis EP, Aggeletopoulou I, et al
    New Insights into the Pathogenesis of Intestinal Fibrosis in Inflammatory Bowel Diseases: Focusing on Intestinal Smooth Muscle Cells.
    Inflamm Bowel Dis. 2025;31:579-592.
    >> Share

  410. LEVINE I, Sekhri S, Schreiber-Stainthorp W, Locke B, et al
    GLP-1 Receptor Agonists Confer No Increased Rates of IBD Exacerbation Among Patients With IBD.
    Inflamm Bowel Dis. 2025;31:467-475.
    >> Share

  411. MISHIMA T, Fujimoto M, Urushima H, Funajima E, et al
    A Role for Leucine-Rich alpha2-Glycoprotein in Leukocyte Trafficking and Mucosal Inflammation in Inflammatory Bowel Disease.
    Inflamm Bowel Dis. 2025 Feb 7:izaf022. doi: 10.1093.
    >> Share

  412. CHIEPPA M, De Santis S, Verna G
    Winnie Mice: A Chronic and Progressive Model of Ulcerative Colitis.
    Inflamm Bowel Dis. 2025 Feb 6:izaf006. doi: 10.1093.
    >> Share

  413. VAN LINSCHOTEN RCA, van der Woude CJ, Visser E, van Leeuwen N, et al
    Variation Between Hospitals in Outcomes and Costs of IBD Care: Results From the IBD Value Study.
    Inflamm Bowel Dis. 2025;31:332-343.
    >> Share

  414. KRUGLIAK CLEVELAND N, Bhondwe KS, Duty CM, Rubin DT, et al
    Intestinal Ultrasound Identified Crohn's Disease In Previously Undiagnosed Siblings.
    Inflamm Bowel Dis. 2025 Feb 4:izaf019. doi: 10.1093.
    >> Share

  415. FRIEDMAN S, Garvik OS, Nielsen J, Jolving LR, et al
    The Consequences of Preterm Birth in the Children of Mothers with Inflammatory Bowel Disease: A Nationwide Cohort Study.
    Inflamm Bowel Dis. 2025 Feb 3:izaf010. doi: 10.1093.
    >> Share

    January 2025
  416. KORNELSEN J, McIver TA, Marrie RA, Patel R, et al
    Resting-State Functional Connectivity of the Cerebellum Differs Between Persons With Inflammatory Bowel Disease and Healthy Controls in Relation to Executive Function.
    Inflamm Bowel Dis. 2025 Jan 31:izaf020. doi: 10.1093.
    >> Share

  417. CHHIBBA T, Frolkis A, Stein LR, Lee S, et al
    Generalizability of Randomized Controlled Trials to Routine Clinical Care in Ulcerative Colitis.
    Inflamm Bowel Dis. 2025 Jan 30:izaf012. doi: 10.1093.
    >> Share

  418. ROSEIRA J, Jairath V
    Bridging the Gap Between Explanatory and Pragmatic Trials in Inflammatory Bowel Disease.
    Inflamm Bowel Dis. 2025 Jan 28:izae314. doi: 10.1093.
    >> Share

  419. TAKEDOMI H, Nunomura S, Nanri Y, Honda Y, et al
    Serum Periostin is Able to Stratify Type 2-Dominant Ulcerative Colitis.
    Inflamm Bowel Dis. 2025 Jan 27:izaf009. doi: 10.1093.
    >> Share

  420. ALLEGRETTI JR, Feuerstadt P, Knapple WL, Orenstein R, et al
    Safety and Efficacy of Fecal Microbiota, Live-jslm (REBYOTA(R)), for the Prevention of Recurrent Clostridioides difficile Infection in Participants With Inflammatory Bowel Disease in PUNCH CD3-OLS.
    Inflamm Bowel Dis. 2025 Jan 25:izae291. doi: 10.1093.
    >> Share

  421. DILLMAN JR, Tkach JA, Fletcher JG, Bruining DH, et al
    Circulating and Magnetic Resonance Imaging Biomarkers of Intestinal Fibrosis in Small Bowel Crohn's Disease.
    Inflamm Bowel Dis. 2025 Jan 24:izae319. doi: 10.1093.
    >> Share

  422. QIN X
    Emerging Connections Between Inflammatory Bowel Disease Subtypes and Sequential Changes in Total Serum Bilirubin.
    Inflamm Bowel Dis. 2025 Jan 20:izaf004. doi: 10.1093.
    >> Share

  423. GOLAN-GERSTL R, Ben Ya'acov A, Musseri M, Goldenberg R, et al
    Expression Profile of MicroRNAs in Breast Milk of Women With Inflammatory Bowel Disease: Correlation With Disease Activity and Medical Treatments.
    Inflamm Bowel Dis. 2025 Jan 17:izae290. doi: 10.1093.
    >> Share

  424. WEINTRAUB Y, Collen LV, Hussey S, Mitrova K, et al
    Effectiveness and Safety of Adalimumab in Patients With Very Early-Onset Inflammatory Bowel Disease: A Retrospective Study on Behalf of the Porto Inflammatory Bowel Disease Working Group of European Society for Pediatric Gastroenterology Hepatology an
    Inflamm Bowel Dis. 2025 Jan 15:izae302. doi: 10.1093.
    >> Share

  425. THOMANN AK, Schmitgen MM, Stephan JC, Knoedler LL, et al
    Disease-State Dependent Associations Between Intrinsic Brain Function and Symptoms of Fatigue, Depression, and Anxiety in Crohn's Disease.
    Inflamm Bowel Dis. 2025 Jan 15:izae318. doi: 10.1093.
    >> Share

  426. SUGIYAMA Y, Konishi H, Dokoshi T, Tanaka H, et al
    hsa_circ_0015388 Reduces Macrophage Derived Reactive Oxygen Species in Crohn's Disease.
    Inflamm Bowel Dis. 2025 Jan 13:izae317. doi: 10.1093.
    >> Share

  427. NISHIDA Y, Hosomi S, Fujimoto K, Kobayashi Y, et al
    Impact of 5-Aminosalicylic Acid on Ustekinumab in Inflammatory Bowel Disease: A Retrospective Medical Claims Analysis.
    Inflamm Bowel Dis. 2025 Jan 11:izaf001. doi: 10.1093.
    >> Share

  428. ZHANG X
    Postpartum Wound Healing for Mothers with Inflammatory Bowel Disease: Cause for Worry? Insights from the Pregnancy in Inflammatory Bowel Disease and Neonatal Outcomes Registry.
    Inflamm Bowel Dis. 2025 Jan 8:izae309. doi: 10.1093.
    >> Share

  429. LIU Y, Sha S, Ran Q, Shi H, et al
    The Correlation Between Fecal Amino Acids, Colonic Mucosal Taste Receptors, and Clinical Features and Indicators of Ulcerative Colitis: A Multicenter Exploratory Study.
    Inflamm Bowel Dis. 2025 Jan 7:izae299. doi: 10.1093.
    >> Share

  430. ESAI SELVAN M, Nathan DI, Guisado D, Collatuzzo G, et al
    Clonal Hematopoiesis of Indeterminate Potential in Crohn's Disease and Ulcerative Colitis.
    Inflamm Bowel Dis. 2025 Jan 6:izae312. doi: 10.1093.
    >> Share

  431. ARUMUGAM P, Saha K, Nighot P
    Intestinal Epithelial Tight Junction Barrier Regulation by Novel Pathways.
    Inflamm Bowel Dis. 2025;31:259-271.
    >> Share

  432. LING F, Chen Y, Li J, Xu M, et al
    Estrogen Receptor beta Activation Mitigates Colitis-associated Intestinal Fibrosis via Inhibition of TGF-beta/Smad and TLR4/MyD88/NF-kappaB Signaling Pathways.
    Inflamm Bowel Dis. 2025;31:11-27.
    >> Share

  433. UCHINO T, Lincango EP, Hernandez Dominguez O, Bhama A, et al
    Rediversion of the Failing Ileoanal Pouch: First Step in Pouch Salvage?
    Inflamm Bowel Dis. 2025;31:105-112.
    >> Share

  434. PLECHSCHMIDT J, Fietkau K, Hepp T, Dietrich P, et al
    Clinical Pharmacist Counselling Improves Long-term Medication Safety and Patient-reported Outcomes in Anti-TNF-treated Patients With Inflammatory Bowel Diseases: The Prospective, Randomized AdPhaNCED Trial.
    Inflamm Bowel Dis. 2025;31:77-86.
    >> Share

  435. DAUNGSUPAWONG H, Wiwanitkit V
    Ozanimod and Vedolizumab as First-Line Advanced Therapies in Ulcerative Colitis.
    Inflamm Bowel Dis. 2025 Jan 2:izae315. doi: 10.1093.
    >> Share

    December 2024
  436. DESAI A, Kochhar GS
    Letter: Ozanimod and Vedolizumab as First-Line Advanced Therapies in Ulcerative Colitis: Authors' Reply.
    Inflamm Bowel Dis. 2024 Dec 27:izae304. doi: 10.1093.
    >> Share

  437. VISSERS E, Wellens J, Giorio L, Zadora W, et al
    Dietary Carrageenan Amplifies the Inflammatory Profile, but not Permeability, of Intestinal Epithelial Cells from Patients With Crohn's Disease.
    Inflamm Bowel Dis. 2024 Dec 24:izae306. doi: 10.1093.
    >> Share

  438. LELONG M, Bourreille A, Mosnier JF, Trang-Poisson C, et al
    Acute Severe Ulcerative Colitis and Cytomegalovirus During Pregnancy: A Case Report.
    Inflamm Bowel Dis. 2024 Dec 24:izae313. doi: 10.1093.
    >> Share

  439. GIBSON G, Rioux JD, Cho JH, Haritunians T, et al
    Eleven Grand Challenges for Inflammatory Bowel Disease Genetics and Genomics.
    Inflamm Bowel Dis. 2024 Dec 19:izae269. doi: 10.1093.
    >> Share

  440. LUND C, Strande V, Hagen M, Bengtson MB, et al
    Low Surgery Rates in Early Crohn's Disease: Results from a Prospective Population-Based Inception Cohort-The Inflammatory Bowel Disease in South-Eastern Norway III Study.
    Inflamm Bowel Dis. 2024 Dec 19:izae297. doi: 10.1093.
    >> Share

  441. UKASHI O, Lahat A, Ungar B, Veisman I, et al
    Intestinal Ultrasound Measures are Strongly Correlated With Small Bowel Endoscopic Lewis Score in Active Crohn's Disease.
    Inflamm Bowel Dis. 2024 Dec 19:izae296. doi: 10.1093.
    >> Share

  442. LEGA S, Bramuzzo M
    Advancing Toward Transmural Healing in Pediatric Crohn's Disease.
    Inflamm Bowel Dis. 2024 Dec 17:izae224. doi: 10.1093.
    >> Share

  443. SCARALLO L, McKay HE, Schneider R, Ricciuto A, et al
    Improvement of Transmural Inflammation With Adalimumab Versus Immunomodulator Maintenance Therapy in Pediatric Crohn's Disease: Single-Center Prospective Evaluation Using the Pediatric Inflammatory Crohn's Magnetic Resonance Enterography Index.
    Inflamm Bowel Dis. 2024 Dec 17:izae227. doi: 10.1093.
    >> Share

  444. KAMP K, Yang PL, Tsai CS, Zhang X, et al
    Gender and Sex Differences in Abdominal Pain, Fatigue, And Psychological Symptoms Among Adults with Inflammatory Bowel Disease: A Network Analysis.
    Inflamm Bowel Dis. 2024 Dec 13:izae279. doi: 10.1093.
    >> Share

  445. SCOTT G, Wands DIF, Wilson DC, Hansen R, et al
    Selecting High-Risk Patients With Pediatric Crohn's Disease for Top-Down Anti-TNF as per the 2021 ECCO-ESPGHAN Guidelines: A 5-Year Nationwide Retrospective Analysis From Scotland (2016-2020).
    Inflamm Bowel Dis. 2024 Dec 13:izae298. doi: 10.1093.
    >> Share

  446. NAKANISHI R, Kuwada T, Shiokawa M, Nishikawa Y, et al
    Anti-integrin alphavbeta6 Antibodies Predict Pouchitis in Patients With Ulcerative Colitis After Restorative Proctocolectomy With Ileal Pouch-Anal Anastomosis.
    Inflamm Bowel Dis. 2024 Dec 6:izae263. doi: 10.1093.
    >> Share

  447. SHARIP MT, Parkes M, Subramanian S
    Predicting Adverse Events to Thiopurines in IBD: Are We a Step Closer?
    Inflamm Bowel Dis. 2024;30:2521-2522.
    >> Share

  448. LAGRANGE J, Ahmed MU, Arnone D, Lacolley P, et al
    Implications of von Willebrand Factor in Inflammatory Bowel Diseases: Beyond Bleeding and Thrombosis.
    Inflamm Bowel Dis. 2024;30:2500-2508.
    >> Share

  449. GU P, Mendonca O, Carter D, Dube S, et al
    AI-luminating Artificial Intelligence in Inflammatory Bowel Diseases: A Narrative Review on the Role of AI in Endoscopy, Histology, and Imaging for IBD.
    Inflamm Bowel Dis. 2024;30:2467-2485.
    >> Share

  450. THAPWONG P, Norton C, Rowland E, Czuber-Dochan W, et al
    Our Life Is a Rollercoaster! A Qualitative Phenomenological Study Exploring the Impact of IBD on Family Members.
    Inflamm Bowel Dis. 2024;30:2395-2404.
    >> Share

  451. DERBEY L, Charlois AL, Buisson A, Roblin X, et al
    Physical Activity and IBD: State of Art and Knowledge, Patients and Healthcare Professionals Points of View, A French Multicenter Cross Sectional Study.
    Inflamm Bowel Dis. 2024;30:2306-2313.
    >> Share

  452. VESTERGAARD T, Holm Meiltoft I, Julsgaard M, Bek Helmig R, et al
    Preterm Birth and in Utero Exposure to Corticosteroids Are Associated With Increased Infection Risk in Children of Mothers With IBD.
    Inflamm Bowel Dis. 2024;30:2297-2305.
    >> Share

  453. ZHAO M, Riis LB, Lo B, Attauabi M, et al
    Histological, But Neither Clinical Nor Endoscopic Activity Predicts the Risk of Colectomy in Patients With Ulcerative Colitis Treated With Biologics.
    Inflamm Bowel Dis. 2024 Dec 4:izae287. doi: 10.1093.
    >> Share

  454. NAKASE H, Danese S, Reinisch W, Ritter T, et al
    Mediators of Filgotinib Treatment Effects in Ulcerative Colitis: Exploring Circulating Biomarkers in the Phase 2b/3 SELECTION Study.
    Inflamm Bowel Dis. 2024 Dec 4:izae278. doi: 10.1093.
    >> Share

  455. KHANNA R, Son S, Zou G, Roshanov PS, et al
    Estimation of the Harvey Bradshaw Index from the Patient-Reported Outcome 2 in Crohn's Disease: Results Based on a Large Scale Randomized Controlled Trial.
    Inflamm Bowel Dis. 2024 Dec 4:izae281. doi: 10.1093.
    >> Share


  456. Correction to: Risankizumab Is Effective for the Management of Crohn's Disease of the Pouch.
    Inflamm Bowel Dis. 2024 Dec 4:izae295. doi: 10.1093.
    >> Share

    November 2024
  457. DULAI PS, Johnson E, Cox K, Eldasher LM, et al
    Provider Education and Clinical Decision Support Tool Improve Proficiency in Advanced Therapies for Inflammatory Bowel Disease.
    Inflamm Bowel Dis. 2024 Nov 29:izae270. doi: 10.1093.
    >> Share

  458. YANG E, Wayne PM, Ahn AC, Korzenik J, et al
    Potential Utility of Laser Speckle Contrast Imaging to Detect Early Microcirculatory Changes Associated With Erythema Nodosum in Crohn's Disease: A Case Report.
    Inflamm Bowel Dis. 2024 Nov 28:izae284. doi: 10.1093.
    >> Share

  459. SHARIF K, Ben-Horin S, Lahat A
    Eco-gastroenterology in Inflammatory Bowel Disease Treatment: A Call for Sustainable Healthcare.
    Inflamm Bowel Dis. 2024 Nov 27:izae280. doi: 10.1093.
    >> Share

  460. NIELSEN J, Friedman S, Norgard BM, Knudsen T, et al
    Glucagon-Like Peptide 1 Receptor Agonists Are Not Associated With an Increased Risk of Ileus or Intestinal Obstruction in Patients with Inflammatory Bowel Disease-A Danish Nationwide Cohort Study.
    Inflamm Bowel Dis. 2024 Nov 27:izae276. doi: 10.1093.
    >> Share

  461. MANESS SB
    Iron Deficiency Anemia in Patients with Inflammatory Bowel Disease: A Call to Action to Improve Patient Care.
    Inflamm Bowel Dis. 2024 Nov 23:izae277. doi: 10.1093.
    >> Share

  462. GOLOB J, Rao K, Berinstein JA, Singh P, et al
    Why Symptoms Linger in Quiescent Crohn's Disease: Investigating the Impact of Sulfidogenic Microbes and Sulfur Metabolic Pathways.
    Inflamm Bowel Dis. 2024 Nov 14:izae238. doi: 10.1093.
    >> Share

  463. HARVEY PR, McNulty D, Coupland B, Kemos P, et al
    The Risk of Venous Thromboembolism in Children With Inflammatory Bowel Disease.
    Inflamm Bowel Dis. 2024 Nov 14:izae249. doi: 10.1093.
    >> Share

  464. FISCHMAN M, Godny L, Friedenberg A, Barkan R, et al
    Factors Associated With Biologic Therapy After Ileal Pouch-Anal Anastomosis in Patients With Ulcerative Colitis.
    Inflamm Bowel Dis. 2024 Nov 14:izae272. doi: 10.1093.
    >> Share

  465. QAPAJA T, Abu-Rumaileh M, Alsabbagh Alchirazi K, Gharaibeh A, et al
    Biologics and Oral Small Molecules Are Not Associated With Increased Major Adverse Cardiovascular Events or Venous Thromboembolism in Inflammatory Bowel Disease.
    Inflamm Bowel Dis. 2024 Nov 13:izae267. doi: 10.1093.
    >> Share


  466. Correction to: Health-Related Quality of Life Outcomes With Etrasimod Treatment in Patients With Ulcerative Colitis: A Post Hoc Analysis of Data From ELEVATE UC 52 and ELEVATE UC 12.
    Inflamm Bowel Dis. 2024 Nov 13:izae252. doi: 10.1093.
    >> Share

  467. SALWEN-DEREMER JK, Westvold SJ, Siegel CA, Smith MT, et al
    The Bidirectional Relationship Between Sleep and Pain in Crohn's Disease: A Daily Diary Study.
    Inflamm Bowel Dis. 2024 Nov 12:izae265. doi: 10.1093.
    >> Share

  468. FANSIWALA K, Limketkai BN
    Stricturing Crohn's Disease: When Biologics May Help or Not?
    Inflamm Bowel Dis. 2024 Nov 12:izae264. doi: 10.1093.
    >> Share

  469. KOJIMA T, Kurachi K, Tatsuta K, Sugiyama K, et al
    Myosteatosis Evaluated Based on Intramuscular Adipose Tissue Content Is a Risk Factor for Postoperative Complications in Crohn's Disease.
    Inflamm Bowel Dis. 2024 Nov 11:izae247. doi: 10.1093.
    >> Share

  470. EDWARDS TS, Ho SSC, Brown SC, Appleton L, et al
    Fecal Myeloperoxidase Levels Reflect Disease Activity in Children With Crohn's Disease.
    Inflamm Bowel Dis. 2024 Nov 11:izae262. doi: 10.1093.
    >> Share

  471. MASSIRONI S, Danese S
    Reply: MIND the Gap: Psychiatric Conditions in Inflammatory Bowel Disease.
    Inflamm Bowel Dis. 2024 Nov 5:izae258. doi: 10.1093.
    >> Share

  472. BRODERSEN JB, Rafaelsen SR, Juel MA, Knudsen T, et al
    Assessment of Treatment Response in Known Crohn's Disease-A Prospective Blinded Study Comparing the Diagnostic Accuracy of Intestinal Ultrasound, Magnetic Resonance Enterocolonography, Panenteric Capsule Endoscopy, and Fecal Calprotectin.
    Inflamm Bowel Dis. 2024 Nov 4:izae254. doi: 10.1093.
    >> Share

  473. ARBABZADA N, Dennett L, Meng G, Peerani F, et al
    The Effectiveness of Oral Vancomycin on Inflammatory Bowel Disease in Patients With Primary Sclerosing Cholangitis: A Systematic Review.
    Inflamm Bowel Dis. 2024 Nov 4:izae257. doi: 10.1093.
    >> Share

  474. KOKKOTIS G, Filidou E, Tarapatzi G, Spathakis M, et al
    Oncostatin M Induces a Pro-inflammatory Phenotype in Intestinal Subepithelial Myofibroblasts.
    Inflamm Bowel Dis. 2024;30:2162-2173.
    >> Share

  475. LIU J, Xu L, Wang L, Wang Q, et al
    Naringin Alleviates Intestinal Fibrosis by Inhibiting ER Stress-Induced PAR2 Activation.
    Inflamm Bowel Dis. 2024;30:1946-1956.
    >> Share

  476. ROSHANOV PS, Khanna R
    The Clinical Interpretation of Noninferiority Trials.
    Inflamm Bowel Dis. 2024;30:2191-2194.
    >> Share

  477. HOELZ H, Bragagna L, Litwin A, Koletzko S, et al
    Pediatric IBD Patients Treated With Infliximab and Proactive Drug Monitoring Benefit From Early Concomitant Immunomodulatory Therapy: A Retrospective Analysis of a 10-Year Real-Life Cohort.
    Inflamm Bowel Dis. 2024;30:2004-2018.
    >> Share


  478. Correction to: TOpClass Class 4 Perineal Crohn's Disease: A Systematic Review and Meta-analysis of Perineal Wound Complication After Proctectomy in Crohn's Patients.
    Inflamm Bowel Dis. 2024 Nov 2:izae268. doi: 10.1093.
    >> Share

    October 2024
  479. KOCHHAR GS, Khataniar H, Hashash JG, Tabaku F, et al
    Comparative Effectiveness of Ozanimod and Vedolizumab as First-Line Advanced Therapies in Ulcerative Colitis: A Propensity-Matched Cohort Analysis.
    Inflamm Bowel Dis. 2024 Oct 30:izae251. doi: 10.1093.
    >> Share

  480. MACALUSO FS, Renna S, Fries W, Viola A, et al
    The Effectiveness of Risankizumab as Induction Therapy for Crohn's Disease: Data From the Sicilian Network for Inflammatory Bowel Diseases.
    Inflamm Bowel Dis. 2024 Oct 26:izae248. doi: 10.1093.
    >> Share

  481. SANDS BE, D'Haens G, Clemow DB, Irving PM, et al
    Three-Year Efficacy and Safety of Mirikizumab Following 152 Weeks of Continuous Treatment for Ulcerative Colitis: Results From the LUCENT-3 Open-Label Extension Study.
    Inflamm Bowel Dis. 2024 Oct 25:izae253. doi: 10.1093.
    >> Share

  482. BAYOUMY AB, Derijks LJJ, de Boer NKH
    DNA-Thioguanine (DNA-TG) Is a Promising Novel Method to Predict Adverse Events to Thiopurine in Inflammatory Bowel Disease.
    Inflamm Bowel Dis. 2024 Oct 24:izae234. doi: 10.1093.
    >> Share

  483. CAO D, Hu M, Yang N, Qian K, et al
    Microbial and Transcriptomic Landscape Associated With Neutrophil Extracellular Traps in Perianal Fistulizing Crohn's Disease.
    Inflamm Bowel Dis. 2024 Oct 22:izae202. doi: 10.1093.
    >> Share

  484. SHAHIN TB, Khan N, Malik TA
    Risankizumab Is Effective for the Management of Crohn's Disease of the Pouch.
    Inflamm Bowel Dis. 2024 Oct 22:izae241. doi: 10.1093.
    >> Share

  485. POULSEN A, Alexdottir MS, Riis LB, Pehrsson M, et al
    Circulating Extracellular Matrix Products as Indicators of Disease Burden and Predictors of Disease Course in Ulcerative Colitis.
    Inflamm Bowel Dis. 2024 Oct 22:izae244. doi: 10.1093.
    >> Share

  486. LIU F, Ai F, Tang A, Yang Z, et al
    Macrophage-Derived Exosomes Promoted the Development and Stemness of Inflammatory Bowel Disease-Related Colorectal Cancer via nuclear paraspeckle assembly transcript 1-Mediated miRNA-34a-5p/phosphoprotein enriched in astrocytes 15 Axis.
    Inflamm Bowel Dis. 2024 Oct 19:izae212. doi: 10.1093.
    >> Share

  487. KUMAR A, Quraishi MN, Al-Hassi HO, Elasrag M, et al
    The Effect of Colesevelam on the Microbiome in Postoperative Crohn's Disease.
    Inflamm Bowel Dis. 2024 Oct 18:izae230. doi: 10.1093.
    >> Share

  488. NICHOLS B, Russell RK, Short B, Papadopoulou R, et al
    Gut Microbial Signatures in Pediatric Crohn's Disease Vary According to Disease Activity Measures and Are Influenced by Proxies of Gastrointestinal Transit Time: An ImageKids Study.
    Inflamm Bowel Dis. 2024 Oct 17:izae199. doi: 10.1093.
    >> Share

  489. DA SILVA BC, Papasotiriou S, Hanauer SB
    Corticosteroid Use in Randomized Clinical Trials of Biologics and Small Molecules in Inflammatory Bowel Disease: A Systematic Review.
    Inflamm Bowel Dis. 2024 Oct 17:izae240. doi: 10.1093.
    >> Share

  490. MOSES J, Adler J, Saeed SA, Firestine AM, et al
    Low Anti-Tumor Necrosis Factor Levels During Maintenance Phase Are Associated With Treatment Failure in Children With Crohn's Disease.
    Inflamm Bowel Dis. 2024 Oct 17:izae239. doi: 10.1093.
    >> Share

  491. KASTL AJ, Brenner EJ, Weaver KN, Zhang X, et al
    Durable Immune Response and Long-term Efficacy of COVID-19 Vaccination in Children With Inflammatory Bowel Disease.
    Inflamm Bowel Dis. 2024 Oct 16:izae225. doi: 10.1093.
    >> Share

  492. HASSAN B, Suchan A, Brown M, Kishan A, et al
    The Impact of Hormone Therapy on Inflammatory Bowel Disease in Transgender and Nonbinary Individuals.
    Inflamm Bowel Dis. 2024 Oct 16:izae236. doi: 10.1093.
    >> Share

  493. CHAABAN L, Cohen B, Cross RK, Kayal M, et al
    Predicting Outcomes in Hospitalized Patients With Acute Severe Ulcerative Colitis in a Prospective Multicenter Cohort.
    Inflamm Bowel Dis. 2024 Oct 9:izae193. doi: 10.1093.
    >> Share

  494. JORDAN AA, Bhat S, Ali T, Brunskill SR, et al
    Healthcare Access for Patients With Inflammatory Bowel Disease in the United States: A Survey by the Crohn's & Colitis Foundation.
    Inflamm Bowel Dis. 2024 Oct 8:izae237. doi: 10.1093.
    >> Share

  495. HYAMS JS, Winter HS, Mulberg AE, Zuckerman E, et al
    An Open Letter to the Food and Drug Administration and Pharmaceutical Industry Concerning Drug Approval for Children With Inflammatory Bowel Disease.
    Inflamm Bowel Dis. 2024 Oct 8:izae226. doi: 10.1093.
    >> Share

  496. ALIPOURIANI A, Erozkan K, Schabl L, Sancheti H, et al
    TOpClass Class 4 Perineal Crohn's Disease: A Systematic Review and Meta-analysis of Perineal Wound Complication After Proctectomy in Crohn's Patients.
    Inflamm Bowel Dis. 2024 Oct 8:izae198. doi: 10.1093.
    >> Share

  497. GLICKMAN D, Dalessio S, Raup-Konsavage WM, Vrana KE, et al
    Response to the Letter to the Editor, "Refining the Understanding of Cannabis Impact on Inflammatory Bowel Disease Outcomes: Recommendations for Enhanced Research and Healthcare Practices".
    Inflamm Bowel Dis. 2024 Oct 3:izae228. doi: 10.1093.
    >> Share

  498. COELHO T, Cheng G, Vazquez Lopez F, Ashton JJ, et al
    Reply: Predicting Adverse Events to Thiopurines in IBD: Are We a Step Closer?
    Inflamm Bowel Dis. 2024;30:1928-1930.
    >> Share

  499. MASPERO M, Otero A, Lavryk O, Holubar SD, et al
    Incidental Dysplasia During Total Proctocolectomy With Ileoanal Pouch: Is It Associated With Worse Outcomes?
    Inflamm Bowel Dis. 2024;30:1740-1747.
    >> Share


  500. Correction to: Endoscopic Skipping, Stricturing, and Penetrating Complications in Crohn's Disease on Tandem Ileo-colonoscopy and Cross-sectional Imaging: A Retrospective Cohort Study.
    Inflamm Bowel Dis. 2024 Oct 1:izae246. doi: 10.1093.
    >> Share

    September 2024
  501. CARVALHO T, Pinto J, Araujo J, Fernandes D, et al
    Challenges in the Management of Acute Severe Ulcerative Colitis in a Patient With Guillain-Barre Syndrome Associated With Infliximab.
    Inflamm Bowel Dis. 2024 Sep 28:izae235. doi: 10.1093.
    >> Share

  502. GE H, Wang C, Zhao H, Chen H, et al
    Targeting NCAPD2 as a Therapeutic Strategy for Crohn's Disease: Implications for Autophagy and Inflammation.
    Inflamm Bowel Dis. 2024 Sep 28:izae211. doi: 10.1093.
    >> Share

  503. ODUFALU FD, Gonzalez S, Hurtado ACM, Hsiao J, et al
    A Review of Cutaneous Extraintestinal Manifestations of Inflammatory Bowel Disease in Skin of Color.
    Inflamm Bowel Dis. 2024 Sep 28:izae222. doi: 10.1093.
    >> Share

  504. PORTH R, Deyhim T, Geeganage G, Smith B, et al
    Proactive Therapeutic Drug Monitoring of Ustekinumab Is Associated With Increased Drug Persistence in Patients With Inflammatory Bowel Disease.
    Inflamm Bowel Dis. 2024 Sep 26:izae231. doi: 10.1093.
    >> Share

  505. UZZAN M, Georgiev G, Peyrin-Biroulet L, Bouhnik Y, et al
    Screen Failures and Causes in Inflammatory Bowel Disease Randomized Controlled Trials: A Study of 16 913 Screened Patients.
    Inflamm Bowel Dis. 2024 Sep 26:izae233. doi: 10.1093.
    >> Share

  506. ARMUZZI A, Rubin DT, Schreiber S, Panes J, et al
    Health-Related Quality of Life Outcomes With Etrasimod Treatment in Patients With Ulcerative Colitis: A Post Hoc Analysis of Data From ELEVATE UC 52 and ELEVATE UC 12.
    Inflamm Bowel Dis. 2024 Sep 26:izae229. doi: 10.1093.
    >> Share


  507. Correction to: Consensus Statement on Managing Anxiety and Depression in Individuals with Inflammatory Bowel Disease.
    Inflamm Bowel Dis. 2024 Sep 25:izae243. doi: 10.1093.
    >> Share

  508. WANDS DIF, Gianolio L, Cameron F, Hansen R, et al
    Pediatric Inflammatory Bowel Disease Type Unclassified: A Nationwide Cohort Study in Scotland With up to 20 Years Follow-up Shows Reclassification in the Majority and Mild Course in Those Whose Diagnosis Is Unchanged.
    Inflamm Bowel Dis. 2024 Sep 25:izae218. doi: 10.1093.
    >> Share

  509. HUSSAIN FS, Potlach T, Chi X, Gurka MJ, et al
    Healthcare Utilization and Geographic Distribution of Advanced Therapy in Minority Race and Ethnic Groups With Inflammatory Bowel Disease.
    Inflamm Bowel Dis. 2024 Sep 25:izae219. doi: 10.1093.
    >> Share

  510. RIPOLLES T, Poza J, Martinez-Perez MJ, Suarez Ferrer C, et al
    Evaluation of Crohn's Disease Activity: Validation of a Segmental Simple Ultrasound Score in a Multicenter Study.
    Inflamm Bowel Dis. 2024 Sep 21:izae213. doi: 10.1093.
    >> Share

  511. DALAL RS
    Limiting Opioid Use for Patients Who Are Hospitalized for Inflammatory Bowel Disease Exacerbations.
    Inflamm Bowel Dis. 2024 Sep 19:izae214. doi: 10.1093.
    >> Share

  512. KARLOVICH N, McConnell R, Velayos F, Mahadevan U, et al
    Opioid Use and Outcomes in Patients Hospitalized With Acute Severe Ulcerative Colitis.
    Inflamm Bowel Dis. 2024 Sep 18:izae216. doi: 10.1093.
    >> Share

  513. RUBIN DT, Kubassova O, Weber CR, Adsul S, et al
    Deployment of an Artificial Intelligence Histology Tool to Aid Qualitative Assessment of Histopathology Using the Nancy Histopathology Index in Ulcerative Colitis.
    Inflamm Bowel Dis. 2024 Sep 16:izae204. doi: 10.1093.
    >> Share


  514. Correction to: Factors Associated With Extraintestinal Manifestations of Inflammatory Bowel Disease in SPARC-IBD.
    Inflamm Bowel Dis. 2024 Sep 14:izae217. doi: 10.1093.
    >> Share

  515. GUO A, Ludvigsson J, Hard Af Segerstad EM, Brantsaeter AL, et al
    Early-Life Diet Diversity and the Subsequent Risk of Inflammatory Bowel Disease: Findings From Two Scandinavian Birth Cohorts.
    Inflamm Bowel Dis. 2024 Sep 13:izae210. doi: 10.1093.
    >> Share

  516. PAPADOPOULOS V, Skendros P
    On the Association Between the E148Q Single-nucleotide Polymorphism of the MEFV Gene and Crohn's Disease.
    Inflamm Bowel Dis. 2024 Sep 12:izae178. doi: 10.1093.
    >> Share

  517. AZIZ S, Akhlaq A, Owings A, Gurz S, et al
    Mortality Trends in Inflammatory Bowel Disease by Age, Sex, and Race in the United States from 1999 to 2020.
    Inflamm Bowel Dis. 2024 Sep 11:izae184. doi: 10.1093.
    >> Share

  518. KELUTH CHAVAN A, Jha P, Perez JA, Harper E, et al
    Risk of Paradoxical Rheumatoid Arthritis in Inflammatory Bowel Disease Patients Exposed to Tumor Necrosis Factor Inhibitors: A Propensity-Matched Multicenter Study.
    Inflamm Bowel Dis. 2024 Sep 11:izae203. doi: 10.1093.
    >> Share

  519. GUO A, Ludvigsson J, Lerchova T, Imberg H, et al
    Association Between Maternal Infections in Pregnancy and the Risk of Inflammatory Bowel Disease in the Offspring: Findings From Two Scandinavian Birth Cohorts.
    Inflamm Bowel Dis. 2024 Sep 9:izae209. doi: 10.1093.
    >> Share

  520. GUO X, Zhao Z, Wang Y
    Refining the Understanding of Cannabis Impact on Inflammatory Bowel Disease Outcomes: Recommendations for Enhanced Research and Healthcare Practices.
    Inflamm Bowel Dis. 2024 Sep 6:izae207. doi: 10.1093.
    >> Share

  521. PANES J, Louis E, Bossuyt P, Joshi N, et al
    Induction of Endoscopic Response, Remission, and Ulcer-Free Endoscopy With Upadacitinib Is Associated With Improved Clinical Outcomes and Quality of Life in Patients With Crohn's Disease.
    Inflamm Bowel Dis. 2024 Sep 4:izae200. doi: 10.1093.
    >> Share

  522. BERNSTEIN CN, Fisk JD, Walld R, Bolton JM, et al
    Psychiatric Comorbidity Does Not Enhance Prescription Opioid Use in Inflammatory Bowel Disease as It Does in the General Population.
    Inflamm Bowel Dis. 2024 Sep 3:izae188. doi: 10.1093.
    >> Share

  523. WANG S, Xu Y, Wang L, Lin J, et al
    TolDC Restores the Balance of Th17/Treg via Aryl Hydrocarbon Receptor to Attenuate Colitis.
    Inflamm Bowel Dis. 2024;30:1546-1555.
    >> Share

  524. GONZALEZ CG, Stevens TW, Verstockt B, Gonzalez DJ, et al
    Crohn's Patient Serum Proteomics Reveals Response Signature for Infliximab but not Vedolizumab.
    Inflamm Bowel Dis. 2024;30:1536-1545.
    >> Share

  525. HE JZ, Hirschtritt ME, Wei J, Ramalingam ND, et al
    Psychiatric Diagnoses, Medication, and Service Use Among Patients Who Receive Emergency Care for Inflammatory Bowel Diseases.
    Inflamm Bowel Dis. 2024;30:1619-1622.
    >> Share

    August 2024
  526. SOLITANO V, Vuyyuru SK, Aruljothy A, Alkhattabi M, et al
    Endoscopic Skipping, Stricturing, and Penetrating Complications in Crohn's Disease on Tandem Ileo-colonoscopy and Cross-sectional Imaging: A Retrospective Cohort Study.
    Inflamm Bowel Dis. 2024 Aug 31:izae192. doi: 10.1093.
    >> Share

  527. MAHADEVAN U, Long M
    Low Placental Transfer Rates of Risankizumab Among Pregnant Women With Inflammatory Bowel Disease.
    Inflamm Bowel Dis. 2024 Aug 31:izae182. doi: 10.1093.
    >> Share

  528. HILLEY P, Wong D, De Cruz P
    How Does an Integrated Pharmacist Add Value in the Management of Inflammatory Bowel Disease in the Era of Values-Based Healthcare?
    Inflamm Bowel Dis. 2024 Aug 29:izae196. doi: 10.1093.
    >> Share

  529. CHAN P, McNamara J, Vernon-Roberts A, Giles EM, et al
    Systematic Review: Practices and Programs in Inflammatory Bowel Disease Transition Care.
    Inflamm Bowel Dis. 2024 Aug 28:izae190. doi: 10.1093.
    >> Share

  530. KANG H, Schmoyer CJ, Weiss A, Lewis JD, et al
    Meta-analysis of the Therapeutic Impact of Cannabinoids in Inflammatory Bowel Disease.
    Inflamm Bowel Dis. 2024 Aug 28:izae158. doi: 10.1093.
    >> Share

  531. JUN YK, Oh HJ, Lee JA, Choi Y, et al
    The Potential of Molecular Remission: Tissue Neutrophil Elastase Is Better Than Histological Activity for Predicting Long-Term Relapse in Patients With Ulcerative Colitis in Endoscopic Remission.
    Inflamm Bowel Dis. 2024 Aug 27:izae194. doi: 10.1093.
    >> Share

  532. DRAGASEVIC S, Stankovic B, Kotur N, Sokic Milutinovic A, et al
    Psychological Distress Is Associated With Inflammatory Bowel Disease Manifestation and Mucosal Inflammation.
    Inflamm Bowel Dis. 2024 Aug 27:izae180. doi: 10.1093.
    >> Share

  533. GSENGER V, Rodriguez A, Araka E, Oza F, et al
    A Study of Patient Concerns in the Modern Therapeutic Era of Inflammatory Bowel Disease.
    Inflamm Bowel Dis. 2024 Aug 27:izae197. doi: 10.1093.
    >> Share

  534. DAMIANOS JA, Osikoya O, Brennan G
    Upadacitinib for Acute Severe Ulcerative Colitis: A Systematic Review.
    Inflamm Bowel Dis. 2024 Aug 26:izae191. doi: 10.1093.
    >> Share

  535. GROSEN A, Bellaguarda E, Liljeqvist-Soltic I, Skytte AB, et al
    Tofacitinib Does Not Impair Sperm Quality in Men With Ulcerative Colitis.
    Inflamm Bowel Dis. 2024 Aug 23:izae195. doi: 10.1093.
    >> Share

  536. MINAWALA R, Kim M, Delau O, Ghiasian G, et al
    Sarcopenia Is a Risk Factor for Postoperative Complications Among Older Adults With Inflammatory Bowel Disease.
    Inflamm Bowel Dis. 2024 Aug 23:izae187. doi: 10.1093.
    >> Share

  537. DAY AS, Ballard TM, Yao CK, Gibson PR, et al
    Food-Based Interventions as Therapy for Inflammatory Bowel Disease: Important Steps in Diet Trial Design and Reporting of Outcomes.
    Inflamm Bowel Dis. 2024 Aug 23:izae185. doi: 10.1093.
    >> Share

  538. HINNANT L, Rios Villacorta N, Chen E, Bacchus D, et al
    Consensus Statement on Managing Anxiety and Depression in Individuals with Inflammatory Bowel Disease.
    Inflamm Bowel Dis. 2024 Aug 22:izae151. doi: 10.1093.
    >> Share

  539. NEIMAN N, Boothroyd D, Anjur K, Bensen R, et al
    Self-Compassion in Adolescents and Young Adults With Inflammatory Bowel Disease: Relationship of Self-Compassion to Psychosocial and Physical Outcomes.
    Inflamm Bowel Dis. 2024 Aug 21:izae170. doi: 10.1093.
    >> Share

  540. DALAL RS, Allegretti JR
    Reply: In Severe Inflammatory Bowel Disease, the Onset of Effectiveness of Biologics and Small Molecules Depends More on the Medication Than on the Diagnosis.
    Inflamm Bowel Dis. 2024 Aug 20:izae181. doi: 10.1093.
    >> Share

  541. ATTAUABI M, Burisch J, Nielsen OH, Seidelin JB, et al
    In Severe Inflammatory Bowel Disease, the Onset of Effectiveness of Biologics and Small Molecules Depends More on the Medication Than on the Diagnosis.
    Inflamm Bowel Dis. 2024 Aug 20:izae183. doi: 10.1093.
    >> Share

  542. MALHAM M, Vestergaard MV, Bataillon T, Villesen P, et al
    The Composition of the Fecal and Mucosa-adherent Microbiota Varies Based on Age and Disease Activity in Ulcerative Colitis.
    Inflamm Bowel Dis. 2024 Aug 16:izae179. doi: 10.1093.
    >> Share

  543. SHEHAB M, Hassan A, Alrashed F, Abbas A, et al
    Comparative Efficacy of Biologics and Small Molecule Therapies in Improving Patient-Reported Outcomes in Ulcerative Colitis: Systematic Review and Network Meta-Analysis.
    Inflamm Bowel Dis. 2024 Aug 13:izae163. doi: 10.1093.
    >> Share

  544. QIU Y, Hu S, Chao K, Huang L, et al
    Developing a Machine-Learning Prediction Model for Infliximab Response in Crohn's Disease: Integrating Clinical Characteristics and Longitudinal Laboratory Trends.
    Inflamm Bowel Dis. 2024 Aug 10:izae176. doi: 10.1093.
    >> Share

  545. GISBERT JP, Schreiber S, Siegel CA, Magro F, et al
    Benefit-Risk Trade-offs and Patient Preferences for Therapy Selection in Ulcerative Colitis: a Multicountry Preference Study.
    Inflamm Bowel Dis. 2024 Aug 10:izae162. doi: 10.1093.
    >> Share

  546. JUDGE C, Lightowler D, Singh A, Yeap BB, et al
    Distribution of Serum Testosterone Concentrations in IBD Males and Associations With Inflammatory Bowel Disease Activity.
    Inflamm Bowel Dis. 2024 Aug 7:izae177. doi: 10.1093.
    >> Share

  547. MARKOPOULOS P, Karmiris K, Dimas I, Voudoukis E, et al
    Efficacy of Vaccination and Revaccination Against Hepatitis B Virus Using 2 Different Strategies in Patients With Inflammatory Bowel Disease.
    Inflamm Bowel Dis. 2024 Aug 5:izae173. doi: 10.1093.
    >> Share

  548. MEKES-ADAMCZYK A, Gausmann N, Oznur O, Pfuhlmann K, et al
    Lifestyle Intervention Modulates the CD4+ T Cell Profile in the Blood of Crohn's Disease Patients.
    Inflamm Bowel Dis. 2024 Aug 5:izae154. doi: 10.1093.
    >> Share

  549. LEE CK, Moon W, Chun J, Kim ES, et al
    One-year Safety and Effectiveness of Ustekinumab in Patients With Crohn's Disease: The K-STAR Study.
    Inflamm Bowel Dis. 2024 Aug 3:izae171. doi: 10.1093.
    >> Share

  550. GEBEYEHU GG, Broglio G, Liu E, Limdi JK, et al
    Comparative Safety and Effectiveness of Ustekinumab and Anti-TNF in Elderly Crohn's Disease Patients.
    Inflamm Bowel Dis. 2024 Aug 3:izae174. doi: 10.1093.
    >> Share

  551. WATSON A, Harris RA, Engevik AC, Oezguen N, et al
    MYO5B and the Polygenic Landscape of Very Early-Onset Inflammatory Bowel Disease in an Ethnically Diverse Population.
    Inflamm Bowel Dis. 2024 Aug 3:izae169. doi: 10.1093.
    >> Share

  552. REGUEIRO M, Fischer M, Bossuyt P, McGinnis K, et al
    Mirikizumab Sustained Impact on Fatigue in Patients with Moderately to Severely Active Crohn's Disease in the Phase 2 AMAG Study.
    Inflamm Bowel Dis. 2024 Aug 2:izae166. doi: 10.1093.
    >> Share

  553. DI MATTIA M, Sallese M, Neri M, Lopetuso LR, et al
    Hypoxic Functional Regulation Pathways in the GI Tract: Focus on the HIF-1alpha and Microbiota's Crosstalk.
    Inflamm Bowel Dis. 2024;30:1406-1418.
    >> Share

  554. IKEGAMI S, Maeda K, Urano T, Mu J, et al
    Monoclonal Antibody Against Mature Interleukin-18 Ameliorates Colitis in Mice and Improves Epithelial Barrier Function.
    Inflamm Bowel Dis. 2024;30:1353-1366.
    >> Share

  555. HOSSAIN M, Plietz M, Khaitov S, Sylla P, et al
    Pouch Body Anastomotic Ulcerations Are Not Associated With an Increased Risk of Pouchitis.
    Inflamm Bowel Dis. 2024;30:1423-1425.
    >> Share

  556. BARNES EL, Esckilsen S, Ashburn J, Barto A, et al
    Extensive Colitis and Smoking Are Associated With Postoperative Complications Within 30 Days of Ileal Pouch-Anal Anastomosis.
    Inflamm Bowel Dis. 2024;30:1326-1333.
    >> Share

  557. LIM SH, Gros B, Sharma E, Lehmann A, et al
    Safety, Effectiveness, and Treatment Persistence of Subcutaneous Vedolizumab in IBD: A Multicenter Study From the United Kingdom.
    Inflamm Bowel Dis. 2024;30:1284-1294.
    >> Share

    July 2024
  558. SANDS BE, Danese S, Chapman JC, Gurjar K, et al
    Mucosal and Transmural Healing and Long-term Outcomes in Crohn's Disease.
    Inflamm Bowel Dis. 2024 Jul 31:izae159. doi: 10.1093.
    >> Share

  559. DE CARVALHO MF, Carlos AS, Kum AST, Bestetti AM, et al
    Invasive Therapeutic Strategies for Stricturing Crohn's Disease in Childhood: A Systematic Review and Meta-Analysis.
    Inflamm Bowel Dis. 2024 Jul 24:izae144. doi: 10.1093.
    >> Share

  560. BEN-TOV A, Achler T, Patalon T, Gazit S, et al
    The Prevalence and Characteristics of Inflammatory Bowel Disease-related Ocular Involvement in Children.
    Inflamm Bowel Dis. 2024 Jul 24:izae160. doi: 10.1093.
    >> Share

  561. KAYAL M, Spencer EA, Smyth M, Raffals L, et al
    Risankizumab Is Effective for The Management of Crohn's Disease of the Pouch.
    Inflamm Bowel Dis. 2024 Jul 22:izae164. doi: 10.1093.
    >> Share

  562. KUENZIG ME, Walters TD, Mack DR, Griffiths AM, et al
    High Healthcare Costs in Childhood Inflammatory Bowel Disease: Development of a Prediction Model Using Linked Clinical and Health Administrative Data.
    Inflamm Bowel Dis. 2024 Jul 19:izae148. doi: 10.1093.
    >> Share

  563. YZET C, Meudjo E, Brazier F, Hautefeuille V, et al
    Intestinal Ultrasound, Fecal Calprotectin, and Their Combination to Predict Endoscopic Mucosal Healing in Ulcerative Colitis: A Real-Life Cross-Sectional Study.
    Inflamm Bowel Dis. 2024 Jul 18:izae145. doi: 10.1093.
    >> Share

  564. REGUEIRO M, Siegmund B, Horst S, Moslin R, et al
    Concomitant Administration of Ozanimod and Serotonergic Antidepressants in Patients With Ulcerative Colitis or Relapsing Multiple Sclerosis.
    Inflamm Bowel Dis. 2024 Jul 17:izae136. doi: 10.1093.
    >> Share

  565. COELHO T, Cheng G, Lewis S, Ashton JJ, et al
    Pharmacogenomic Assessment of Genes Implicated in Thiopurine Metabolism and Toxicity in a UK Cohort of Pediatric Patients With Inflammatory Bowel Disease.
    Inflamm Bowel Dis. 2024 Jul 16:izae126. doi: 10.1093.
    >> Share

  566. DAHIYA DS, Jena A, Bapaye J, Mohan BP, et al
    Endoscopic Balloon Dilatation of Ileal Pouch-Anal Anastomosis Strictures in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis.
    Inflamm Bowel Dis. 2024 Jul 16:izae128. doi: 10.1093.
    >> Share

  567. PETROV JC, Desai AA, Kochhar GS, Crosby SK, et al
    Metformin Is Associated With Improved Inflammatory Bowel Disease Outcomes in Patients With Type 2 Diabetes Mellitus: A Propensity-Matched Cohort Study.
    Inflamm Bowel Dis. 2024 Jul 12:izae147. doi: 10.1093.
    >> Share

  568. KERBIRIOU C, Dickson C, Nichols B, Logan M, et al
    Treatment of Active Crohn's Disease With Exclusive Enteral Nutrition Diminishes the Immunostimulatory Potential of Fecal Microbial Products.
    Inflamm Bowel Dis. 2024 Jul 9:izae124. doi: 10.1093.
    >> Share

  569. URQUHART SA, Chedid VG, Kane SV
    Use of Upadacitinib as Salvage Therapy for Ulcerative Colitis in Pregnancy: A Case Report.
    Inflamm Bowel Dis. 2024 Jul 5:izae146. doi: 10.1093.
    >> Share

  570. RYAN K, Salozzo C, Schwartz S, Hart M, et al
    Following Through: The Impact of Culinary Medicine on Mediterranean Diet Uptake in Inflammatory Bowel Disease.
    Inflamm Bowel Dis. 2024 Jul 5:izae141. doi: 10.1093.
    >> Share

  571. QIN X
    Antibacterial Agents May Have Shifted Impacts on Inflammatory Bowel Diseases Along with Decrease in Gut Bacteria.
    Inflamm Bowel Dis. 2024;30:1228-1231.
    >> Share

  572. OUAHED JD, Griffith A, Collen LV, Snapper SB, et al
    Breaking Down Barriers: Epithelial Contributors to Monogenic IBD Pathogenesis.
    Inflamm Bowel Dis. 2024;30:1189-1206.
    >> Share

  573. LETHEN I, Lechner-Grimm K, Gabel M, Knauss A, et al
    Tofacitinib Affects M1-like and M2-like Polarization and Tissue Factor Expression in Macrophages of Healthy Donors and IBD Patients.
    Inflamm Bowel Dis. 2024;30:1151-1163.
    >> Share

  574. SANTIAGO P, Quinn KP, Chen J, Friton JJ, et al
    Altered Bile Acid and Pouch Microbiota Composition in Patients With Chronic Pouchitis.
    Inflamm Bowel Dis. 2024;30:1062-1070.
    >> Share

  575. VESTERGAARD T, Kelsen J, Julsgaard M
    Specialized Prenatal Care for Women With IBD Makes a Difference.
    Inflamm Bowel Dis. 2024;30:1218-1219.
    >> Share

  576. LOEB L, Kinnucan J
    Cannabis Use in IBD Is Associated With Increased Healthcare Utilization but not With Surgery or Death.
    Inflamm Bowel Dis. 2024;30:1215-1217.
    >> Share

  577. PORTH R, Deyhim T, Zullow S, Rabinowitz LG, et al
    Proactive Therapeutic Drug Monitoring Is Associated With Increased Drug Persistence in Patients With Inflammatory Bowel Disease Treated With Intravenous Vedolizumab.
    Inflamm Bowel Dis. 2024 Jul 2:izae140. doi: 10.1093.
    >> Share

  578. ERTEM FU, Rivers CR, Ghaffari AA, Watson AR, et al
    Efficacy of Ustekinumab and Vedolizumab Among Postoperative Crohn's Disease Patients as Postoperative Prophylaxis and Rescue Therapy: Real-world Data.
    Inflamm Bowel Dis. 2024 Jul 2:izae137. doi: 10.1093.
    >> Share

    June 2024
  579. FRIEDMAN S, Thorarinsson CT, Wod M, Fedder J, et al
    Paternal Inflammatory Bowel Disease and the Risk of Pregnancy Loss.
    Inflamm Bowel Dis. 2024 Jun 29:izae132. doi: 10.1093.
    >> Share

  580. NAITO T, Osaka R, Kakuta Y, Kawai Y, et al
    Genetically Predicted Higher Levels of Caffeic Acid Are Protective Against Ulcerative Colitis: A Comprehensive Metabolome Analysis.
    Inflamm Bowel Dis. 2024 Jun 29:izae143. doi: 10.1093.
    >> Share

  581. TIMMER A, Neuser J, de Sordi D, Schmidt-Lauber M, et al
    Integrating the Patient Perspective to Validate a Measure of Disease Severity in Inflammatory Bowel Disease: Online Survey of Patients and Their Physicians.
    Inflamm Bowel Dis. 2024 Jun 29:izae127. doi: 10.1093.
    >> Share

  582. DOHERTY J, Ryan AW, Quinn E, Conroy J, et al
    HLA-DQA1*05 Allele Carriage and Anti-TNF Therapy Persistence in Inflammatory Bowel Disease.
    Inflamm Bowel Dis. 2024 Jun 27:izae138. doi: 10.1093.
    >> Share

  583. RUSHER A, Araka E, Ananthakrishnan AN, Ritchie C, et al
    IBD Is Like a Tree: Reflections From Older Adults With Inflammatory Bowel Disease.
    Inflamm Bowel Dis. 2024 Jun 27:izae139. doi: 10.1093.
    >> Share

  584. WHITE B, Svolos V, Gervais L, Jatkowska A, et al
    Inflammation-related Proteins Support Diagnosis of Inflammatory Bowel Disease and Are Modified by Exclusive Enteral Nutrition in Children With Crohn's Disease, Especially of Ileal Phenotype.
    Inflamm Bowel Dis. 2024 Jun 26:izae107. doi: 10.1093.
    >> Share

  585. AKIYAMA S, Ollech JE, Cohen NA, Traboulsi C, et al
    Endoscopic Normalization and Transition of J-Pouch Phenotypes Over Time in Patients With Inflammatory Bowel Disease.
    Inflamm Bowel Dis. 2024 Jun 25:izae106. doi: 10.1093.
    >> Share

  586. SAFRONEEVA E, Thorne H, Gerstner O, Laoun R, et al
    Similar Efficacy of Mesalazine in Adult and Older Adult Ulcerative Colitis Patients: Post Hoc Analysis of a Randomized Noninferiority Trial of 1600 mg vs 400 mg Tablets.
    Inflamm Bowel Dis. 2024 Jun 21:izae123. doi: 10.1093.
    >> Share

  587. BERTANI L, Antonioli L, Fornili M, D'Antongiovanni V, et al
    Baseline Assessment of Serum Cytokines Predicts Clinical and Endoscopic Response to Ustekinumab in Patients With Crohn's Disease: A Prospective Pilot Study.
    Inflamm Bowel Dis. 2024 Jun 12:izae133. doi: 10.1093.
    >> Share

  588. HONAP S, Danese S, Peyrin-Biroulet L
    Target Trial Emulation: Improving the Quality of Observational Studies in Inflammatory Bowel Disease Using the Principles of Randomized Trials.
    Inflamm Bowel Dis. 2024 Jun 11:izae131. doi: 10.1093.
    >> Share

  589. BROCHARD C, Siproudhis L, Fathallah N, Zerbib P, et al
    Allogenic Stem Cells in Anal Fistulas of Crohn's Disease: From Promising Premises to Real Life Experience.
    Inflamm Bowel Dis. 2024 Jun 11:izae065. doi: 10.1093.
    >> Share

  590. BURISCH J, Hart A, Sturm A, Rudolph C, et al
    Residual Disease Burden Among European Patients With Inflammatory Bowel Disease: A Real-World Survey.
    Inflamm Bowel Dis. 2024 Jun 7:izae119. doi: 10.1093.
    >> Share

  591. JOSEPH A, Bachour SP, Shah R, El Halabi J, et al
    Postoperative Crohn's Disease Recurrence Risk and Optimal Biologic Timing After Temporary Diversion Following Ileocolic Resection.
    Inflamm Bowel Dis. 2024 Jun 6:izae117. doi: 10.1093.
    >> Share

  592. EISENSTEIN S
    Surgery in Crohn's Disease: Past Performance Does Predict Future Results.
    Inflamm Bowel Dis. 2024 Jun 6:izae110. doi: 10.1093.
    >> Share

  593. DAVIES JM, Teh JJ, Ewais T, Begun J, et al
    Does Improving Depression Symptoms in Young Adults With Inflammatory Bowel Disease Alter Their Microbiome?
    Inflamm Bowel Dis. 2024 Jun 5:izae121. doi: 10.1093.
    >> Share

  594. FALLOON K, Dossaji Z, Mude P, Abushamma S, et al
    Diagnosis of Inflammatory Bowel Disease-Associated Peripheral Arthritis: A Systematic Review.
    Inflamm Bowel Dis. 2024 Jun 5:izae114. doi: 10.1093.
    >> Share

  595. NIELSEN KR, Lophaven SN, Midjord J, Langholz E, et al
    Mortality of Patients With Inflammatory Bowel Disease in the Faroe Islands From 1966-2020.
    Inflamm Bowel Dis. 2024 Jun 3:izae120. doi: 10.1093.
    >> Share

  596. LEDDER O, Dolinger M, Dubinsky MC, Stein R, et al
    Tofacitinib in Pediatric Ulcerative Colitis: A Retrospective Multicenter Experience.
    Inflamm Bowel Dis. 2024 Jun 3:izae112. doi: 10.1093.
    >> Share

  597. CHEN M, Wei S, Wu X, Xiang Z, et al
    2'-Hydroxycinnamaldehyde Alleviates Intestinal Inflammation by Attenuating Intestinal Mucosal Barrier Damage Via Directly Inhibiting STAT3.
    Inflamm Bowel Dis. 2024;30:992-1008.
    >> Share

  598. ABOUBAKR A, Lukin DJ
    Freeing Time and Reducing Costs: The Value of a Specialized Nursing Service in IBD.
    Inflamm Bowel Dis. 2024;30:1046-1047.
    >> Share

  599. WITTEK A, Steglich B, Casar C, Seiz O, et al
    A Gradient of Intestinal Inflammation in Primary Sclerosing Cholangitis.
    Inflamm Bowel Dis. 2024;30:900-910.
    >> Share


  600. Correction to: Implication of Inflammatory Bowel Disease Diagnosed Before the Age of 18 for Achieving an Upper Secondary Education: A Nationwide Population-Based Cohort Study.
    Inflamm Bowel Dis. 2024 Jun 1:izae134. doi: 10.1093.
    >> Share

    May 2024
  601. KAYAL M, Barnes EL, Schwartzberg DM
    The Pouch Corner: A Review of Functional Pouch Disorders.
    Inflamm Bowel Dis. 2024 May 29:izae118. doi: 10.1093.
    >> Share

  602. FANSIWALA K, Spartz EJ, Roney AR, Kwaan MR, et al
    Increasing Rates of Bowel Resection Surgery for Stricturing Crohn's Disease in the Biologic Era.
    Inflamm Bowel Dis. 2024 May 25:izae113. doi: 10.1093.
    >> Share

  603. KENNEDY AM, Griffiths AM, Muise AM, Walters TD, et al
    Landscape of TPMT and NUDT15 Pharmacogenetic Variation in a Cohort of Canadian Pediatric Inflammatory Bowel Disease Patients.
    Inflamm Bowel Dis. 2024 May 24:izae109. doi: 10.1093.
    >> Share

  604. LIMKETKAI BN, Godoy-Brewer G, Shah ND, Maas L, et al
    Prebiotics for Induction and Maintenance of Remission in Inflammatory Bowel Disease: Systematic Review and Meta-Analysis.
    Inflamm Bowel Dis. 2024 May 23:izae115. doi: 10.1093.
    >> Share

  605. SYED S, Boland BS, Bourke LT, Chen LA, et al
    Challenges in IBD Research 2024: Precision Medicine.
    Inflamm Bowel Dis. 2024;30.
    >> Share

  606. CIORBA MA, Konnikova L, Hirota SA, Lucchetta EM, et al
    Challenges in IBD Research 2024: Preclinical Human IBD Mechanisms.
    Inflamm Bowel Dis. 2024;30.
    >> Share

  607. HELLER C, Moss AC, Rubin DT
    Overview to Challenges in IBD 2024-2029.
    Inflamm Bowel Dis. 2024;30.
    >> Share

  608. PRASAD S, Cross RK, Monroe MB, Dolinger MT, et al
    Challenges in IBD Research 2024: Novel Technologies.
    Inflamm Bowel Dis. 2024;30.
    >> Share

  609. ANANTHAKRISHNAN AN, Gerasimidis K, Ho SM, Mayer E, et al
    Challenges in IBD Research 2024: Environmental Triggers.
    Inflamm Bowel Dis. 2024;30.
    >> Share

  610. ALLEGRETTI JR, Bordeianou LG, Damas OM, Eisenstein S, et al
    Challenges in IBD Research 2024: Pragmatic Clinical Research.
    Inflamm Bowel Dis. 2024;30.
    >> Share

  611. OUBOTER LF, Lindelauf C, Jiang Q, Schreurs M, et al
    Activated HLA-DR+CD38+ Effector Th1/17 Cells Distinguish Crohn's Disease-associated Perianal Fistulas from Cryptoglandular Fistulas.
    Inflamm Bowel Dis. 2024 May 22:izae103. doi: 10.1093.
    >> Share

  612. DANG N, Kumar S, Kwon M, Cradeur M, et al
    Predictive Factors of Inactive Patient Participation in an Inflammatory Bowel Disease Learning Health System: A Longitudinal Cohort Study.
    Inflamm Bowel Dis. 2024 May 22:izae099. doi: 10.1093.
    >> Share

  613. ATIA O, Buchuk R, Lujan R, Greenfeld S, et al
    Predictors of Complicated Disease Course in Children and Adults With Ulcerative Colitis: A Nationwide Study From the epi-IIRN.
    Inflamm Bowel Dis. 2024 May 20:izae094. doi: 10.1093.
    >> Share

  614. YIN J, El-Najjar Y, Cordova N, Touma MJ, et al
    Short-Term Use of Upadacitinib in Combination With Biologic Therapy for Inducing Clinical Remission in Patients With Active Inflammatory Bowel Disease.
    Inflamm Bowel Dis. 2024 May 20:izae105. doi: 10.1093.
    >> Share

  615. THOMAS DM, Mundhra SK, Prasad S, Swaroop S, et al
    Combined or High Dose Immunosuppression in Inflammatory Bowel Disease patients who are NUDT15 Homozygous Harbors Risk of Developing Invasive Fungal Infections: A Case Series.
    Inflamm Bowel Dis. 2024 May 17:izae104. doi: 10.1093.
    >> Share

  616. BOHRA A, Van Langenberg DR
    Authors' Response to Letter to Editor: "Evaluating Serum Free Thiols in Inflammatory Bowel Disease: Contribution of Albumin to Extracellular Free Thiol Status".
    Inflamm Bowel Dis. 2024 May 14:izae108. doi: 10.1093.
    >> Share

  617. DILLMAN JR, Tkach JA, Fletcher JG, Bruining DH, et al
    MRI and Blood-based Biomarkers Are Associated With Surgery in Children and Adults With Ileal Crohn's Disease.
    Inflamm Bowel Dis. 2024 May 13:izae101. doi: 10.1093.
    >> Share

  618. ISHIKAWA D, Zhang X, Nomura K, Shibuya T, et al
    Anti-inflammatory Effects of Bacteroidota Strains Derived From Outstanding Donors of Fecal Microbiota Transplantation for the Treatment of Ulcerative Colitis.
    Inflamm Bowel Dis. 2024 May 11:izae080. doi: 10.1093.
    >> Share

  619. CHOI J, Wang Q, Beaton M, Kim RB, et al
    Infliximab Tissue Concentrations in Patients With Stable Ulcerative Colitis Are Correlated With More Durable Infliximab-associated Disease Remission.
    Inflamm Bowel Dis. 2024 May 8:izae097. doi: 10.1093.
    >> Share

  620. BOURGONJE AR, Geertsema S, Holstein HJ, Bulthuis MLC, et al
    Evaluating Serum Free Thiols in Inflammatory Bowel Disease: Contribution of Albumin to Extracellular Free Thiol Status.
    Inflamm Bowel Dis. 2024 May 4:izae102. doi: 10.1093.
    >> Share

  621. VERNON-ROBERTS A, Chan P, Christensen B, Havrlant R, et al
    Pediatric to Adult Transition in Inflammatory Bowel Disease: Consensus Guidelines for Australia and New Zealand.
    Inflamm Bowel Dis. 2024 May 3:izae087. doi: 10.1093.
    >> Share

  622. QIAN XX
    The Association of Extra-oral Halitosis With Small Intestinal Bacterial Overgrowth in Inflammatory Bowel Disease.
    Inflamm Bowel Dis. 2024 May 2:izae056. doi: 10.1093.
    >> Share

  623. YANG C, Merlin D
    Unveiling Colitis: A Journey through the Dextran Sodium Sulfate-induced Model.
    Inflamm Bowel Dis. 2024;30:844-853.
    >> Share

  624. SCHWARTZBERG DM, Kayal M, Barnes EL
    The Ileal Pouch-Anal Anastomosis: Identifying Structural Disorders.
    Inflamm Bowel Dis. 2024;30:863-867.
    >> Share

  625. COOK L, Wong MQ, Rees WD, Schick A, et al
    Dysregulated Immunity to Clostridioides difficile in IBD Patients Without a History of Recognized Infection.
    Inflamm Bowel Dis. 2024;30:820-828.
    >> Share

  626. BODEN EK, Kongala R, Hindmarch DC, Shows DM, et al
    Vedolizumab Efficacy Is Associated With Decreased Intracolonic Dendritic Cells, Not Memory T Cells.
    Inflamm Bowel Dis. 2024;30:704-717.
    >> Share

  627. LIMKETKAI BN, Maas L, Krishna M, Dua A, et al
    Machine Learning-based Characterization of Longitudinal Health Care Utilization Among Patients With Inflammatory Bowel Diseases.
    Inflamm Bowel Dis. 2024;30:697-703.
    >> Share

    April 2024

  628. Correction to: Two-Year Efficacy and Safety of Mirikizumab Following 104 Weeks of Continuous Treatment for Ulcerative Colitis: Results From the LUCENT-3 Open-Label Extension Study.
    Inflamm Bowel Dis. 2024 Apr 27:izae096. doi: 10.1093.
    >> Share

  629. WANG Y, Pan CW, Huang Y, Zheng X, et al
    Global Epidemiology and Geographic Variations of Pediatric-Onset Inflammatory Bowel Disease: A Comprehensive Analysis of the Global Burden of Disease Study 1990 to 2019.
    Inflamm Bowel Dis. 2024 Apr 27:izae093. doi: 10.1093.
    >> Share

  630. KHANNA R, Feagan BG, Zou G, Stitt LW, et al
    Reliability and Responsiveness of Clinical and Endoscopic Outcome Measures in Crohn's Disease.
    Inflamm Bowel Dis. 2024 Apr 25:izae089. doi: 10.1093.
    >> Share

  631. CHIN S, Fox L, Majumdar A, Oliver M, et al
    Pneumocystis jirovecii Pneumonia Complicating Use of Upadacitinib in a Patient With Ulcerative Colitis and Primary Sclerosing Cholangitis: A Case Report.
    Inflamm Bowel Dis. 2024 Apr 24:izae091. doi: 10.1093.
    >> Share

  632. FUKUDA T, Aoki Y, Kiyohara H, Yokoyama A, et al
    Efficacy of Dose Escalation of Oral 5-Aminosalicylic Acid for Ulcerative Colitis With a Mayo Endoscopic Subscore of 1: An Open Label Randomized Controlled Trial.
    Inflamm Bowel Dis. 2024 Apr 24:izae088. doi: 10.1093.
    >> Share

  633. KRUIS W, Bokemeyer B, Jessen P, Hoesl M, et al
    Prospective Evaluation of the Prediction Score for a Mild Course of Crohn's Disease (PreMiCC) in Newly Diagnosed Patients With Crohn's Disease: The PROGNOS Study.
    Inflamm Bowel Dis. 2024 Apr 22:izae086. doi: 10.1093.
    >> Share

  634. DESAI A, Khataniar H, Hashash JG, Farraye FA, et al
    Effectiveness and Safety of Semaglutide for Weight Loss in Patients With Inflammatory Bowel Disease and Obesity.
    Inflamm Bowel Dis. 2024 Apr 20:izae090. doi: 10.1093.
    >> Share

  635. AL RADI ZMA, Prins FM, Collij V, Vich Vila A, et al
    Exploring the Predictive Value of Gut Microbiome Signatures for Therapy Intensification in Patients With Inflammatory Bowel Disease: A 10-Year Follow-up Study.
    Inflamm Bowel Dis. 2024 Apr 18:izae064. doi: 10.1093.
    >> Share

  636. HAWKINS RL, Zia M, Hind D, Lobo AJ, et al
    Inequalities in Healthcare Access, Experience and Outcomes in Adults With Inflammatory Bowel Disease: A Scoping Review.
    Inflamm Bowel Dis. 2024 Apr 11:izae077. doi: 10.1093.
    >> Share

  637. INNOCENTI T, Dragoni G
    Bowel Damage and Disability in Crohn's Disease: Is it Really Two Birds with One Stone?
    Inflamm Bowel Dis. 2024 Apr 10:izae050. doi: 10.1093.
    >> Share

  638. CARTIER L, Loiez A, Nachury M, Azahaf M, et al
    Changes Over Time in the Lemann Index and the Inflammatory Bowel Disease Disability Index in a Prospective Cohort of Patients With Crohn's Disease.
    Inflamm Bowel Dis. 2024 Apr 10:izae073. doi: 10.1093.
    >> Share

  639. ROWAN C, Yeaman F, Ernest-Suarez K, Martin ML, et al
    Tofacitinib as a Rescue Therapy for Ulcerative Colitis in Pregnancy.
    Inflamm Bowel Dis. 2024 Apr 9:izae076. doi: 10.1093.
    >> Share

  640. IWAMA I, Yoshida M, Miyazawa A, Hara T, et al
    Ustekinumab Offers Long-Term Clinical Remission With Safety in Very Early-Onset Inflammatory Bowel Disease.
    Inflamm Bowel Dis. 2024 Apr 8:izae078. doi: 10.1093.
    >> Share

  641. KAYALI S, Fantasia S, Gaiani F, Cavallaro LG, et al
    NOD2 and Crohn's Disease Clinical Practice: From Epidemiology to Diagnosis and Therapy, Rewired.
    Inflamm Bowel Dis. 2024 Apr 6:izae075. doi: 10.1093.
    >> Share

  642. DRYGIANNAKIS I, Kolios G, Filidou E, Bamias G, et al
    Intestinal Stromal Cells in the Turmoil of Inflammation and Defective Connective Tissue Remodeling in Inflammatory Bowel Disease.
    Inflamm Bowel Dis. 2024 Apr 6:izae066. doi: 10.1093.
    >> Share

  643. ATIA O, Friss C, Focht G, Magen Rimon R, et al
    Durability of the First Biologic in Children and Adults With Ulcerative Colitis: A Nationwide Study from the epi-IIRN.
    Inflamm Bowel Dis. 2024 Apr 5:izae067. doi: 10.1093.
    >> Share

  644. ZAMANI M, Malekzadeh R
    Reply: On the Risk of Neurological Disorders in Patients With Inflammatory Bowel Disease.
    Inflamm Bowel Dis. 2024 Apr 3:izae079. doi: 10.1093.
    >> Share

  645. LEITAO AMF, Gondim FAA
    On the Risk of Neurological Disorders in Patients With Inflammatory Bowel Disease.
    Inflamm Bowel Dis. 2024 Apr 3:izae074. doi: 10.1093.
    >> Share

  646. LIN ZH, Li CP, Sun CK, Cho DY, et al
    Increased Risk of Inflammatory Bowel Disease Among Patients With Nontyphoidal Salmonella Infections: A Population-Based Cohort Study.
    Inflamm Bowel Dis. 2024 Apr 3:izae053. doi: 10.1093.
    >> Share

  647. MAEDA K, Kawashima H
    Reply: Interleukin-18 Inhibition in Inflammatory Bowel Diseases: A Delicate Balance.
    Inflamm Bowel Dis. 2024;30:695-696.
    >> Share

  648. BAJAJ A, Markandey M, Singh M, Sahu P, et al
    Exclusive Enteral Nutrition Mediates Beneficial Gut Microbiome Enrichment in Acute Severe Colitis.
    Inflamm Bowel Dis. 2024;30:641-650.
    >> Share

  649. KHALAJI A, Babajani N, Amirsardari Z, Saeedian B, et al
    Unveiling the Ghrelin and Obestatin Roles in Inflammatory Bowel Diseases: A Systematic Review and Meta-Analysis Assessing Their Pathogenic Implications and Biomarker Utility.
    Inflamm Bowel Dis. 2024;30:629-640.
    >> Share

  650. PIOVANI D, Armuzzi A, Bonovas S
    Association of Depression With Incident Inflammatory Bowel Diseases: A Systematic Review and Meta-Analysis.
    Inflamm Bowel Dis. 2024;30:573-584.
    >> Share

  651. MARK-CHRISTENSEN A, Kristiansen EB, Laurberg S, Erichsen R, et al
    Prior Appendectomy Is Associated With a Milder Clinical Course in Crohn's Disease: A Nationwide Population-based Cohort Study.
    Inflamm Bowel Dis. 2024 Apr 2:izae059. doi: 10.1093.
    >> Share

  652. UMAR N, Harvey P, Adderley NJ, Haroon S, et al
    The Time to Inflammatory Bowel Disease Diagnosis for Patients Presenting with Abdominal Symptoms in Primary Care and its Association with Emergency Hospital Admissions and Surgery: A Retrospective Cohort Study.
    Inflamm Bowel Dis. 2024 Apr 2:izae057. doi: 10.1093.
    >> Share

    March 2024
  653. COLMAN RJ, Solitano V, MacDonald JK, Ma C, et al
    Operating Properties of Disease Activity Indices in Pediatric Inflammatory Bowel Disease: A Systematic Review.
    Inflamm Bowel Dis. 2024 Mar 28:izae060. doi: 10.1093.
    >> Share

  654. HASHASH JG, Yu Ci Ng F, Farraye FA, Wang Y, et al
    Inter- and Intraobserver Variability on Endoscopic Scoring Systems in Crohn's Disease and Ulcerative Colitis: A Systematic Review and Meta-Analysis.
    Inflamm Bowel Dis. 2024 Mar 28:izae051. doi: 10.1093.
    >> Share

  655. BERNSTEIN CN, Panaccione R, Nugent Z, Marshall DA, et al
    Crohn's Disease Phenotypes and Associations With Comorbidities, Surgery Risk, Medications and Nonmedication Approaches: The MAGIC in IMAGINE Study.
    Inflamm Bowel Dis. 2024 Mar 27:izae055. doi: 10.1093.
    >> Share

  656. BOHRA A, Batt N, Dutt K, Sluka P, et al
    Prospective Evaluation of Serum Free Thiols in Inflammatory Bowel Disease: A Candidate to Replace C-Reactive Protein for Disease Activity Assessment?
    Inflamm Bowel Dis. 2024 Mar 27:izae069. doi: 10.1093.
    >> Share

  657. YARUR AJ, Ungaro R, Huang K, Wang W, et al
    Real-World Effectiveness of Ustekinumab in Ulcerative Colitis in a United States Multicenter Cohort Consortium.
    Inflamm Bowel Dis. 2024 Mar 26:izae058. doi: 10.1093.
    >> Share

  658. OLIVA S, Veraldi S, Russo G, Aloi M, et al
    Pan-enteric Capsule Endoscopy to Characterize Crohn's Disease Phenotypes and Predict Clinical Outcomes in Children and Adults: The Bomiro Study.
    Inflamm Bowel Dis. 2024 Mar 26:izae052. doi: 10.1093.
    >> Share

  659. POSNER H, Lombard R, Akiyama S, Cohen NA, et al
    Extensive Disease and Exposure to Multiple Biologics Precolectomy Is Associated with Endoscopic Cuffitis Post-Ileal Pouch-Anal Anastomosis in Patients With Ulcerative Colitis.
    Inflamm Bowel Dis. 2024 Mar 23:izae029. doi: 10.1093.
    >> Share

  660. SHAHUB S, Kumar RM, Lin KC, Banga I, et al
    Continuous Monitoring of CRP, IL-6, and Calprotectin in Inflammatory Bowel Disease Using a Perspiration-Based Wearable Device.
    Inflamm Bowel Dis. 2024 Mar 23:izae054. doi: 10.1093.
    >> Share

  661. GARCIA-MATEO S, Martinez-Dominguez SJ, Gargallo-Puyuelo CJ, Gallego B, et al
    Healthy Lifestyle Is a Protective Factor from Moderate and Severe Relapses and Steroid Use in Inflammatory Bowel Disease: A Prospective Cohort Study.
    Inflamm Bowel Dis. 2024 Mar 23:izae062. doi: 10.1093.
    >> Share

  662. BASTON-REY I, Rodriguez-Lago I, Luque AM, Caballol B, et al
    The Natural History of Patients With Pre-Existing and De Novo Inflammatory Bowel Disease After Solid Organ Transplantation: EITOS Study of GETECCU.
    Inflamm Bowel Dis. 2024 Mar 22:izae041. doi: 10.1093.
    >> Share

  663. JAIRATH V, Hunter Gibble T, Potts Bleakman A, Chatterton K, et al
    Patient Perspectives of Bowel Urgency and Bowel Urgency-Related Accidents in Ulcerative Colitis and Crohn's Disease.
    Inflamm Bowel Dis. 2024 Mar 21:izae044. doi: 10.1093.
    >> Share

  664. JOLVING LR, Zegers FD, Lund K, Wod M, et al
    Children and Adolescents Diagnosed With Inflammatory Bowel Disease Are at Increased Risk of Developing Diseases With a Possible Autoimmune Pathogenesis.
    Inflamm Bowel Dis. 2024 Mar 20:izae047. doi: 10.1093.
    >> Share

  665. FIORINO G, Bent-Ennakhil N, Varriale P, Braegger F, et al
    Patient Preferences for Treatment Attributes in Inflammatory Bowel Disease: Results From a Large Survey Across Seven European Countries Using a Discrete Choice Experiment.
    Inflamm Bowel Dis. 2024 Mar 20:izae015. doi: 10.1093.
    >> Share


  666. Correction to: Fungal Microbiota Composition in Inflammatory Bowel Disease Patients: Characterization in Different Phenotypes and Correlation With Clinical Activity and Disease Course.
    Inflamm Bowel Dis. 2024 Mar 14:izae070. doi: 10.1093.
    >> Share

  667. ALSOUD D, Van Calster B
    Beyond Discrimination: A Call for Comprehensive Assessment of Clinical Prediction Models in Inflammatory Bowel Disease.
    Inflamm Bowel Dis. 2024 Mar 9:izae048. doi: 10.1093.
    >> Share

  668. SANDS BE, D'Haens G, Clemow DB, Irving PM, et al
    Two-Year Efficacy and Safety of Mirikizumab Following 104 Weeks of Continuous Treatment for Ulcerative Colitis: Results From the LUCENT-3 Open-Label Extension Study.
    Inflamm Bowel Dis. 2024 Mar 9:izae024. doi: 10.1093.
    >> Share

  669. FAMUTIMI D, Alayo QA, Deepak P
    Reply to: Beyond Discrimination: A Call for Comprehensive Assessment of Clinical Prediction Models in Inflammatory Bowel Disease.
    Inflamm Bowel Dis. 2024 Mar 8:izae049. doi: 10.1093.
    >> Share

  670. PILLAY L, Subramanian S
    The Long View: 2-Year Outcomes of Mirikizumab for Ulcerative Colitis.
    Inflamm Bowel Dis. 2024 Mar 7:izae025. doi: 10.1093.
    >> Share

  671. GEERTSEMA S, Fagundes RR, Otten AT, Dijkstra G, et al
    Interleukin-18 Inhibition in Inflammatory Bowel Disease: A Delicate Balance.
    Inflamm Bowel Dis. 2024 Mar 5:izae042. doi: 10.1093.
    >> Share

  672. HOXHA T, Youssef M, Huang V, Tandon P, et al
    Inflammatory Bowel Disease and Breastfeeding: A Narrative Review.
    Inflamm Bowel Dis. 2024 Mar 4:izae033. doi: 10.1093.
    >> Share

  673. OURANOS K, Saleem H, Vassilopoulos S, Vassilopoulos A, et al
    Risk of Infection in Patients With Inflammatory Bowel Disease Treated With Interleukin-Targeting Agents: A Systematic Review and Meta-Analysis.
    Inflamm Bowel Dis. 2024 Mar 1:izae031. doi: 10.1093.
    >> Share

  674. GREYWOODE R, Nahvi S, Ullman T, Keefer L, et al
    Feasibility and Acceptability of Digital Behavioral Interventions Among Black and Hispanic Patients With Inflammatory Bowel Disease: A Randomized Pilot Study.
    Inflamm Bowel Dis. 2024 Mar 1:izae034. doi: 10.1093.
    >> Share

  675. D'AMICO F, Peyrin-Biroulet L, Danese S
    Disease Clearance is not Synonymous with Cure.
    Inflamm Bowel Dis. 2024;30:509.
    >> Share

  676. HESAMPOUR F, Bernstein CN, Ghia JE
    Brain-Gut Axis: Invasive and Noninvasive Vagus Nerve Stimulation, Limitations, and Potential Therapeutic Approaches.
    Inflamm Bowel Dis. 2024;30:482-495.
    >> Share

  677. TSE CS, Hunt MG, Brown LA, Lewis JD, et al
    Inflammatory Bowel Diseases-related Disability: Risk Factors, Outcomes, and Interventions.
    Inflamm Bowel Dis. 2024;30:501-507.
    >> Share

  678. GEESALA R, Zhang K, Lin YM, Johnson JC, et al
    Exclusive Enteral Nutrition Alleviates Th17-Mediated Inflammation via Eliminating Mechanical Stress-Induced Th17-Polarizing Cytokines in Crohn's-like Colitis.
    Inflamm Bowel Dis. 2024;30:429-440.
    >> Share

    February 2024
  679. SWAMINATHAN A, Borichevsky GM, Frampton CM, Day AS, et al
    Comparison of Fecal Calprotectin and Myeloperoxidase in Predicting Outcomes in Inflammatory Bowel Disease.
    Inflamm Bowel Dis. 2024 Feb 28:izae032. doi: 10.1093.
    >> Share

  680. GONG T, Brew BK, Lundholm C, Smew AI, et al
    Comorbidity Between Inflammatory Bowel Disease and Asthma and Allergic Diseases: A Genetically Informed Study.
    Inflamm Bowel Dis. 2024 Feb 27:izae027. doi: 10.1093.
    >> Share

  681. DALAL RS, Winter RW, Gupta S, Sasson GF, et al
    Clinical Outcomes at 8-16 Weeks After Upadacitinib Initiation for Acute Severe Ulcerative Colitis: A Case Series in the United States.
    Inflamm Bowel Dis. 2024 Feb 26:izae038. doi: 10.1093.
    >> Share

  682. QING X, Zhang C, Zhong Z, Zhang T, et al
    Causal Association Analysis of Periodontitis and Inflammatory Bowel Disease: A Bidirectional Mendelian Randomization Study.
    Inflamm Bowel Dis. 2024 Feb 26:izad188. doi: 10.1093.
    >> Share

  683. MARTINELLI M, Miele E, Staiano A
    Surgical Complications Need to Be Carefully Excluded Before Ruling Out a Diagnosis of De Novo Crohn's Disease.
    Inflamm Bowel Dis. 2024 Feb 24:izae026. doi: 10.1093.
    >> Share

  684. DE JONG D, Reijntjes M, Buskens C, Hompes R, et al
    Response to "De Novo Crohn's Disease in Children With Ulcerative Colitis Undergoing Ileal Pouch Anal Anastomosis: A Multicenter, Retrospective Study From the Pediatric IBD Porto Group of the ESPGHAN".
    Inflamm Bowel Dis. 2024 Feb 22:izae021. doi: 10.1093.
    >> Share

  685. GREEN Z, Ashton JJ, Rodrigues A, Spray C, et al
    Sustained Increase in Pediatric Inflammatory Bowel Disease Incidence Across the South West United Kingdom Over the Last 10 Years.
    Inflamm Bowel Dis. 2024 Feb 19:izad302. doi: 10.1093.
    >> Share

  686. FAN X, Liu Y, He Z, Bai Y, et al
    Associations of Fish and Fish Oil Consumption With Incident Inflammatory Bowel Disease: A Population-Based Prospective Cohort Study.
    Inflamm Bowel Dis. 2024 Feb 16:izae019. doi: 10.1093.
    >> Share

  687. KUENZIG ME, Bitton A, Carroll MW, Otley AR, et al
    Health Services Utilization and Specialist Care in Pediatric Inflammatory Bowel Disease: A Multiprovince Population-Based Cohort Study.
    Inflamm Bowel Dis. 2024 Feb 16:izae010. doi: 10.1093.
    >> Share

  688. URRETE J, Mitra T, Boland BS, Bertrand K, et al
    Vedolizumab Does Not Affect Antibody Secreting Cell Recruitment to the Lactating Mammary Gland of Mothers With Inflammatory Bowel Disease.
    Inflamm Bowel Dis. 2024 Feb 9:izae023. doi: 10.1093.
    >> Share

  689. ATIA O, Lujan R, Buchuk R, Greenfeld S, et al
    Predictors of Complicated Disease Course in Adults and Children With Crohn's Disease: A Nationwide Study from the epi-IIRN.
    Inflamm Bowel Dis. 2024 Feb 8:izae014. doi: 10.1093.
    >> Share

  690. PRENTICE R, Flanagan E, Wright E, Hardikar W, et al
    Thrombocytosis and Transaminitis in Infants Born to Women With Inflammatory Bowel Disease Is Associated With Exposure to Maternal Inflammation In Utero.
    Inflamm Bowel Dis. 2024 Feb 8:izae008. doi: 10.1093.
    >> Share

  691. SUTTICHAIMONGKOL T, Coelho-Prabhu N, Bruining DH, Tariq R, et al
    Diagnostic Performance of a Fecal Calprotectin Assay as a Biomarker for Mayo Endoscopic Subscore in Ulcerative Colitis: Result From a Tertiary Referral Center.
    Inflamm Bowel Dis. 2024 Feb 3:izae005. doi: 10.1093.
    >> Share

  692. WANG C, Yang F, Qiao L, Wang X, et al
    Monitoring-Based Model for Personalizing Fecal Incontinence in Patients With Crohn's Disease: A Multicenter Inception Cohort Study.
    Inflamm Bowel Dis. 2024 Feb 3:izae006. doi: 10.1093.
    >> Share

  693. SKEJO C, Thim S, Sellmer A, Julsgaard M, et al
    Early Onset Sepsis and Lobar Pneumonia in a Newborn Exposed In Utero to Ustekinumab and Azathioprine.
    Inflamm Bowel Dis. 2024;30:314-315.
    >> Share

  694. SHI Y, Ullah S, Liu BR
    Think Again Before Resecting an Organ: Appendectomy or Endoscopic Retrograde Appendicitis Therapy?
    Inflamm Bowel Dis. 2024;30:320-321.
    >> Share

  695. WANG Z, Dreesen E
    Therapeutic Drug Monitoring 2.0: Time to Assemble the Puzzle.
    Inflamm Bowel Dis. 2024;30:316-317.
    >> Share

  696. VESTERGAARD T, Rosok J, Julsgaard M, Bek Helmig R, et al
    Time to Diagnosis and Birth Outcomes of Pregnancy-onset IBD.
    Inflamm Bowel Dis. 2024;30:222-229.
    >> Share

  697. POWERS JC, Cohen BL, Rieder F, Click BH, et al
    Preoperative Use of Multiple Advanced Therapies Is Not Associated With Endoscopic Inflammatory Pouch Diseases.
    Inflamm Bowel Dis. 2024;30:203-212.
    >> Share

  698. DARLINGTON K, Wang A, Herfarth HH, Barnes EL, et al
    The Safety of Dilation of Ileoanal Strictures With Mechanical or Balloon Dilation Is Similar Among Patients After Ileal Pouch-Anal Anastomosis.
    Inflamm Bowel Dis. 2024;30:196-202.
    >> Share

    January 2024
  699. BRIGGS K, Tomar V, Ollberding N, Haberman Y, et al
    Crohn's Disease-Associated Pathogenic Mutation in the Manganese Transporter ZIP8 Shifts the Ileal and Rectal Mucosal Microbiota Implicating Aberrant Bile Acid Metabolism.
    Inflamm Bowel Dis. 2024 Jan 30:izae003. doi: 10.1093.
    >> Share

  700. ZAMANI M, Ebrahimtabar F, Alizadeh-Tabari S, Kasner SE, et al
    Risk of Common Neurological Disorders in Adult Patients with Inflammatory Bowel Disease: A Systematic Review and Meta-analysis.
    Inflamm Bowel Dis. 2024 Jan 25:izae012. doi: 10.1093.
    >> Share

  701. D'HAENS G, Higgins PDR, Peyrin-Biroulet L, Sands BE, et al
    Extended Induction and Prognostic Indicators of Response in Patients Treated with Mirikizumab with Moderately to Severely Active Ulcerative Colitis in the LUCENT Trials.
    Inflamm Bowel Dis. 2024 Jan 25:izae004. doi: 10.1093.
    >> Share

  702. NAMBU R, Miyazawa A, Yoshida M, Hara T, et al
    Long-term Efficacy and Safety of Tacrolimus Plus Ustekinumab Combination Therapy in Children With Steroid-refractory Ulcerative Colitis.
    Inflamm Bowel Dis. 2024 Jan 24:izae013. doi: 10.1093.
    >> Share

  703. DUBINSKY MC, Charles L, Selmaj KW, Comi G, et al
    Pregnancy Outcomes in the Ozanimod Clinical Development Program in Patients With Ulcerative Colitis, Crohn's Disease, and Relapsing Multiple Sclerosis.
    Inflamm Bowel Dis. 2024 Jan 24:izae011. doi: 10.1093.
    >> Share

  704. KRASNOVSKY L, Weber AT, Gershuni V, Pettke E, et al
    Preoperative Exclusive Enteral Nutrition Is Associated With Reduced Skin and Soft Tissue and Intra-abdominal Infections in Patients With Crohn's Disease Undergoing Intestinal Surgery: Results from a Meta-Analysis.
    Inflamm Bowel Dis. 2024 Jan 23:izad304. doi: 10.1093.
    >> Share

  705. KATSOUDAS N, Tavakoli P, Wu N, Shapiro A, et al
    Dietary Emulsifier Exposure in People With Inflammatory Bowel Disease Compared With Healthy Controls: Is There a Cause for Concern?
    Inflamm Bowel Dis. 2024 Jan 19:izad318. doi: 10.1093.
    >> Share

  706. ALAYO QA, Famutimi D, Ayoub M, De Las Fuentes L, et al
    Performance of ASCVD Risk Prediction Models in Individuals With Inflammatory Bowel Disease: A UK Biobank Study.
    Inflamm Bowel Dis. 2024 Jan 18:izae007. doi: 10.1093.
    >> Share

  707. ALSOUD D, Sabino J, Franchimont D, Cremer A, et al
    Real-world Effectiveness and Safety of Risankizumab in Patients with Moderate to Severe Multirefractory Crohn's Disease: A Belgian Multicentric Cohort Study.
    Inflamm Bowel Dis. 2024 Jan 12:izad315. doi: 10.1093.
    >> Share

  708. WATSON A, Karam LB, Kellermayer R
    Failure Rate of Anti-Tumor Necrosis Factor alpha Biologics in Very Early Onset Inflammatory Bowel Disease.
    Inflamm Bowel Dis. 2024 Jan 11:izad313. doi: 10.1093.
    >> Share

  709. FRETZ KM, Hunker KE, Tripp DA
    The Impact of Inflammatory Bowel Disease on Intimacy: A Multimethod Examination of Patients' Sexual Lives and Associated Healthcare Experiences.
    Inflamm Bowel Dis. 2024 Jan 11:izad106. doi: 10.1093.
    >> Share

  710. COLLEN LV, Snapper SB
    Response to Letter to the Editor: "Failure Rate of Antitumor Necrosis Factor Alpha Biologics in Very Early Onset Inflammatory Bowel Disease".
    Inflamm Bowel Dis. 2024 Jan 11:izad317. doi: 10.1093.
    >> Share

  711. LIU M, Zhang Y, Liu J, Xiang C, et al
    Revisiting the Role of Valeric Acid in Manipulating Ulcerative Colitis.
    Inflamm Bowel Dis. 2024 Jan 11:izad187. doi: 10.1093.
    >> Share

  712. ATIA O, Friss C, Focht G, Magen Rimon R, et al
    Durability of Adalimumab and Infliximab in Children With Crohn's Disease: A Nationwide Comparison From the epi-IIRN Cohort.
    Inflamm Bowel Dis. 2024 Jan 8:izad301. doi: 10.1093.
    >> Share

  713. ERFAN R, Shaker OG, Khalil MAF, Mahmoud FAM, et al
    Circulating miR-199a and long noncoding-RNA ANRIL as Promising Diagnostic Biomarkers for Inflammatory Bowel Disease.
    Inflamm Bowel Dis. 2024 Jan 8:izad210. doi: 10.1093.
    >> Share

  714. KHADEMI Z, Pourreza S, Amjadifar A, Torkizadeh M, et al
    Dietary Patterns and Risk of Inflammatory Bowel Disease: A Systematic Review of Observational Studies.
    Inflamm Bowel Dis. 2024 Jan 5:izad297. doi: 10.1093.
    >> Share

  715. ALVISI P, Faraci S, Scarallo L, Congiu M, et al
    Major Abdominal Surgery for Pediatric Crohn's Disease in the Anti-TNF Era: 10-Year Analysis of Data From the IBD Registry of Italian Society of Pediatric Gastroenterology, Hepatology, and Nutrition.
    Inflamm Bowel Dis. 2024 Jan 5:izad310. doi: 10.1093.
    >> Share

  716. BLESL A, Wurm P, Waschina S, Grochenig HP, et al
    Prediction of Response to Systemic Corticosteroids in Active UC by Microbial Composition-A Prospective Multicenter Study.
    Inflamm Bowel Dis. 2024;30:9-19.
    >> Share

  717. FU SC, Qu JY, Li LX, Yang XX, et al
    Excessive Mitochondrial Fission Suppresses Mucosal Repair by Impairing Butyrate Metabolism in Colonocytes.
    Inflamm Bowel Dis. 2024;30:114-124.
    >> Share

  718. TUBAU-JUNI N, Bassaganya-Riera J, Leber AJ, Alva SS, et al
    Oral Omilancor Treatment Ameliorates Clostridioides difficile Infection During IBD Through Novel Immunoregulatory Mechanisms Mediated by LANCL2 Activation.
    Inflamm Bowel Dis. 2024;30:103-113.
    >> Share

  719. ODUFALU FD, Sewell JL, Rudrapatna V, Somsouk M, et al
    Assessing the Impact of COVID-19 on IBD Outcomes Among Vulnerable Patient Populations in a Large Metropolitan Center.
    Inflamm Bowel Dis. 2024;30:29-37.
    >> Share

  720. GOLDOWSKY A, Singh R, Moss A
    Speaker Diversity and Audience Ratings at a National Inflammatory Bowel Diseases Conference.
    Inflamm Bowel Dis. 2024;30:78-82.
    >> Share

  721. LEDDER O, Harel S, Lujan R, Friss C, et al
    Residence in Peripheral Regions and Low Socioeconomic Status Are Associated With Worse Outcomes of Inflammatory Bowel Diseases: A Nationwide Study From the epi-IIRN.
    Inflamm Bowel Dis. 2024;30:1-8.
    >> Share

  722. FAYE AS, Lee KE, Hudesman D, Dervieux T, et al
    Older Adults With Inflammatory Bowel Disease Are at Higher Risk of Developing Antibodies to Infliximab.
    Inflamm Bowel Dis. 2024 Jan 3:izad305. doi: 10.1093.
    >> Share

  723. COLMAN RJ, Vuijk SA, Mathot RAA, Van Limbergen J, et al
    Infliximab Monotherapy vs Combination Therapy for Pediatric Crohn's Disease Exhibit Similar Pharmacokinetics.
    Inflamm Bowel Dis. 2024 Jan 3:izad307. doi: 10.1093.
    >> Share

    December 2023
  724. FORBES AJ, Frampton CMA, Day AS, Kaplan GG, et al
    The Epidemiology of Inflammatory Bowel Disease in Oceania: A Systematic Review and Meta-Analysis of Incidence and Prevalence.
    Inflamm Bowel Dis. 2023 Dec 30:izad295. doi: 10.1093.
    >> Share

  725. TEWS HC, Schmelter F, Kandulski A, Buchler C, et al
    Unique Metabolomic and Lipidomic Profile in Serum From Patients With Crohn's Disease and Ulcerative Colitis Compared With Healthy Control Individuals.
    Inflamm Bowel Dis. 2023 Dec 29:izad298. doi: 10.1093.
    >> Share

  726. DUBINSKY M, Rice A, Yarlas A, Hur P, et al
    Systematic Literature Review: Ability of the IBDQ-32 to Detect Meaningful Change in Ulcerative Colitis Health Indicators.
    Inflamm Bowel Dis. 2023 Dec 27:izad282. doi: 10.1093.
    >> Share

  727. FANSIWALA K, Rusher A, Shore B, Herfarth HH, et al
    Oral vs Intravenous Discharge Antibiotic Regimens in the Management of Intra-abdominal Abscesses in Penetrating Crohn's Disease.
    Inflamm Bowel Dis. 2023 Dec 27:izad299. doi: 10.1093.
    >> Share

  728. ANIRVAN P, Giri S
    Tofacitinib in Ulcerative Colitis: Beyond Biologics?
    Inflamm Bowel Dis. 2023 Dec 24:izad308. doi: 10.1093.
    >> Share

  729. DALAL RS, Allegretti JR
    Reply: Tofacitinib in Ulcerative Colitis: Beyond Biologics?
    Inflamm Bowel Dis. 2023 Dec 24:izad309. doi: 10.1093.
    >> Share

  730. DUNLEAVY KA, Santiago P, Forde G, Harmsen WS, et al
    Total Proctocolectomy vs Subtotal/total Colectomy for Neoplasia in Patients With Inflammatory Bowel Disease and Primary Sclerosing Cholangitis.
    Inflamm Bowel Dis. 2023 Dec 23:izad278. doi: 10.1093.
    >> Share

  731. LEVINE J, McKibbin J, Ham R, Cohen-Mekelburg S, et al
    Use of Upadacitinib in 16 Tofacitinib-refractory Ulcerative Colitis Patients: A Single-center Case 2Series.
    Inflamm Bowel Dis. 2023 Dec 23:izad279. doi: 10.1093.
    >> Share

  732. VUYYURU SK, Ma C, Sharma T, Nguyen TM, et al
    Characteristics of Interventional Trials for Patients Living With Intestinal Stoma Registered in ClinicalTrials.gov With a Focus on Inflammatory Bowel Disease.
    Inflamm Bowel Dis. 2023 Dec 22:izad293. doi: 10.1093.
    >> Share

  733. SPENCER EA, Bergstein S, Dolinger M, Pittman N, et al
    Single-center Experience With Upadacitinib for Adolescents With Refractory Inflammatory Bowel Disease.
    Inflamm Bowel Dis. 2023 Dec 22:izad300. doi: 10.1093.
    >> Share

  734. SWAMINATHAN A, Fulforth JM, Frampton CM, Borichevsky GM, et al
    The Disease Severity Index for Inflammatory Bowel Disease Is a Valid Instrument that Predicts Complicated Disease.
    Inflamm Bowel Dis. 2023 Dec 22:izad294. doi: 10.1093.
    >> Share

  735. BRADY RE, Salwen-Deremer JK, Tunnell NC, Winter MW, et al
    Understanding Medication Nonadherence in Crohn's Disease Patients: A Qualitative Evaluation.
    Inflamm Bowel Dis. 2023 Dec 22:izad296. doi: 10.1093.
    >> Share

  736. CATALAN-SERRA I, Thorsvik S, Beisvag V, Bruland T, et al
    Fungal Microbiota Composition in Inflammatory Bowel Disease Patients: Characterization in Different Phenotypes and Correlation With Clinical Activity and Disease Course.
    Inflamm Bowel Dis. 2023 Dec 16:izad289. doi: 10.1093.
    >> Share

  737. ALIZADEH M, Motwani K, Siaton BC, Abutaleb A, et al
    Factors Associated With Extraintestinal Manifestations of Inflammatory Bowel Disease in SPARC-IBD.
    Inflamm Bowel Dis. 2023 Dec 15:izad280. doi: 10.1093.
    >> Share

  738. TAO S, Long X, Gong P, Yu X, et al
    Phosphoproteomics Reveals Novel Insights into the Pathogenesis and Identifies New Therapeutic Kinase Targets of Ulcerative Colitis.
    Inflamm Bowel Dis. 2023 Dec 12:izad291. doi: 10.1093.
    >> Share


  739. Correction to: Addressing the Risks of Respiratory Syncytial Virus for Patients With Inflammatory Bowel Disease in the Era of Novel Vaccines.
    Inflamm Bowel Dis. 2023;29:2014-2015.
    >> Share


  740. Inflammatory Bowel Diseases Is Moving to Online Only Publication.
    Inflamm Bowel Dis. 2023;29:2006.
    >> Share

  741. BARNES EL, Kayal M, Schwartzberg DM
    The Rational Use of Advanced Therapies for Inflammatory Conditions of the Pouch.
    Inflamm Bowel Dis. 2023;29:2007-2009.
    >> Share

  742. CHEN X, Zhang M, Zhou F, Gu Z, et al
    SIRT3 Activator Honokiol Inhibits Th17 Cell Differentiation and Alleviates Colitis.
    Inflamm Bowel Dis. 2023;29:1929-1940.
    >> Share

  743. PELLINO G, Garcia-Granero A
    3D Imaging and Printing in Inflammatory Bowel Diseases: Limitations, Barriers, and Opportunities Toward "Haute Couture" Surgical Approaches.
    Inflamm Bowel Dis. 2023;29:1999-2000.
    >> Share

  744. BARNES EL, Chang S
    Shedding New Light on High-Risk Phenotypes for Pouchitis.
    Inflamm Bowel Dis. 2023;29:2003-2005.
    >> Share

  745. BAJZAT D, Keri AF, Imrei M, Koi T, et al
    Safety Analysis of Preoperative Anti-TNF-alpha Therapy in Pediatric IBD After Intestinal Resection: A Systematic Review and Meta-analysis.
    Inflamm Bowel Dis. 2023;29:1971-1980.
    >> Share

    November 2023
  746. COLOMBEL JF, Martin-Arranz MD, Brinkman B, Guan M, et al
    HLA-DQA1*05 Not Associated With Ustekinumab Loss of Response and Antidrug Antibodies in Ulcerative Colitis and Crohn's Disease Patients.
    Inflamm Bowel Dis. 2023 Nov 29:izad273. doi: 10.1093.
    >> Share

  747. DE VOOGD FA, Bots SJ, van Wassenaer EA, de Jong M, et al
    Early Intestinal Ultrasound Predicts Clinical and Endoscopic Treatment Response and Demonstrates Drug-Specific Kinetics in Moderate-to-Severe Ulcerative Colitis.
    Inflamm Bowel Dis. 2023 Nov 27:izad274. doi: 10.1093.
    >> Share

  748. GAO Y, Zhang B, Zhao D, Li S, et al
    Automatic Segmentation and Radiomics for Identification and Activity Assessment of CTE Lesions in Crohn's Disease.
    Inflamm Bowel Dis. 2023 Nov 27:izad285. doi: 10.1093.
    >> Share

  749. TARIQ R, Dilmaghani S
    Machine Learning and Radiomics: Changing the Horizon of Crohn's Disease Assessment.
    Inflamm Bowel Dis. 2023 Nov 27:izad284. doi: 10.1093.
    >> Share

  750. SAYAR S, Ozturk O
    A Case of Stricturing Crohn's Disease Treated With Multiple Session Balloon Dilatation and Self-Expandable Metal Stent.
    Inflamm Bowel Dis. 2023 Nov 24:izad287. doi: 10.1093.
    >> Share

  751. YAN ANG Q, Plichta D, Kim S, Hyun-A Kim I, et al
    Differential Impact of Smoking on Methylome and Transcriptome in Crohn's Disease and Ulcerative Colitis.
    Inflamm Bowel Dis. 2023 Nov 24:izad268. doi: 10.1093.
    >> Share

  752. DISTANTE M, Rotulo S, Ranalli M, Pedace E, et al
    Clusters of Disease Activity and Early Risk Factors of Clinical Course of Pediatric Crohn's Disease.
    Inflamm Bowel Dis. 2023 Nov 23:izad275. doi: 10.1093.
    >> Share

  753. ROSHANOV PS, Khanna R
    The Use of Placebo in Clinical Trials of Inflammatory Bowel Disease.
    Inflamm Bowel Dis. 2023 Nov 21:izad281. doi: 10.1093.
    >> Share

  754. SHAW VR, Byun J, Pettit RW, Hou JK, et al
    An Atlas Characterizing the Shared Genetic Architecture of Inflammatory Bowel Disease with Clinical and Behavioral Traits.
    Inflamm Bowel Dis. 2023 Nov 20:izad269. doi: 10.1093.
    >> Share

  755. FERNANDES SR, Bernardo S, Saraiva S, Rita Goncalves A, et al
    Proactive Infliximab Monitoring Improves the Rates of Transmural Remission in Crohn's Disease: A Propensity Score-Matched Analysis.
    Inflamm Bowel Dis. 2023 Nov 20:izad272. doi: 10.1093.
    >> Share

  756. SIGALL BONEH R, Westoby C, Oseran I, Sarbagili-Shabat C, et al
    The Crohn's Disease Exclusion Diet: A Comprehensive Review of Evidence, Implementation Strategies, Practical Guidance, and Future Directions.
    Inflamm Bowel Dis. 2023 Nov 18:izad255. doi: 10.1093.
    >> Share

  757. FIELD J, Fenton C, Zhang L, Brickman C, et al
    Inflammatory Bowel Disease and the Risk of Anal Squamous Intraepithelial Lesions and Anal Cancer in Men Who Have Sex With Men.
    Inflamm Bowel Dis. 2023 Nov 10:izad266. doi: 10.1093.
    >> Share

  758. WONG SY, Colombel JF
    Cancer Screening in Patients With Inflammatory Bowel Disease: Don't Forget the Anus!
    Inflamm Bowel Dis. 2023 Nov 10:izad267. doi: 10.1093.
    >> Share

  759. YAMADA S, Honzawa Y, Yamamoto S, Matsuura M, et al
    Single Nucleotide Polymorphisms of the MEFV Gene E148Q Are Highly Associated With Disease Phenotype in Crohn's Disease.
    Inflamm Bowel Dis. 2023 Nov 10:izad259. doi: 10.1093.
    >> Share

  760. LITTLE RD, Swaine A, Reynolds R, Gibson DJ, et al
    Adalimumab Drug Levels at Secondary Loss of Response Do Not Predict Response to Dose-intensification in Crohn's Disease: A Retrospective, International Multicenter Study.
    Inflamm Bowel Dis. 2023 Nov 10:izad248. doi: 10.1093.
    >> Share

  761. CHEW DCH, Khoo XH, Lee TS, Chin KY, et al
    A Systematic Review on the Increasing Incidence of Inflammatory Bowel Disease in Southeast Asia: Looking Beyond the Urbanization Phenomenon.
    Inflamm Bowel Dis. 2023 Nov 3:izad189. doi: 10.1093.
    >> Share

  762. GONZALEZ CUETO E, Edmans M, Wellens J, Cadwell K, et al
    Antibody, not Cellular, Immune Responses to SARS-CoV-2 Vaccination Outperform Infection in Inflammatory Bowel Disease Patients.
    Inflamm Bowel Dis. 2023 Nov 3:izad265. doi: 10.1093.
    >> Share

  763. TUBAU-JUNI N, Hontecillas R, Leber AJ, Alva SS, et al
    Treating Autoimmune Diseases With LANCL2 Therapeutics: A Novel Immunoregulatory Mechanism for Patients With Ulcerative Colitis and Crohn's Disease.
    Inflamm Bowel Dis. 2023 Nov 2:izad258. doi: 10.1093.
    >> Share

  764. RUBIN DT, Torres J, Dotan I, Xu LT, et al
    An Insight into Patients' Perspectives of Ulcerative Colitis Flares via Analysis of Online Public Forum Posts.
    Inflamm Bowel Dis. 2023 Nov 2:izad247. doi: 10.1093.
    >> Share

  765. FEATHERS A, Lovasi GS, Grigoryan Z, Beem K, et al
    Crohn's Disease Mortality and Ambient Air Pollution in New York City.
    Inflamm Bowel Dis. 2023 Nov 2:izad243. doi: 10.1093.
    >> Share

  766. CHANG S, Hong S, Hudesman D, Remzi F, et al
    Histologic Predictors of Clinical Outcomes and Healthcare Utilization in Patients With Ileal Pouch-Anal Anastomosis.
    Inflamm Bowel Dis. 2023;29:1769-1777.
    >> Share

  767. LUO Y, Schmidt N, Dubinsky MC, Jaffin B, et al
    Evaluating lleal Pouch Anal Anastomosis Function: Time to Expand Our ARM-amentarium.
    Inflamm Bowel Dis. 2023;29:1819-1825.
    >> Share

  768. NARDONE OM, Calabrese G, Barberio B, Giglio MC, et al
    Rates of Endoscopic Recurrence In Postoperative Crohn's Disease Based on Anastomotic Techniques: A Systematic Review And Meta-Analysis.
    Inflamm Bowel Dis. 2023 Nov 1:izad252. doi: 10.1093.
    >> Share

    October 2023
  769. KRUGLIAK CLEVELAND N, Ghosh S, Chastek B, Bancroft T, et al
    Real-World Persistence of Successive Biologics in Patients With Inflammatory Bowel Disease: Findings From ROTARY.
    Inflamm Bowel Dis. 2023 Oct 31:izad245. doi: 10.1093.
    >> Share

  770. GUO A, Ostensson M, Stordal K, Ludvigsson J, et al
    Early-Life Hygiene-Related Factors and Risk of Inflammatory Bowel Disease: A Scandinavian Birth Cohort Study.
    Inflamm Bowel Dis. 2023 Oct 31:izad257. doi: 10.1093.
    >> Share

  771. RIGGOTT C, Fairbrass KM, Selinger CP, Gracie DJ, et al
    Impact of Opioid Use on the Natural History of Inflammatory Bowel Disease: Prospective Longitudinal Follow-up Study.
    Inflamm Bowel Dis. 2023 Oct 31:izad256. doi: 10.1093.
    >> Share


  772. Correction to: Low Fecal Calprotectin Predicts Histological Healing in Patients with Ulcerative Colitis with Endoscopic Remission and Leads to Prolonged Clinical Remission.
    Inflamm Bowel Dis. 2023 Oct 27:izad261. doi: 10.1093.
    >> Share

  773. FU J, Chai C, Chen L, Cai M, et al
    Associations of Fish and Fish Oil Consumption With Incident Inflammatory Bowel Disease: A Population-Based Prospective Cohort Study.
    Inflamm Bowel Dis. 2023 Oct 27:izad262. doi: 10.1093.
    >> Share

  774. HUANG Z, Cheng W, Chao K, Tang J, et al
    Baseline and Postinduction Intestinal Ultrasound Findings Predict Long-term Transmural and Mucosal Healing in Patients With Crohn's Disease.
    Inflamm Bowel Dis. 2023 Oct 27:izad251. doi: 10.1093.
    >> Share

  775. ASSADSANGABI A, Evans CA, Corfe BM, Lobo AJ, et al
    Exploring Predictive Biomarkers of Relapse in Ulcerative Colitis: A Proteomics Approach.
    Inflamm Bowel Dis. 2023 Oct 27:izad241. doi: 10.1093.
    >> Share

  776. WELLENS J, Chen J, Fu T, Zhang Y, et al
    Dietary Inflammatory Indices Are Not Associated With Inflammatory Bowel Disease Incidence and Progression.
    Inflamm Bowel Dis. 2023 Oct 25:izad249. doi: 10.1093.
    >> Share

  777. SHEEHAN JL, Jordan AA, Newman KL, Johnson LA, et al
    Are Depression and Anxiety Underdiagnosed in Socially Vulnerable Patients With Inflammatory Bowel Disease?
    Inflamm Bowel Dis. 2023 Oct 25:izad246. doi: 10.1093.
    >> Share


  778. Correction to: Comparative Efficacy of Biologic Therapies for Inducing Response and Remission in Fistulizing Crohn's Disease: Systematic Review and Network Meta-Analysis of Randomized Controlled Trials.
    Inflamm Bowel Dis. 2023 Oct 25:izad260. doi: 10.1093.
    >> Share

  779. LUND K, Zegers FD, Nielsen J, Brodersen JB, et al
    Inflammatory Bowel Disease in Adults and Elderly: The Use of Selected Non-IBD Medication Examined in a Nationwide Cohort Study.
    Inflamm Bowel Dis. 2023 Oct 24:izad244. doi: 10.1093.
    >> Share

  780. DIMOPOULOS-VERMA A, Hong S, Axelrad JE
    Enteric Infection at Flare of Inflammatory Bowel Disease Impacts Outcomes at 2 Years.
    Inflamm Bowel Dis. 2023 Oct 20:izad253. doi: 10.1093.
    >> Share

  781. DONNELLY M, Driever D, Ryan EJ, Elliott JA, et al
    Obesity, Sarcopenia and Myosteatosis: Impact on Clinical Outcomes in the Operative Management of Crohn's Disease.
    Inflamm Bowel Dis. 2023 Oct 20:izad225. doi: 10.1093.
    >> Share

  782. DAL BUONO A, Armuzzi A
    Transperineal Ultrasonography in the Assessment of Rectal Inflammation: Beyond the Monitoring of Ulcerative Colitis.
    Inflamm Bowel Dis. 2023 Oct 20:izad254. doi: 10.1093.
    >> Share

  783. MASSIRONI S, Sileri P, Danese S
    Get Fit: Muscle Health for Crohn's Disease Surgical Outcome Optimization.
    Inflamm Bowel Dis. 2023 Oct 20:izad235. doi: 10.1093.
    >> Share

  784. PRAKASH P, Dua A, Blumenfeld Y, Chen PH, et al
    Longitudinal Trends in Pregnancy Outcomes Among Women With Inflammatory Bowel Disease in the Era of Biologics: A 20-Year Nationwide Analysis.
    Inflamm Bowel Dis. 2023 Oct 19:izad250. doi: 10.1093.
    >> Share

  785. HEYDARI R, Fayazzadeh S, Shahrokh S, Shekari F, et al
    Plasma Extracellular Vesicle LncRNA H19 as a Potential Diagnostic Biomarker for Inflammatory Bowel Diseases.
    Inflamm Bowel Dis. 2023 Oct 19:izad219. doi: 10.1093.
    >> Share

  786. COLLEN LV, Mitsialis V, Kim DY, Bresnahan M, et al
    Efficacy and Safety of Anti-Tumor Necrosis Factor Alpha in Very Early Onset Inflammatory Bowel Disease.
    Inflamm Bowel Dis. 2023 Oct 17:izad196. doi: 10.1093.
    >> Share

  787. KRUGLIAK CLEVELAND N, Miyatani Y, Picker EA, Rubin DT, et al
    At-home Disease Monitoring by Patient-performed Intestinal Ultrasound in Severe Ulcerative Colitis.
    Inflamm Bowel Dis. 2023 Oct 16:izad237. doi: 10.1093.
    >> Share

  788. DALAL RS, Sharma PP, Bains K, Pruce JC, et al
    Clinical and Endoscopic Outcomes Through 78 Weeks of Tofacitinib Therapy for Ulcerative Colitis in a US Cohort.
    Inflamm Bowel Dis. 2023 Oct 16:izad242. doi: 10.1093.
    >> Share

  789. SCHMOYER CJ, Sun K, Zack J, Kumar P, et al
    Adverse Events and Compliance Among Inflammatory Bowel Disease Patients Treated With Home- vs Office-Based Biologic Infusions.
    Inflamm Bowel Dis. 2023 Oct 11:izad226. doi: 10.1093.
    >> Share

  790. TARIQ R, Loftus EV
    Home-based Biologic Infusions for Inflammatory Bowel Disease: Are We Ready for Prime Time?
    Inflamm Bowel Dis. 2023 Oct 11:izad240. doi: 10.1093.
    >> Share

  791. SMITH RA, Desai A, Hashash JG, Hayney MS, et al
    Addressing the Risks of Respiratory Syncytial Virus for Patients With Inflammatory Bowel Disease in the Era of Novel Vaccines.
    Inflamm Bowel Dis. 2023 Oct 10:izad233. doi: 10.1093.
    >> Share

  792. MARTINELLI M, Romeo E, Caldaro T, Dimakou K, et al
    De Novo Crohn's Disease in Children With Ulcerative Colitis Undergoing Ileal Pouch-Anal Anastomosis: A Multicenter, Retrospective Study From the Pediatric IBD Porto Group of the ESPGHAN.
    Inflamm Bowel Dis. 2023 Oct 10:izad199. doi: 10.1093.
    >> Share

  793. O'SHEA D, Picoraro JA
    De Novo Crohn's Disease in the Pediatric Pouch.
    Inflamm Bowel Dis. 2023 Oct 10:izad231. doi: 10.1093.
    >> Share

  794. KLEEBAYOON A, Wiwanitkit V
    SARS-CoV-2 Serological Response in Patients With Inflammatory Bowel Disease.
    Inflamm Bowel Dis. 2023 Oct 10:izad230. doi: 10.1093.
    >> Share


  795. Correction to: Induction of Remission With Exclusive Enteral Nutrition in Children With Crohn's Disease: Determinants of Higher Adherence and Response.
    Inflamm Bowel Dis. 2023 Oct 9:izad239. doi: 10.1093.
    >> Share

  796. REIJNTJES M, de Jong D, Wessels E, Goetgebuer R, et al
    Crohn's Disease of the Ileoanal Pouch: A High Rate of Potential Overdiagnoses.
    Inflamm Bowel Dis. 2023 Oct 6:izad228. doi: 10.1093.
    >> Share

  797. RAO V, Cockburn E, Segal JP
    Is Ulcerative Colitis Really Ever "Cleared?".
    Inflamm Bowel Dis. 2023 Oct 5:izad234. doi: 10.1093.
    >> Share

  798. LAHEIJ RLH, van Knippenberg YMW, Heil ALJ, Mannaerts BJW, et al
    The Efficacy of an Over-the-Counter Multivitamin and Mineral Supplement to Prevent Infections in Patients With Inflammatory Bowel Disease in Remission With Immunomodulators and/or Biological Agents: A Randomized, Double-Blind, Placebo-Controlled Clini
    Inflamm Bowel Dis. 2023 Oct 4:izad216. doi: 10.1093.
    >> Share

  799. BISLENGHI G, Van Den Bossch J, Fieuws S, Wolthuis A, et al
    Appearance of the Bowel and Mesentery During Surgery Is Not Predictive of Postoperative Recurrence After Ileocecal Resection for Crohn's Disease: A Prospective Monocentric Study.
    Inflamm Bowel Dis. 2023 Oct 4:izad227. doi: 10.1093.
    >> Share

  800. YANG W, Cong Y
    Exploring Colitis through Dynamic T Cell Adoptive Transfer Models.
    Inflamm Bowel Dis. 2023;29:1673-1680.
    >> Share

  801. YIN Y, Wan J, Yu J, Wu K, et al
    Molecular Pathogenesis of Colitis-associated Colorectal Cancer: Immunity, Genetics, and Intestinal Microecology.
    Inflamm Bowel Dis. 2023;29:1648-1657.
    >> Share

  802. WEIDINGER C, Siegmund B
    Deciphering Cellular Networks in Creeping Fat.
    Inflamm Bowel Dis. 2023;29:1670-1672.
    >> Share

    September 2023
  803. TYRODE G, Lakkis Z, Vernerey D, Falcoz A, et al
    KONO-S Anastomosis Is Not Superior to Conventional Anastomosis for the Reduction of Postoperative Endoscopic Recurrence in Crohn's Disease.
    Inflamm Bowel Dis. 2023 Sep 30:izad214. doi: 10.1093.
    >> Share

  804. LEE YJ, Li D, Mujukian A, Debbas P, et al
    Postvaccination Symptoms After a Fourth Dose of mRNA SARS-CoV-2 Vaccination in Patients With Inflammatory Bowel Disease.
    Inflamm Bowel Dis. 2023 Sep 29:izad198. doi: 10.1093.
    >> Share

  805. CATASSI G, D'Arcangelo G, Norsa L, Bramuzzo M, et al
    Outcome of Very Early Onset Inflammatory Bowel Disease Associated With Primary Sclerosing Cholangitis: A Multicenter Study From the Pediatric IBD Porto Group of ESPGHAN.
    Inflamm Bowel Dis. 2023 Sep 28:izad218. doi: 10.1093.
    >> Share

  806. METWALY A, Haller D
    The TNF?ARE Model of Crohn's Disease-like Ileitis.
    Inflamm Bowel Dis. 2023 Sep 26:izad205. doi: 10.1093.
    >> Share

  807. LIU GXH, Day AS
    Plant-based Diets for Inflammatory Bowel Disease: What Is the Evidence?
    Inflamm Bowel Dis. 2023 Sep 25:izad213. doi: 10.1093.
    >> Share

  808. PATEL R, Marrie RA, Bernstein CN, Bolton JM, et al
    Vascular Disease Is Associated With Differences in Brain Structure and Lower Cognitive Functioning in Inflammatory Bowel Disease: A Cross-Sectional Study.
    Inflamm Bowel Dis. 2023 Sep 22:izad204. doi: 10.1093.
    >> Share

  809. SIGVARDSSON I, Stordal K, Ostensson M, Guo A, et al
    Childhood Socioeconomic Characteristics and Risk of Inflammatory Bowel Disease: A Scandinavian Birth Cohort Study.
    Inflamm Bowel Dis. 2023 Sep 22:izad220. doi: 10.1093.
    >> Share

  810. GLICKMAN D, Dalessio S, Raup-Konsavage WM, Vrana KE, et al
    Reply: "Cannabis Use: A Marker of Clinical Severity in Inflammatory Bowel Disease?".
    Inflamm Bowel Dis. 2023 Sep 21:izad222. doi: 10.1093.
    >> Share

  811. ERRIDGE S, Sodergren MH
    Cannabis Use: A Marker of Clinical Severity in Inflammatory Bowel Disease?
    Inflamm Bowel Dis. 2023 Sep 21:izad221. doi: 10.1093.
    >> Share

  812. BARBER GE, Zhuo J, Okafor PN, Streett S, et al
    Gastroenterology Clinic Follow-Up Reduces Gastroenterology-Specific Readmissions Among Patients With Severe Ulcerative Colitis.
    Inflamm Bowel Dis. 2023 Sep 21:izad207. doi: 10.1093.
    >> Share

  813. SNINSKY JA, Staicu AM, Barnes EL
    In Acute Severe Ulcerative Colitis Patients Who Receive Rescue Therapy, Prior Maintenance Therapy and Day 3 C-Reactive Protein After Rescue Therapy Are Associated With 12-Month Colectomy Risk.
    Inflamm Bowel Dis. 2023 Sep 21:izad215. doi: 10.1093.
    >> Share

  814. LASA J, Nazario E, De Sanctis G, Fernandez Recalde M, et al
    Endoscopically Active Ulcerative Colitis Is Associated With Asymptomatic Atherosclerotic Vascular Disease: A Case-Control Study.
    Inflamm Bowel Dis. 2023 Sep 21:izad217. doi: 10.1093.
    >> Share

  815. LI WAI SUEN CFD, Seah D, Choy MC, De Cruz P, et al
    Factors Associated With Response to Rescue Therapy in Acute Severe Ulcerative Colitis.
    Inflamm Bowel Dis. 2023 Sep 19:izad183. doi: 10.1093.
    >> Share

  816. NASEEM K, Sohail A, Quang Nguyen V, Khan A, et al
    Predictors of Hospital-related Outcomes of COVID-19 Infection in Patients With Inflammatory Bowel Disease in the Early Pandemic Phase: A Nationwide Inpatient Database Survey.
    Inflamm Bowel Dis. 2023 Sep 19:izad200. doi: 10.1093.
    >> Share

  817. SHAH S, Shillington AC, Kabagambe EK, Deering KL, et al
    Racial and Ethnic Disparities in Patients With Inflammatory Bowel Disease: An Online Survey.
    Inflamm Bowel Dis. 2023 Sep 13:izad194. doi: 10.1093.
    >> Share

  818. GUGLIELMI G, Crucitta S, Bertani L, Ruglioni M, et al
    Expression of Circulating let-7e and miR-126 May Predict Clinical Remission in Patients With Crohn's Disease Treated With Anti-TNF-alpha Biologics.
    Inflamm Bowel Dis. 2023 Sep 11:izad181. doi: 10.1093.
    >> Share

  819. DEL CHIERICO F, Cardile S, Baldelli V, Alterio T, et al
    Characterization of the Gut Microbiota and Mycobiota in Italian Pediatric Patients With Primary Sclerosing Cholangitis and Ulcerative Colitis.
    Inflamm Bowel Dis. 2023 Sep 11:izad203. doi: 10.1093.
    >> Share


  820. Correction to: Research Progress of Interleukin-27 in Inflammatory Bowel Disease.
    Inflamm Bowel Dis. 2023 Sep 9:izad223. doi: 10.1093.
    >> Share

  821. MIYATANI Y, Micic D
    Revisiting the Risk of Hospital Readmission in Severe Ulcerative Colitis.
    Inflamm Bowel Dis. 2023 Sep 8:izad212. doi: 10.1093.
    >> Share

  822. KIM SH, Buhle A, Roberts A, Singh N, et al
    Multidisciplinary Inflammatory Bowel Disease Conference: The Impact of the Expert Pathologist on Patient Care.
    Inflamm Bowel Dis. 2023 Sep 6:izad192. doi: 10.1093.
    >> Share

  823. SITKIN S, Pokrotnieks J
    Targeted Probiotics Against Bacterial-Fungal Biofilms: A New Concept Seems to Bring Us Closer to Microbiome-modulating Therapy for Inflammatory Bowel Disease.
    Inflamm Bowel Dis. 2023 Sep 6:izad209. doi: 10.1093.
    >> Share

  824. DI MARTINO L
    Reply: "Targeted Probiotics Against Bacterial-Fungal Biofilms: A New Concept Seems to Bring Us Closer to Microbiome-Modulating Therapy for Inflammatory Bowel Disease".
    Inflamm Bowel Dis. 2023 Sep 6:izad206. doi: 10.1093.
    >> Share

  825. SINGH A, Midha V, Kochhar GS, Shen B, et al
    Management of Perianal Fistulizing Crohn's Disease.
    Inflamm Bowel Dis. 2023 Sep 6:izad195. doi: 10.1093.
    >> Share

  826. CROUWEL F, Bayoumy AB, Mulder CJJ, Peters JHC, et al
    The Effectiveness and Safety of First-Line Thioguanine in Thiopurine-Naive Inflammatory Bowel Disease Patients.
    Inflamm Bowel Dis. 2023 Sep 2:izad197. doi: 10.1093.
    >> Share

  827. HERRERA-DEGUISE C, Varela E, Sarrabayrouse G, Pozuelo Del Rio M, et al
    Gut Microbiota Composition in Long-Remission Ulcerative Colitis is Close to a Healthy Gut Microbiota.
    Inflamm Bowel Dis. 2023;29:1362-1369.
    >> Share

  828. RUTHERFORD D, Ho GT
    Therapeutic Potential of Human Intestinal Organoids in Tissue Repair Approaches in Inflammatory Bowel Diseases.
    Inflamm Bowel Dis. 2023;29:1488-1498.
    >> Share

  829. NORGARD BM, Zegers FD, Nielsen J, Knudsen T, et al
    COVID-19 Does Not Lead to an Increase in Corticosteroid Prescriptions in IBD Patients: A Nationwide Cohort Study.
    Inflamm Bowel Dis. 2023;29:1470-1476.
    >> Share

  830. AKIYAMA S, Cohen NA, Kayal M, Dubinsky MC, et al
    Treatment of Chronic Inflammatory Pouch Conditions With Tofacitinib: A Case Series From 2 Tertiary IBD Centers in the United States.
    Inflamm Bowel Dis. 2023;29:1504-1507.
    >> Share

  831. AINSWORTH MA
    How to Minimize Placebo Response and Remission Rates.
    Inflamm Bowel Dis. 2023;29:1508-1509.
    >> Share

  832. IACUCCI M, Jeffery L, Acharjee A, Grisan E, et al
    Computer-Aided Imaging Analysis of Probe-Based Confocal Laser Endomicroscopy With Molecular Labeling and Gene Expression Identifies Markers of Response to Biological Therapy in IBD Patients: The Endo-Omics Study.
    Inflamm Bowel Dis. 2023;29:1409-1420.
    >> Share

  833. OUTTIER A, Gijbels L, Noman M, Verstockt B, et al
    Screening Failure in a Large Clinical Trial Centre for Inflammatory Bowel Diseases: Rates, Causes, and Outcomes.
    Inflamm Bowel Dis. 2023;29:1440-1445.
    >> Share

  834. MASSIRONI S, Pirola L, Mulinacci G, Ciaccio A, et al
    Use of IBD Drugs in Patients With Hepatobiliary Comorbidities: Tips and Tricks.
    Inflamm Bowel Dis. 2023;29:1477-1487.
    >> Share

  835. CUOMO M, Carobbio A, Aloi M, Alvisi P, et al
    Induction of Remission With Exclusive Enteral Nutrition in Children With Crohn's Disease: Determinants of Higher Adherence and Response.
    Inflamm Bowel Dis. 2023;29:1380-1389.
    >> Share

    August 2023
  836. LIU T, Lin CH, Chen YL, Yeh CC, et al
    Relationship Between Rectal Swab and Tissue Samples in Mucosa-associated Microbiota in Patients With Inflammatory Bowel Disease.
    Inflamm Bowel Dis. 2023 Aug 31:izad179. doi: 10.1093.
    >> Share

  837. BHAT S, Lyu R, Agarwal M, Becker M, et al
    Defining the Roles of Inflammatory Bowel Disease Clinical Pharmacists in the United States: A Systematic Review and National RAND/UCLA Consensus.
    Inflamm Bowel Dis. 2023 Aug 31:izad143. doi: 10.1093.
    >> Share

  838. JACOBS JP, Sauk JS, Ahdoot AI, Liang F, et al
    Microbial and Metabolite Signatures of Stress Reactivity in Ulcerative Colitis Patients in Clinical Remission Predict Clinical Flare Risk.
    Inflamm Bowel Dis. 2023 Aug 31:izad185. doi: 10.1093.
    >> Share

  839. YU N, Wu K, Samyue T, Fry S, et al
    Outcomes of a Comprehensive Specialist Inflammatory Bowel Disease Nursing Service.
    Inflamm Bowel Dis. 2023 Aug 29:izad145. doi: 10.1093.
    >> Share

  840. TOKUSHIMA K, Jimbo K, Suzuki M, Endo Y, et al
    Differentiation of Active Ulcerative Colitis vs Noninflammatory Bowel Disease Proctitis by Transperineal Superb Microvascular Imaging.
    Inflamm Bowel Dis. 2023 Aug 29:izad186. doi: 10.1093.
    >> Share

  841. REN H, Kang J, Wang J, Su J, et al
    Efficacy of Ustekinumab Optimization by 2 Initial Intravenous Doses in Adult Patients With Severe Crohn's Disease.
    Inflamm Bowel Dis. 2023 Aug 24:izad184. doi: 10.1093.
    >> Share

  842. MOULTON CD, Jordan C, Hayee B, Chalder T, et al
    All-or-Nothing Behavior and Catastrophic Thinking Predict Fatigue in Inflammatory Bowel Disease: A Prospective Cohort Study.
    Inflamm Bowel Dis. 2023 Aug 24:izad193. doi: 10.1093.
    >> Share

  843. DALAL RS, Sharma PP, Bains K, Pruce JC, et al
    1-Year Comparison of Clinical and Endoscopic Outcomes of Tofacitinib vs Vedolizumab for Ulcerative Colitis After Anti-Tumor Necrosis Factor Failure: A Real-World Cohort Study in the United States.
    Inflamm Bowel Dis. 2023 Aug 24:izad165. doi: 10.1093.
    >> Share

  844. WANDS DIF, Gianolio L, Wilson DC, Hansen R, et al
    Nationwide Real-World Exclusive Enteral Nutrition Practice Over Time: Persistence of Use as Induction for Pediatric Crohn's Disease and Emerging Combination Strategy With Biologics.
    Inflamm Bowel Dis. 2023 Aug 24:izad167. doi: 10.1093.
    >> Share

  845. LONG MD, Parlett L, Lewis JD, Haynes K, et al
    Corticosteroids but not Anti-TNF Are Associated With Increased COVID-19 Complications in Patients With Inflammatory Bowel Disease.
    Inflamm Bowel Dis. 2023 Aug 23:izad176. doi: 10.1093.
    >> Share

  846. ZINGER CH, Ringel Y, Eitan M, Openhaim M, et al
    Upadacitinib for Acute Severe Ulcerative Colitis.
    Inflamm Bowel Dis. 2023 Aug 23:izad180. doi: 10.1093.
    >> Share

  847. BROWNSON E, Saunders J, Jatkowska A, White B, et al
    Micronutrient Status and Prediction of Disease Outcome in Adults With Inflammatory Bowel Disease Receiving Biologic Therapy.
    Inflamm Bowel Dis. 2023 Aug 23:izad174. doi: 10.1093.
    >> Share

  848. MARTINEZ-DOMINGUEZ SJ, Garcia-Mateo S, Gargallo-Puyuelo CJ, Gallego-Llera B, et al
    Inflammatory Bowel Disease Is an Independent Risk Factor for Metabolic Dysfunction-Associated Steatotic Liver Disease in Lean Individuals.
    Inflamm Bowel Dis. 2023 Aug 22:izad175. doi: 10.1093.
    >> Share

  849. TRACY MS, Challa PK, Lopes EW, Khalili H, et al
    Prevalence and Treatment Patterns of Inflammatory Bowel Disease in the All of Us Research Program.
    Inflamm Bowel Dis. 2023 Aug 21:izad170. doi: 10.1093.
    >> Share

  850. COONEY R, Tang D, Barrett K, Russell RK, et al
    Children and Young Adults With Inflammatory Bowel Disease Have an Increased Incidence and Risk of Developing Mental Health Conditions: A UK Population-Based Cohort Study.
    Inflamm Bowel Dis. 2023 Aug 21:izad169. doi: 10.1093.
    >> Share

  851. TRAVIS S, Potts Bleakman A, Dubinsky MC, Schreiber S, et al
    The Communicating Needs and Features of IBD Experiences (CONFIDE) Study: US and European Patient and Health Care Professional Perceptions of the Experience and Impact of Symptoms of Moderate-to-Severe Ulcerative Colitis.
    Inflamm Bowel Dis. 2023 Aug 21:izad142. doi: 10.1093.
    >> Share

  852. D'ARCANGELO G, Russo G, Aloi M, Ruggiero C, et al
    A Treat-to-Target Strategy Guided by Pan-Enteric Evaluation in Children With Crohn's Disease Improves Outcomes at 2 Years.
    Inflamm Bowel Dis. 2023 Aug 21:izad173. doi: 10.1093.
    >> Share

  853. RASMUSSEN J, Norgard BM, Nielsen RG, Boggild H, et al
    Implication of Inflammatory Bowel Disease Diagnosed Before the Age of 18 for Achieving an Upper Secondary Education: A Nationwide Population-Based Cohort Study.
    Inflamm Bowel Dis. 2023 Aug 21:izad157. doi: 10.1093.
    >> Share

  854. OSHIMA N, Hiraoka S, Hayashi R, Takahashi S, et al
    Predictive Factors for Efficacy of Oral Tacrolimus Induction Therapy in Moderate to Severe Ulcerative Colitis Patients: Large Multicenter Retrospective Cohort Study.
    Inflamm Bowel Dis. 2023 Aug 19:izad150. doi: 10.1093.
    >> Share

  855. HANZEL J, Ma C, De Silva TA, Alphonsus L, et al
    Approval Timelines for Advanced Therapeutics in Inflammatory Bowel Disease: A Comparison Between the European Medicines Agency and the Food and Drug Administration.
    Inflamm Bowel Dis. 2023 Aug 17:izad168. doi: 10.1093.
    >> Share

  856. GLICKMAN D, Dalessio S, Raup-Konsavage WM, Vrana KE, et al
    The Impact of Cannabis Use on Clinical Outcomes in Inflammatory Bowel Disease: A Population-based Longitudinal Cohort Study.
    Inflamm Bowel Dis. 2023 Aug 14:izad151. doi: 10.1093.
    >> Share

  857. ZHU Z, Jia Y, Li FR, Li Y, et al
    Inflammatory Bowel Disease and Risk of Global Cardiovascular Diseases and Type 2 Diabetes.
    Inflamm Bowel Dis. 2023 Aug 14:izad163. doi: 10.1093.
    >> Share

  858. MUJUKIAN A, Kumar R, Li D, Debbas P, et al
    Postvaccination Symptoms After SARS-CoV-2 mRNA Vaccination Among Patients With Inflammatory Bowel Disease: A Prospective, Comparative Study.
    Inflamm Bowel Dis. 2023 Aug 9:izad114. doi: 10.1093.
    >> Share

  859. D'AMICO F, Magro F, Siegmund B, Kobayashi T, et al
    Disease Clearance as a New Outcome in Ulcerative Colitis: a Systematic Review and Expert Consensus.
    Inflamm Bowel Dis. 2023 Aug 7:izad159. doi: 10.1093.
    >> Share

  860. RESAL T, Bacsur P, Keresztes C, Balint A, et al
    Real-Life Efficacy of Tofacitinib in Various Situations in Ulcerative Colitis: A Retrospective Worldwide Multicenter Collaborative Study.
    Inflamm Bowel Dis. 2023 Aug 5:izad135. doi: 10.1093.
    >> Share

  861. DUBOIS KE, Blake CE, Rudisill C, Harrison SE, et al
    Ulcerative Colitis Is Associated With Diet-related Inflammation and Physical Activity in the IBD Partners E-cohort.
    Inflamm Bowel Dis. 2023 Aug 5:izad139. doi: 10.1093.
    >> Share

  862. DI PETRILLO A, Kumar A, Onali S, Favale A, et al
    GPR120/FFAR4: A Potential New Therapeutic Target for Inflammatory Bowel Disease.
    Inflamm Bowel Dis. 2023 Aug 5:izad161. doi: 10.1093.
    >> Share

  863. SHEHAB M, Al Akram S, Hassan A, Alrashed F, et al
    Histological Disease Activity as Predictor of Clinical Relapse, Hospitalization, and Surgery in Inflammatory Bowel Disease: Systematic Review and Meta-Analysis.
    Inflamm Bowel Dis. 2023 Aug 4:izad119. doi: 10.1093.
    >> Share

  864. DESAI A, Soni A, Hayney MS, Hashash JG, et al
    Increased Risk of Herpes Zoster in Adult Patients with Inflammatory Bowel Disease After SARS-CoV2 Infection: A Propensity-Matched Cohort Study.
    Inflamm Bowel Dis. 2023 Aug 4:izad162. doi: 10.1093.
    >> Share

  865. WANG Q, Chen F, Peng Y, Yi X, et al
    Research Progress of Interleukin-27 in Inflammatory Bowel Disease.
    Inflamm Bowel Dis. 2023 Aug 4:izad153. doi: 10.1093.
    >> Share

  866. VIGANO C, Palermo A, Mulinacci G, Pirola L, et al
    Prevalence of Disease-Related Malnutrition and Micronutrients Deficit in Patients with Inflammatory Bowel Disease: A Multicentric Cross-Sectional Study by the GSMII (Inflammatory Bowel Disease Study Group).
    Inflamm Bowel Dis. 2023 Aug 3:izad146. doi: 10.1093.
    >> Share

  867. ALDARS-GARCIA L, Gil-Redondo R, Embade N, Riestra S, et al
    Serum and Urine Metabolomic Profiling of Newly Diagnosed Treatment-Naive Inflammatory Bowel Disease Patients.
    Inflamm Bowel Dis. 2023 Aug 3:izad154. doi: 10.1093.
    >> Share

  868. ZHU N, Zhu J, Mei Q
    Low-density Granulocytes as a Novel Biomarkers of Disease Activity in IBD.
    Inflamm Bowel Dis. 2023;29:e31.
    >> Share

  869. XIE K, Ortiz Cerda T, Schroder A, Shiung N, et al
    Response to Low-density Granulocytes as Novel Biomarkers of Disease Activity in IBD.
    Inflamm Bowel Dis. 2023;29:e32.
    >> Share

  870. BAMIAS G, Kitsou K, Rivera-Nieves J
    The Underappreciated Role of Secretory IgA in IBD.
    Inflamm Bowel Dis. 2023;29:1327-1341.
    >> Share

  871. ROSEIRA J, Santiago M, Estevinho MM, Moreira P, et al
    Impact of Crohn's Disease Therapies on Histology in Randomized Controlled Trials: Systematic Review With Meta-analysis.
    Inflamm Bowel Dis. 2023;29:1231-1243.
    >> Share

  872. KAMP KJ, Hawes SE, Tse CS, Singh S, et al
    Concordance and Discordance Between Patient-reported Remission, Patient-reported Outcomes, and Physician Global Assessment.
    Inflamm Bowel Dis. 2023;29:1255-1262.
    >> Share

  873. PRAY C, Wong ECL, Aruljothy A, Dulai PS, et al
    Ulcer Size After Induction Therapy Performs Better Than Symptom Assessment for Prediction of One Year Endoscopic Remission in Crohn's Disease: A Post Hoc Analysis.
    Inflamm Bowel Dis. 2023;29:1263-1271.
    >> Share

    July 2023
  874. CROWLEY E, Ma C, Guizzetti L, Zou G, et al
    Recommendations for Standardizing MRI-based Evaluation of Perianal Fistulizing Disease Activity in Pediatric Crohn's Disease Clinical Trials.
    Inflamm Bowel Dis. 2023 Jul 31:izad134. doi: 10.1093.
    >> Share

  875. MARK-CHRISTENSEN A, Kristiansen EB, Myrelid P, Laurberg S, et al
    Appendectomy and Risk of Advanced Colorectal Neoplasia in Inflammatory Bowel Disease: A Nationwide Population-based Cohort Study.
    Inflamm Bowel Dis. 2023 Jul 31:izad141. doi: 10.1093.
    >> Share

  876. OTTEN AT, Dijkstra G, Visschedijk MC, Bourgonje AR, et al
    The Future of Therapeutic Drug Monitoring in Inflammatory Bowel Disease: An Emphasis on the Essential Ingredients.
    Inflamm Bowel Dis. 2023 Jul 31:izad144. doi: 10.1093.
    >> Share

  877. DALAL RS, Lund K, Zegers FD, Friedman S, et al
    Use of Tramadol vs Traditional Opioids and Adverse Outcomes in Patients with Inflammatory Bowel Disease: A Danish Nationwide Cohort Study.
    Inflamm Bowel Dis. 2023 Jul 31:izad156. doi: 10.1093.
    >> Share

  878. BOKEMEYER B, Plachta-Danielzik S, di Giuseppe R, Efken P, et al
    Real-World Effectiveness of Vedolizumab vs Anti-TNF in Biologic-naive Crohn's Disease Patients: A 2-year Propensity-score-adjusted Analysis from the VEDOIBD-Study.
    Inflamm Bowel Dis. 2023 Jul 31:izad138. doi: 10.1093.
    >> Share

  879. LAW CCY, Tkachuk B, Lieto S, Narula N, et al
    Early Biologic Treatment Decreases Risk of Surgery in Crohn's Disease but not in Ulcerative Colitis: Systematic Review and Meta-Analysis.
    Inflamm Bowel Dis. 2023 Jul 28:izad149. doi: 10.1093.
    >> Share

  880. OKITA M, Nakashima K, Yamamura T, Matsui S, et al
    Systematic Review and Meta-Analysis of the Use of Serum Leucine-Rich Alpha-2 Glycoprotein to Assess Crohn's Disease Activity.
    Inflamm Bowel Dis. 2023 Jul 28:izad128. doi: 10.1093.
    >> Share

  881. LEE S, Seow CH, Nerenberg K, Bertazzon S, et al
    Despite Increased Disease Activity, Women who Attended a Dedicated Inflammatory Bowel Disease and Pregnancy Clinic Had Infants With Higher Apgar Scores: A Population-Based Study.
    Inflamm Bowel Dis. 2023 Jul 27:izad147. doi: 10.1093.
    >> Share

  882. DALAL RS, Kallumkal G, Cabral HJ, Bachour S, et al
    Clinical and Endoscopic Outcomes After Upadacitinib Induction for Ulcerative Colitis: A Multicenter Retrospective Cohort Study.
    Inflamm Bowel Dis. 2023 Jul 27:izad155. doi: 10.1093.
    >> Share

  883. MCNAMARA J, Connor SJ, Andrews JM
    The Evolving Role of Technology in Delivering Patient-centric, Empowered Health Care in Inflammatory Bowel Disease: Patient Experience Using Crohn's Colitis Care e-Health Consumer Platform.
    Inflamm Bowel Dis. 2023 Jul 25:izad148. doi: 10.1093.
    >> Share

  884. MARAFINI I, De Cristofaro E, Salvatori S, Calabrese E, et al
    Niclosamide Enema for Active Distal Ulcerative Colitis: A Phase 1, Open-Label Study.
    Inflamm Bowel Dis. 2023 Jul 21:izad125. doi: 10.1093.
    >> Share

  885. ALIZADEH M, Ali O, Cross RK
    Assessing Progression of Biologic Therapies Based on Smoking Status in Patients With Crohn's Disease.
    Inflamm Bowel Dis. 2023 Jul 21:izad131. doi: 10.1093.
    >> Share

  886. ROMANO D, Chesterman S, Fuller-Tyszkiewicz M, Evans S, et al
    Feasibility, Acceptability, and Preliminary Efficacy of Acceptance Commitment Therapy for Adults Living With Inflammatory Bowel Disease and Distress.
    Inflamm Bowel Dis. 2023 Jul 21:izad122. doi: 10.1093.
    >> Share

  887. PASCUAL-OLIVER A, Casas-Deza D, Cuaran C, Garcia-Lopez S, et al
    HLA-DQA1*05 Was Not Associated With Primary Nonresponse or Loss of Response to First Anti-TNF in Real-World Inflammatory Bowel Disease Patients.
    Inflamm Bowel Dis. 2023 Jul 18:izad130. doi: 10.1093.
    >> Share

  888. LIU F, Xu W, Wang Y, Huang Z, et al
    LAMB3 Promotes Intestinal Inflammation Through SERPINA3 and Is Directly Transcriptionally Regulated by P65 in Inflammatory Bowel Disease.
    Inflamm Bowel Dis. 2023 Jul 15:izad140. doi: 10.1093.
    >> Share

  889. MCHENRY S, Glover M, Ahmed A, Alayo Q, et al
    NAFLD Is Associated With Quiescent Rather Than Active Crohn's Disease.
    Inflamm Bowel Dis. 2023 Jul 15:izad129. doi: 10.1093.
    >> Share

  890. BHAT S, Click B, Regueiro M
    Safety and Monitoring of Inflammatory Bowel Disease Advanced Therapies.
    Inflamm Bowel Dis. 2023 Jul 14:izad120. doi: 10.1093.
    >> Share

  891. ROOSENBOOM B, Wahab PJ, Smids C, Meijer J, et al
    Mucosal alpha4beta7+ Lymphocytes and MAdCAM+ Venules Predict Response to Vedolizumab in Ulcerative Colitis.
    Inflamm Bowel Dis. 2023 Jul 12:izad123. doi: 10.1093.
    >> Share

  892. KOGAN L, Townsend MJ, Raj D, Levy AN, et al
    Prognostic Value of Inflammatory Bowel Disease-associated Biomarkers in Patients With Immune Checkpoint Inhibitor Enterocolitis: A Retrospective Cohort Study.
    Inflamm Bowel Dis. 2023 Jul 8:izad121. doi: 10.1093.
    >> Share

  893. ZENG Z, Cheng S, Li X, Liu H, et al
    Glycolytic Activation of CD14+ Intestinal Macrophages Contributes to the Inflammatory Responses via Exosomal Membrane Tumor Necrosis Factor in Crohn's Disease.
    Inflamm Bowel Dis. 2023 Jul 5:izad117. doi: 10.1093.
    >> Share

  894. DAI C, Huang YH
    Frail Phenotype in Patients With Inflammatory Bowel Disease.
    Inflamm Bowel Dis. 2023;29:e30.
    >> Share

  895. RAUSCH P, Ellul S, Pisani A, Bang C, et al
    Microbial Dynamics in Newly Diagnosed and Treatment Naive IBD Patients in the Mediterranean.
    Inflamm Bowel Dis. 2023;29:1118-1132.
    >> Share

  896. GARCIA-HERNANDEZ V, Raya-Sandino A, Azcutia V, Miranda J, et al
    Inhibition of Soluble Stem Cell Factor Promotes Intestinal Mucosal Repair.
    Inflamm Bowel Dis. 2023;29:1133-1144.
    >> Share

  897. LAM GA, Albarrak H, McColl CJ, Pizarro A, et al
    The Oral-Gut Axis: Periodontal Diseases and Gastrointestinal Disorders.
    Inflamm Bowel Dis. 2023;29:1153-1164.
    >> Share

  898. ADLER J, Colletti RB, Noonan L, Berzin TM, et al
    Validating the Simplified Endoscopic Mucosal Assessment for Crohn's Disease: A Novel Method for Assessing Disease Activity.
    Inflamm Bowel Dis. 2023;29:1089-1097.
    >> Share

  899. SIGURDSSON GV, Schmidt S, Mellstrom D, Ohlsson C, et al
    Young Adult Male Patients With Childhood-onset IBD Have Increased Risks of Compromised Cortical and Trabecular Bone Microstructures.
    Inflamm Bowel Dis. 2023;29:1065-1072.
    >> Share

  900. WONG ECL, Dulai PS, Marshall JK, Jairath V, et al
    Comparative Efficacy of Infliximab vs Ustekinumab for Maintenance of Clinical Response in Biologic Naive Crohn's Disease.
    Inflamm Bowel Dis. 2023;29:1015-1023.
    >> Share

  901. PROIETTI E, Pauwels RWM, van der Woude CJ, Doukas M, et al
    Ustekinumab Tissue and Serum Levels in Patients With Crohn's Disease Are Closely Correlated Though Not Consistently Associated With Objective Response After Induction.
    Inflamm Bowel Dis. 2023;29:1038-1046.
    >> Share

  902. CHANDAN S, Dhindsa BS, Khan SR, Deliwala S, et al
    Endoscopic Stenting in Crohn's Disease-related Strictures: A Systematic Review and Meta-analysis of Outcomes.
    Inflamm Bowel Dis. 2023;29:1145-1152.
    >> Share

    June 2023
  903. MACALUSO FS, Principi M, Facciotti F, Contaldo A, et al
    Lack of Seroconversion Following COVID-19 Vaccination Is an Independent Risk Factor for SARS-CoV-2 Infection in Patients With Inflammatory Bowel Disease: Data from ESCAPE-IBD, an IG-IBD Study.
    Inflamm Bowel Dis. 2023 Jun 30:izad118. doi: 10.1093.
    >> Share

  904. ADIMADHYAM S, Lewis JD, Simon AL, Wolfe AE, et al
    Real-world Evidence Comparing Tofacitinib and Vedolizumab in Anti-TNF-experienced Patients With Ulcerative Colitis.
    Inflamm Bowel Dis. 2023 Jun 26:izad115. doi: 10.1093.
    >> Share

  905. WONG SY, Wellens J, Helmus D, Marlow L, et al
    Geography Influences Susceptibility to SARS-CoV-2 Serological Response in Patients With Inflammatory Bowel Disease: Multinational Analysis From the ICARUS-IBD Consortium.
    Inflamm Bowel Dis. 2023 Jun 24:izad097. doi: 10.1093.
    >> Share

  906. ITO N, Kudo T, Eguchi H, Jimbo K, et al
    Attenuated Expression of SLCO2A1 Caused by DNA Methylation in Pediatric Inflammatory Bowel Disease.
    Inflamm Bowel Dis. 2023 Jun 16:izad116. doi: 10.1093.
    >> Share

  907. TE GROEN M, Derikx LAAP, van Lierop L, Ylstra B, et al
    Clonal Patterns Between Pouch Neoplasia and Prior Colorectal Neoplasia in Inflammatory Bowel Disease Patients: An Exploratory Cohort Study.
    Inflamm Bowel Dis. 2023 Jun 16:izad112. doi: 10.1093.
    >> Share

  908. MULES TC, Lavender B, Maclean K, Vacca F, et al
    Controlled Hookworm Infection for Medication-free Maintenance in Patients with Ulcerative Colitis: A Pilot, Double-blind, Randomized Control Trial.
    Inflamm Bowel Dis. 2023 Jun 15:izad110. doi: 10.1093.
    >> Share

  909. SEHGAL P, Su S, Zech J, Nobel Y, et al
    Visceral Adiposity Independently Predicts Time to Flare in Inflammatory Bowel Disease but Body Mass Index Does Not.
    Inflamm Bowel Dis. 2023 Jun 12:izad111. doi: 10.1093.
    >> Share

  910. TANEJA V, Anand RS, El-Dallal M, Dong J, et al
    Safety of Biologic and Small Molecule Therapy for Inflammatory Bowel Disease Among Solid Organ Transplant Recipients: Systematic Review and Meta-Analysis.
    Inflamm Bowel Dis. 2023 Jun 10:izad108. doi: 10.1093.
    >> Share

  911. ODUFALU FD, Dubinsky MC, Peyrin-Biroulet L, Ylanne K, et al
    Health Care Disparities, Social Determinants of Health, and Emotional Impacts in Patients with Ulcerative Colitis: Results from a Global Ulcerative Colitis Narrative Patient Survey.
    Inflamm Bowel Dis. 2023 Jun 10:izad102. doi: 10.1093.
    >> Share

  912. RHUDY CN, Perry CL, Hawk GS, Flomenhoft DR, et al
    Inflammatory Bowel Disease in Appalachian Kentucky: An Investigation of Outcomes and Health Care Utilization.
    Inflamm Bowel Dis. 2023 Jun 6:izad096. doi: 10.1093.
    >> Share

  913. SCALDAFERRI F, D'Onofrio AM, Calia R, Di Vincenzo F, et al
    Gut Microbiota Signatures Are Associated With Psychopathological Profiles in Patients With Ulcerative Colitis: Results From an Italian Tertiary IBD Center.
    Inflamm Bowel Dis. 2023 Jun 6:izad091. doi: 10.1093.
    >> Share

  914. SUTTICHAIMONGKOL T, Loftus EV
    Characteristics, Clinical Outcomes, and Prognosis of Anal and Pouch-related Carcinoma in Patients With Crohn's Disease.
    Inflamm Bowel Dis. 2023 Jun 6:izad104. doi: 10.1093.
    >> Share

  915. SARTER H, Savoye G, Marot G, Ley D, et al
    A Novel 8-Predictors Signature to Predict Complicated Disease Course in Pediatric-onset Crohn's Disease: A Population-based Study.
    Inflamm Bowel Dis. 2023 Jun 2:izad090. doi: 10.1093.
    >> Share

  916. OTTEN AT, van der Meulen HH, Steenhuis M, Loeff FC, et al
    Clinical Validation of a Capillary Blood Home-Based Self-Sampling Technique for Monitoring of Infliximab, Vedolizumab, and C-Reactive Protein Concentrations in Patients With Inflammatory Bowel Disease.
    Inflamm Bowel Dis. 2023 Jun 2:izad103. doi: 10.1093.
    >> Share

  917. LIGHTNER AL, Otero-Pineiro A, Reese J, Ream J, et al
    A Phase I Study of Ex Vivo Expanded Allogeneic Bone Marrow-Derived Mesenchymal Stem Cells for the Treatment of Pediatric Perianal Fistulizing Crohn's Disease.
    Inflamm Bowel Dis. 2023 Jun 1:izad100. doi: 10.1093.
    >> Share

  918. CARPINETI C, Mugheddu C, Cadoni M, Anedda J, et al
    Multiple Orocutaneous Extraintestinal Manifestations in Ulcerative Colitis Patient: Complete Response to Ustekinumab.
    Inflamm Bowel Dis. 2023 Jun 1:izad107. doi: 10.1093.
    >> Share

  919. KHROM M, Li D, Naito T, Lee HS, et al
    Sex-Dimorphic Analyses Identify Novel and Sex-Specific Genetic Associations in Inflammatory Bowel Disease.
    Inflamm Bowel Dis. 2023 Jun 1:izad089. doi: 10.1093.
    >> Share

  920. EL HAJJ W, Buisson A, Olympie A, Ravel MH, et al
    Impact of Inflammatory Bowel Disease on Patients' Caregivers: Results From a French Survey.
    Inflamm Bowel Dis. 2023 Jun 1:izad093. doi: 10.1093.
    >> Share

  921. TSOUNIS EP, Aggeletopoulou I, Mouzaki A, Triantos C, et al
    Creeping Fat in the Pathogenesis of Crohn's Disease: An Orchestrator or a Silent Bystander?
    Inflamm Bowel Dis. 2023 Jun 1:izad095. doi: 10.1093.
    >> Share

  922. HONG SN, Song JH, Kim SJ, Park YH, et al
    One-Year Clinical Outcomes of Subcutaneous Infliximab Maintenance Therapy Compared With Intravenous Infliximab Maintenance Therapy in Patients With Inflammatory Bowel Disease: A Prospective Cohort Study.
    Inflamm Bowel Dis. 2023 Jun 1:izad094. doi: 10.1093.
    >> Share

  923. KARIME C, Farraye FA, Hashash JG
    Use of Immune Checkpoint Inhibitors in Patients With Inflammatory Bowel Disease After Ileal Pouch-Anal Anastomosis.
    Inflamm Bowel Dis. 2023 Jun 1:izad098. doi: 10.1093.
    >> Share

  924. CUSHING KC, Chen Y, Du X, Chen V, et al
    Risk Variants in or Near ZBTB40 AND NFATC1 Increase the Risk of Both IBD and Adverse Bone Health Outcomes Highlighting Common Genetic Underpinnings Across Both Diseases.
    Inflamm Bowel Dis. 2023;29:938-945.
    >> Share

  925. SOUSA P, Noor NM
    Revisiting Drug Development for Older Molecules in IBD.
    Inflamm Bowel Dis. 2023;29:1012-1013.
    >> Share

  926. BOUHNIK Y, Atreya R, Casey D, Gorecki M, et al
    Cost-effectiveness Analysis of Subcutaneous Infliximab for Inflammatory Bowel Diseases in Sequential Biologic Treatment.
    Inflamm Bowel Dis. 2023;29:898-913.
    >> Share

  927. RIVIERE P, Kanters C, Pellet G, Ni A, et al
    Comparative Effectiveness of Ustekinumab and Anti-TNF Agent as First-Line Biological Therapy in Luminal Crohn's Disease: A Retrospective Study From 2 Referral Centers.
    Inflamm Bowel Dis. 2023;29:923-931.
    >> Share

  928. SHORE BM, Weaver KN, Allegretti JR, Herfarth HH, et al
    Prevalence of Clostridioides difficile Infection After Ileal Pouch-anal Anastomosis in Patients With Chronic Antibiotic-dependent Pouchitis and Crohn's-like Disease of the Pouch.
    Inflamm Bowel Dis. 2023;29:932-937.
    >> Share

  929. AXELRAD JE, Li T, Bachour SP, Nakamura TI, et al
    Early Initiation of Antitumor Necrosis Factor Therapy Reduces Postoperative Recurrence of Crohn's Disease Following Ileocecal Resection.
    Inflamm Bowel Dis. 2023;29:888-897.
    >> Share

  930. FAN Y, Zhang L, Omidakhsh N, Bohn RL, et al
    Patients With Stricturing or Penetrating Crohn's Disease Phenotypes Report High Disease Burden and Treatment Needs.
    Inflamm Bowel Dis. 2023;29:914-922.
    >> Share

  931. WONG ECL, Yusuf A, Pokryszka J, Dulai PS, et al
    Increased Expression of Interleukin-13 Receptor in Ileum Associated With Nonresponse to Adalimumab in Ileal Crohn's Disease.
    Inflamm Bowel Dis. 2023;29:875-882.
    >> Share

  932. SEDANO R, Guizzetti L, McDonald C, Beaton M, et al
    Clinical, Endoscopic, and Radiological Effectiveness of Ustekinumab in Bio-naive Versus Bio-experienced Patients With Crohn's Disease: Real-world Experience From a Large Canadian Center.
    Inflamm Bowel Dis. 2023;29:866-874.
    >> Share

    May 2023
  933. HSU P, Choi EJ, Patel SA, Wong WH, et al
    Responsiveness to Vedolizumab Therapy in Ulcerative Colitis is Associated With Alterations in Immune Cell-Cell Communications.
    Inflamm Bowel Dis. 2023 May 26:izad084. doi: 10.1093.
    >> Share

  934. CHAVANNES M, Hart L, Hayati Rezvan P, Dillman JR, et al
    Bedside Intestinal Ultrasound Predicts Disease Severity and the Disease Distribution of Pediatric Patients With Inflammatory Bowel Disease: A Pilot Cross-sectional Study.
    Inflamm Bowel Dis. 2023 May 25:izad083. doi: 10.1093.
    >> Share

  935. HSIA K, Zhao N, Chung M, Algarrahi K, et al
    Alterations in the Fungal Microbiome in Ulcerative Colitis.
    Inflamm Bowel Dis. 2023 May 23:izad082. doi: 10.1093.
    >> Share

  936. DALAL RS, Sharma PP, Bains K, Pruce JC, et al
    1-Year Comparative Effectiveness of Tofacitinib vs Ustekinumab for Patients With Ulcerative Colitis and Prior Antitumor Necrosis Factor Failure.
    Inflamm Bowel Dis. 2023 May 20:izad087. doi: 10.1093.
    >> Share

  937. LOEB L, Nasir A, Picco MF, Hashash JG, et al
    Prior Authorization of Biologics in the Management of Inflammatory Bowel Disease.
    Inflamm Bowel Dis. 2023 May 17:izad088. doi: 10.1093.
    >> Share

  938. MA R, Zhu Y, Li X, Hu S, et al
    A Novel Serum Metabolomic Panel for the Diagnosis of Crohn's Disease.
    Inflamm Bowel Dis. 2023 May 17:izad080. doi: 10.1093.
    >> Share

  939. KOPYLOV U, Burisch J, Ben-Horin S, Braegger F, et al
    Impact of Vedolizumab on Extraintestinal Manifestations in Inflammatory Bowel Disease: Results From a Descriptive, Retrospective, Real-world Study.
    Inflamm Bowel Dis. 2023 May 9:izad075. doi: 10.1093.
    >> Share

  940. MCDONALD C, Kerr H, Gibbons E, Lukose T, et al
    Higher Ustekinumab Levels in Maintenance Therapy are Associated with Greater Mucosal Healing and Mucosal Response in Crohn's Disease: An Experience of 2 IBD Centers.
    Inflamm Bowel Dis. 2023 May 9:izad073. doi: 10.1093.
    >> Share

  941. CHEN X, Elson CO, Dunkin D
    Epicutaneous Immunotherapy with CBir1 Alleviates Intestinal Inflammation.
    Inflamm Bowel Dis. 2023;29:798-807.
    >> Share

  942. LAI HJ, Doan HT, Lin EY, Chiu YL, et al
    Histones of Neutrophil Extracellular Traps Directly Disrupt the Permeability and Integrity of the Intestinal Epithelial Barrier.
    Inflamm Bowel Dis. 2023;29:783-797.
    >> Share

  943. CAO H, Diao J, Liu H, Liu S, et al
    The Pathogenicity and Synergistic Action of Th1 and Th17 Cells in Inflammatory Bowel Diseases.
    Inflamm Bowel Dis. 2023;29:818-829.
    >> Share

  944. BEZZIO C, Fiorino G, Ribaldone DG, Armuzzi A, et al
    IBD Flare in the COVID-19 Pandemic: Therapy Discontinuation Is to Blame.
    Inflamm Bowel Dis. 2023;29:834-836.
    >> Share

  945. DALAL RS, Pruce JC, Allegretti JR
    Long-Term Outcomes After Ustekinumab Dose Intensification for Inflammatory Bowel Diseases.
    Inflamm Bowel Dis. 2023;29:830-833.
    >> Share

  946. HUTFLESS S, Jasper RA, Tilak A, Ghosh T, et al
    A Systematic Review of Crohn's Disease Case Definitions in Administrative or Claims Databases.
    Inflamm Bowel Dis. 2023;29:705-715.
    >> Share

  947. CHAN M, Fung M, Chin Koon Siw K, Khanna R, et al
    Examination Under Anesthesia May Not Be Universally Required Prior to Anti-TNF Therapy in Perianal Crohn's Disease: A Comparative Cohort Study.
    Inflamm Bowel Dis. 2023;29:763-770.
    >> Share

  948. HOLKO P, Kawalec P, Sajak-Szczerba M, Avedano L, et al
    Indirect Costs of Inflammatory Bowel Diseases: A Comparison of Patient-Reported Outcomes Across 12 European Countries.
    Inflamm Bowel Dis. 2023;29:752-762.
    >> Share

  949. NARULA N, Wong ECL, Dulai PS, Marshall JK, et al
    The Performance of the Rutgeerts Score, SES-CD, and MM-SES-CD for Prediction of Postoperative Clinical Recurrence in Crohn's Disease.
    Inflamm Bowel Dis. 2023;29:716-725.
    >> Share

    April 2023
  950. WONG ECL, Dulai PS, Marshall JK, Jairath V, et al
    Predicting Endoscopic Improvement in Ulcerative Colitis Using the Ulcerative Colitis Severity Index.
    Inflamm Bowel Dis. 2023 Apr 28:izad074. doi: 10.1093.
    >> Share

  951. ZITTAN E, Mahajna H, Salomon N
    Attitudes Toward Integrative Medicine in Inflammatory Bowel Disease: A Survey Among Israeli Inflammatory Bowel Disease Experts.
    Inflamm Bowel Dis. 2023 Apr 28:izad072. doi: 10.1093.
    >> Share

  952. GKIKAS K, Wan M, Svolos V, Nichols B, et al
    YouTube as a Source of Information for Food, Diet-Related Items, and Advisory Comments for the Management of Inflammatory Bowel Disease.
    Inflamm Bowel Dis. 2023 Apr 26:izad076. doi: 10.1093.
    >> Share

  953. ATIA O, Magen Rimon R, Ledderman N, Greenfeld S, et al
    Prevalence and Outcomes of No Treatment Versus 5-ASA in Ulcerative Colitis: A Nationwide Analysis From the epi-IIRN.
    Inflamm Bowel Dis. 2023 Apr 21:izad057. doi: 10.1093.
    >> Share

  954. YANG X, Shi J, Wang G, Chen H, et al
    Novel mRNA Signature for Anti-TNF-alpha Therapy Primary Response in Patients With Ulcerative Colitis.
    Inflamm Bowel Dis. 2023 Apr 20:izad060. doi: 10.1093.
    >> Share

  955. MCBRIDE RB, Suarez-Farinas M, Ko HM, Chen X, et al
    Density of Biopsy Sampling Required to Ensure Accurate Histological Assessment of Inflammation in Active Ulcerative Colitis.
    Inflamm Bowel Dis. 2023 Apr 19:izad063. doi: 10.1093.
    >> Share

  956. YANG Y, Carrero JJ
    Reply: Causal Relationship Between Estimated Glomerular Filtration Rate and Inflammatory Bowel Disease: Genetic Evidence From Bidirectional Mendelian Randomization Analysis.
    Inflamm Bowel Dis. 2023 Apr 19:izad069. doi: 10.1093.
    >> Share

  957. LIU M, Ye Z, Sun Z
    Causal Relationship Between Estimated Glomerular Filtration Rate and Inflammatory Bowel Disease: Genetic Evidence From Bidirectional Mendelian Randomization Analysis.
    Inflamm Bowel Dis. 2023 Apr 19:izad067. doi: 10.1093.
    >> Share

  958. SCHELL TL, Ramirez O, Almasry M, Farraye FA, et al
    Additional COVID-19 Booster Doses Increase Anti-spike Serum Antibody Concentrations Among Patients With Inflammatory Bowel Disease.
    Inflamm Bowel Dis. 2023 Apr 18:izad068. doi: 10.1093.
    >> Share

  959. VASUDEVAN A, Tharayil V, Raffals LH, Bruining DH, et al
    Systematic Review and Meta-analysis: The Association Between Serum Ustekinumab Trough Concentrations and Treatment Response in Inflammatory Bowel Disease.
    Inflamm Bowel Dis. 2023 Apr 18:izad065. doi: 10.1093.
    >> Share

  960. NOURELDIN M, Newman KL, Higgins PDR, Piette JD, et al
    Profiles of Web-based Portal Users with Inflammatory Bowel Disease.
    Inflamm Bowel Dis. 2023 Apr 18:izad056. doi: 10.1093.
    >> Share

  961. DAWWAS GK, Weiss A, Constant BD, Parlett LE, et al
    Development and Validation of Claims-Based Definitions to Identify Incident and Prevalent Inflammatory Bowel Disease in Administrative Healthcare Databases.
    Inflamm Bowel Dis. 2023 Apr 12:izad053. doi: 10.1093.
    >> Share

  962. YERUSHALMY-FELER A, Olbjorn C, Kolho KL, Aloi M, et al
    Dual Biologic or Small Molecule Therapy in Refractory Pediatric Inflammatory Bowel Disease (DOUBLE-PIBD): A Multicenter Study from the Pediatric IBD Porto Group of ESPGHAN.
    Inflamm Bowel Dis. 2023 Apr 12:izad064. doi: 10.1093.
    >> Share

  963. KILIC Y, Kamal S, Jaffar F, Sriranganathan D, et al
    Prevalence of Extraintestinal Manifestations in Inflammatory Bowel Disease: A Systematic Review and Meta-analysis.
    Inflamm Bowel Dis. 2023 Apr 12:izad061. doi: 10.1093.
    >> Share

  964. LOLY JP, Vieujean S, Reenaers C, Van Kemseke C, et al
    In-Depth Assessment of Endoscopic Remission in Inflammatory Bowel Disease Treated by Anti-TNF or Vedolizumab.
    Inflamm Bowel Dis. 2023 Apr 12:izad066. doi: 10.1093.
    >> Share

  965. TSE CS, Weng CH, Kwon M, Wolk CB, et al
    Increased Risks for Suicide, Self-Harm, Substance Use, and Psychiatric Disorders in Adults With Inflammatory Bowel Disease: A Nationwide Study in the United States From 2007 to 2017.
    Inflamm Bowel Dis. 2023 Apr 7:izad062. doi: 10.1093.
    >> Share

  966. CHEN D, Tang H, Li Y, Yang H, et al
    Vitamin D3 and Lactobacillus rhamnosus GG/p40 Synergize to Protect Mice From Colitis by Promoting Vitamin D Receptor Expression and Epithelial Proliferation.
    Inflamm Bowel Dis. 2023;29:620-632.
    >> Share

  967. ASHTON JJ, Cheng G, Stafford IS, Kellermann M, et al
    Prediction of Crohn's Disease Stricturing Phenotype Using a NOD2-derived Genomic Biomarker.
    Inflamm Bowel Dis. 2023;29:511-521.
    >> Share

  968. NOOR NM, Lee JC
    The Endoscopic Healing Index in Crohn's Disease: A Serum Proteomic Biomarker for Monitoring Disease Activity.
    Inflamm Bowel Dis. 2023;29:669-671.
    >> Share

  969. HOLMER AK, Boland BS, Singh S, Neill J, et al
    A Serum Biomarker Panel Can Accurately Identify Mucosal Ulcers in Patients With Crohn's Disease.
    Inflamm Bowel Dis. 2023;29:555-562.
    >> Share

  970. PARK J, Chun J, Yoon H, Cheon JH, et al
    Feasibility of a Clinical Decision Support Tool for Ustekinumab to Predict Clinical Remission and Relapse in Patients With Crohn's Disease: A Multicenter Observational Study.
    Inflamm Bowel Dis. 2023;29:548-554.
    >> Share

  971. RISPO A, de Sire R, Mainenti PP, Imperatore N, et al
    David Against Goliath: Direct Comparison of Handheld Bowel Sonography and Magnetic Resonance Enterography for Diagnosis of Crohn's Disease.
    Inflamm Bowel Dis. 2023;29:563-569.
    >> Share

  972. D'AMICO F, Tasopoulou O, Fiorino G, Zilli A, et al
    Early Biological Therapy in Operated Crohn's Disease Patients Is Associated With a Lower Rate of Endoscopic Recurrence and Improved Long-term Outcomes: A Single-center Experience.
    Inflamm Bowel Dis. 2023;29:539-547.
    >> Share

  973. VUYYURU SK, Nguyen TM, Hogan M, Raine T, et al
    Endoscopic and Histological Placebo Rates in Crohn's Disease Clinical Trials: A Systematic Review and Meta-analysis.
    Inflamm Bowel Dis. 2023 Apr 1:izad052. doi: 10.1093.
    >> Share

    March 2023
  974. DENG L, He S, Li Y, Ding R, et al
    Identification of Lipocalin 2 as a Potential Ferroptosis-related Gene in Ulcerative Colitis.
    Inflamm Bowel Dis. 2023 Mar 31:izad050. doi: 10.1093.
    >> Share

  975. DERKS MEW, van Lierop LMA, Te Groen M, Kuijpers CCHJ, et al
    Long-Term Impact of the COVID-19 Pandemic on Inflammatory Bowel Disease Healthcare Utilization: A 2-Year Nationwide Update.
    Inflamm Bowel Dis. 2023 Mar 31:izad055. doi: 10.1093.
    >> Share

  976. TANDON P, Chhibba T, Natt N, Singh Brar G, et al
    Significant Racial and Ethnic Disparities Exist in Health Care Utilization in Inflammatory Bowel Disease: A Systematic Review and Meta-analysis.
    Inflamm Bowel Dis. 2023 Mar 28:izad045. doi: 10.1093.
    >> Share

  977. AKIYA A, Takahashi K, Akimoto S, Hosono Y, et al
    Novel Findings of Early Cardiac Dysfunction in Patients With Childhood-Onset Inflammatory Bowel Disease Using Layer-Specific Strain Analysis.
    Inflamm Bowel Dis. 2023 Mar 27:izad031. doi: 10.1093.
    >> Share

  978. ANYANE-YEBOA A, Buadu MAE, Khalili H, Cozier YC, et al
    Epidemiology of Inflammatory Bowel Disease in a Cohort of US Black Women.
    Inflamm Bowel Dis. 2023 Mar 22:izad049. doi: 10.1093.
    >> Share

  979. LU X, Zhou ZY, Xin Y, Wang MJ, et al
    Matching-Adjusted Indirect Comparisons of Filgotinib vs Vedolizumab, Tofacitinib, and Ustekinumab for Moderately to Severely Active Ulcerative Colitis.
    Inflamm Bowel Dis. 2023 Mar 22:izad037. doi: 10.1093.
    >> Share

  980. KAYAL M, Posner H, Milwidsky HM, Plietz M, et al
    Acute Severe Ulcerative Colitis Is Associated With an Increased Risk of Acute Pouchitis.
    Inflamm Bowel Dis. 2023 Mar 20:izad039. doi: 10.1093.
    >> Share

  981. RABINOWITZ LG
    Gender Biases and Diagnostic Delay in Inflammatory Bowel Disease: Multicenter Observational Study.
    Inflamm Bowel Dis. 2023 Mar 18:izad047. doi: 10.1093.
    >> Share

  982. COLLEN LV
    Rapid Clinical Remission With Upadacitinib in a Pediatric Patient With Refractory Crohn's Disease.
    Inflamm Bowel Dis. 2023 Mar 18:izad048. doi: 10.1093.
    >> Share

  983. GOODSALL TM, Day AS, Andrews JM, Ruszkiewicz A, et al
    Composite Assessment Using Intestinal Ultrasound and Calprotectin Is Accurate in Predicting Histological Activity in Ulcerative Colitis: A Cohort Study.
    Inflamm Bowel Dis. 2023 Mar 16:izad043. doi: 10.1093.
    >> Share

  984. MARRIE RA, Fisk JD, Dolovich C, Lix LM, et al
    Psychometric Performance of Fatigue Scales in Inflammatory Bowel Disease.
    Inflamm Bowel Dis. 2023 Mar 14:izad038. doi: 10.1093.
    >> Share

  985. VARMA S, Trudeau SJ, Li J, Freedberg DE, et al
    Proton pump Inhibitors and Risk of Enteric Infection in Inflammatory Bowel Disease: A Self-controlled Case Series.
    Inflamm Bowel Dis. 2023 Mar 14:izad035. doi: 10.1093.
    >> Share

  986. BUIE MJ, Coward S, Shaheen AA, Holroyd-Leduc J, et al
    Hospitalization Rates for Inflammatory Bowel Disease Are Decreasing Over Time: A Population-based Cohort Study.
    Inflamm Bowel Dis. 2023 Mar 14:izad020. doi: 10.1093.
    >> Share

  987. AGOSTINI A, Benuzzi F, Ballotta D, Rizzello F, et al
    Differential Brain Structural and Functional Patterns in Crohn's Disease Patients are Associated with Different Disease Stages.
    Inflamm Bowel Dis. 2023 Mar 10:izad029. doi: 10.1093.
    >> Share

  988. ALMOMEN HS, Al-Bawardy B
    Oral Vancomycin Induced and Maintained Clinical and Endoscopic Remission in Ulcerative Colitis and Primary Sclerosing Cholangitis Post-liver Transplantation.
    Inflamm Bowel Dis. 2023 Mar 8:izad040. doi: 10.1093.
    >> Share

  989. LIU R, Li Z, Ye L, Hu J, et al
    Risk of Tuberculosis and Hepatitis B Reactivation in Patients With Crohn's Disease on Ustekinumab: A Nationwide Real-World Study.
    Inflamm Bowel Dis. 2023 Mar 6:izad032. doi: 10.1093.
    >> Share

  990. KUNISAKI R, Ikeda A, Yaguchi K, Onishi M, et al
    To Be in Remission or in Corticosteroid-free Remission: That Is the Question for Women With Inflammatory Bowel Disease at Conception.
    Inflamm Bowel Dis. 2023 Mar 6:izad023. doi: 10.1093.
    >> Share

  991. MOURAD FH, Maalouf RG, Aoun R, Gustavo Kotze P, et al
    Are the New Biologics Effective in the Management of Postoperative Crohn's Disease?
    Inflamm Bowel Dis. 2023 Mar 4:izad033. doi: 10.1093.
    >> Share

  992. SCHROEDER MK, Tan SA, Touma MJ, Basit M, et al
    Automated Clinical Pathway Utilizing Custom Risk Stratification Identifies Substantial Rates of Overdue Follow-up Among Patients With Inflammatory Bowel Disease and Facilitates Population Health Interventions.
    Inflamm Bowel Dis. 2023 Mar 2:izad026. doi: 10.1093.
    >> Share

  993. CHIBA M, Hosoba M, Yamada K
    Plant-Based Diet Recommended for Inflammatory Bowel Disease.
    Inflamm Bowel Dis. 2023 Mar 1:izac279. doi: 10.1093.
    >> Share

  994. LIMKETKAI BN
    Reply: Plant-Based Diet Recommended for Inflammatory Bowel Disease.
    Inflamm Bowel Dis. 2023 Mar 1:izad022. doi: 10.1093.
    >> Share

  995. GEERTSEMA S, Otten AT, Bouwknegt DG, Visschedijk MC, et al
    Assessment of Fecal Glycosylated Mucins as Novel Biomarkers in Inflammatory Bowel Diseases.
    Inflamm Bowel Dis. 2023;29:e10-e11.
    >> Share

  996. MASSELOT CR, Cordier C, Marsac B, Nachury M, et al
    Fecal Mucin O-Glycans as Novel Biomarkers in Inflammatory Bowel Diseases.
    Inflamm Bowel Dis. 2023;29:e12.
    >> Share

  997. CHIRRA P, Sharma A, Bera K, Cohn HM, et al
    Integrating Radiomics With Clinicoradiological Scoring Can Predict High-Risk Patients Who Need Surgery in Crohn's Disease: A Pilot Study.
    Inflamm Bowel Dis. 2023;29:349-358.
    >> Share

  998. MCKENNA NP, Kelley SR, Bews KA, Behm KT, et al
    Surgical Management of Enterovesical Fistula in Crohn's Disease in the Biologic Era.
    Inflamm Bowel Dis. 2023;29:480-482.
    >> Share

  999. GU P, Dube S, McGovern DPB
    Medical and Surgical Implications of Mesenteric Adipose Tissue in Crohn's Disease: A Review of the Literature.
    Inflamm Bowel Dis. 2023;29:458-469.
    >> Share

  1000. SHEHAB M, Alrashed F, Heron V, Restellini S, et al
    Comparative Efficacy of Biologic Therapies for Inducing Response and Remission in Fistulizing Crohn's Disease: Systematic Review and Network Meta-Analysis of Randomized Controlled Trials.
    Inflamm Bowel Dis. 2023;29:367-375.
    >> Share

  1001. TURSI A, Mocci G, Allegretta L, Aragona G, et al
    Comparison of Performances of Adalimumab Biosimilars SB5, ABP501, GP2017, and MSB11022 in Treating Patients with Inflammatory Bowel Diseases: A Real-Life, Multicenter, Observational Study.
    Inflamm Bowel Dis. 2023;29:376-383.
    >> Share

  1002. KASSIM G, Yzet C, Nair N, Debebe A, et al
    Long-Term Outcomes of the Excluded Rectum in Crohn's Disease: A Multicenter International Study.
    Inflamm Bowel Dis. 2023;29:417-422.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016